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CHAPTER 1
INTRODUCTION

The Internet is a major source of information for health issues for the
general public. According to the Pew Internet Project (2002), 62% of Internet
users, or 73 million people in the United States, have gone online in search of
health information. The growth of online direct-to-consumer advertising of
prescription drugs in the United States is a growing phenomenon resulting in the
proliferation of web sites for specific medical “conditions” and pharmaceutical
“treatments.” As such, the dramatic increase in accessibility and availability of
online information about prescription medications raises interesting questions
about the Internet as a fluid marketing medium. In particular, consumer-targeted
prescription drug advertising serves as an interesting lens through which we can
begin to examine the portrayal of menopause in online drug advertisements.
Therefore, the aim of this study was to explore the portrayal of menopause on
web sites sponsored by pharmaceutical companies for hormone therapies (HT).
Advertisements are one of the most important cultural factors molding and
reflecting our lives (Williamson, 2002). Their very existence is more than a
medium, advertising forms a “vast superstructure” with an immense influence to
create structures of meaning (Williamson, 2002, p. 11). Direct-to-consumer
advertising (DTCA) is defined as “any promotional effort by a pharmaceutical
company to present prescription drug information to the general public through
the lay media” such as popular magazines and television (Bradley and Zito,
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1997, p. 86). Web sites are not merely just an informational venue rather they are
another way that DTCA can reach consumers (Khim, 2009). In fact, 30% of
Americans surveyed state that they have talked with a doctor about a specific
medication as a result of some form of direct-to-consumer advertising (Kaiser
Family Foundation, 2001). Because the selling of prescription drugs in the United
States requires the cooperation of health care providers, direct-to-consumer
advertisements contain messages that may function to motivate consumers to
take action in the form of seeking out health care providers in order to obtain
certain pharmaceutical products (Cline and Young, 2004).
As Conrad and Leiter (2008) note, the Internet has become “another direct
avenue from pharmaceutical companies to consumers, and one that is not limited
to national boundaries” (p. 834). Broadly speaking, the Internet may provide
unprecedented access to individuals and new opportunities for information
retrieval, pharmaceutical marketing, and consumption (Fox, Ward, and O’Rourke,
2006). Indeed, the Internet has further expanded the potential to reach specific
audiences for pharmaceutical products. Therefore, how pharmaceutical web sites
frame and construct messages is of particular interest because these messages
play an important role in shaping cultural attitudes and beliefs. Interestingly, there
are no specific regulations for Internet marketing in the United States and
pharmaceutical web sites are expected to conform to the same guidelines
established for any DTCA (Woodlock, 2005). Due to the lack of regulation
pertaining to Internet marketing and DTCA, the role of direct-to-consumer
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advertising of pharmaceuticals in a global information environment warrants
further investigation.
Previous research has examined the topics of women and menopause in the
popular media, such as print, television, and radio advertisements. A standard
definition of menopause found in the medical literature is the absence of
menstrual periods for one year (Mansfield and Voda, 1997). The assumption that
menopause will be accompanied by hot flashes, night sweats, vaginal changes,
irritability, and depression has become ingrained in medical and popular culture
in North America (Kaufert, 1996). Yet, research has shown that menopause is
not a universal experience. Some women may experience difficulty during this
transition while others will experience little, if any, discomfort (Mansfield and
Voda, 1997). In this study, menopause is defined more broadly as a natural part
of the aging process, rather than an event that limits women’s psychological or
physical capacities (McCrea, 1983).
The existing literature demonstrates that representations of menopause in
newspapers and popular magazines as a hormone deficiency disease that can
be easily “fixed” with drugs are common in the print media (Carlson, Li, and
Holm, 1997; Cimons, 2008; Gannon and Stevens; 1998; Hust and Andsager,
2003; Lyons and Griffin, 2003; Shoebridge and Steed, 1999). Previous research
has also shown that hormone therapies (HT) have been frequently portrayed as
the remedy for menopausal symptoms and even as an “elixir of life” in helping
women to maintain youthfulness (Watkins, 2007, p.1). The term hormone
therapies (HT) refers to when a woman takes supplements of hormones, such as

4
estrogen alone or estrogen with another hormone called progesterone (progestin
in its synthetic form) for menopause (FDA, 2008b).
Hormone therapies come in many forms and dosages, including skin patches,
vaginal tablets or creams, and prescription pills. In addition, implants, shots, or
vaginal ring inserts are also available (National Institute on Aging, 2009). As
Conrad (2007) notes, early medical articles reported that estrogen could “reduce
menopausal symptoms” (p. 121). In addition, some medical articles also claimed
the preventive benefits of estrogen, such as preventing breast cancer (McCrea,
1983). Other presumed benefits for women taking HT were thought to be a
“lower risk of coronary heart disease, hip and spinal fracture, vaginal atrophy,
urinary incontinence and, possibly, Alzheimer’s disease” (Kaufert and Lock,
1997, p. 84). Furthermore, magazines and newspapers periodically run articles
about menopause and the results of major medical studies relating to HT are
reported. As a result, menopause and HT have become popular topics in the
print media.
In 1997, hormone therapies were part of a large set of clinical trials called
the Women's Health Initiative (WHI). These large, multi-center trials were part of
the largest coordinated study of women's health ever undertaken by the National
Institutes of Health. Although the WHI study began in 1997 and was expected to
run at least 10 years, the National Institutes of Health abruptly terminated a major
clinical trial in June 2002 when unexpected results indicated increased risks for
heart disease, stokes, blood clots, and breast cancer for those using HT. In light
of the landmark decision to stop the WHI clinical trial early, there has been an
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explosion of “media attention leading to confusion among women and health
professionals about the benefits, risks, and uncertainties” regarding hormone
therapies (Rees, 2005, p. 287).
Despite these risks, the HT industry continues to be a multi-billion dollar
business “admonishing women to do everything within their power to resist
hormonal decline and atrophy” (Perz and Ussher, 2008, p. 294). Existing
research on direct-to-consumer marketing shows that HT was advertised heavily
to health professionals via medial journals and featured drugs for hormone
replacement. As such, advertisements for HT published in professional and trade
journals portrayed menopause as a “deficiency disease” advocating for HT as a
widespread treatment for women (Richter, 2002; Whittaker, 1998). Yet, little is
known about online direct-to-consumer advertising strategies and campaigns for
hormone therapies aimed directly at the general public. In fact, Worcester and
Whatley (1992) speak of the importance of evaluating and critiquing the mass
marketing of hormones. Furthermore, Worcester (2004) states that “consumer
literacy and action related to demanding safe, effective products, marketed by
ethical corporations, and administered by physicians who have accurate,
science-based information is urgent” (p. 62). Thus, an important step in
unraveling the DTCA strategies employed on pharmaceutical web sites is to
explore the representation of menopause in online advertisements for hormone
therapies. Specifically, I am interested in exploring the information content and
how menopause is portrayed on web sites for hormone therapies sponsored by
pharmaceutical companies.
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Purpose of Study

To better understand the construction of menopause in online DTCA drug
advertisements, the purpose of this study was to explore how menopause was
being

portrayed

on

web

sites

for

hormone

therapies

sponsored

by

pharmaceutical companies. In examining the web sites, I was curious about the
portrayal of menopause and information content presented on DTCA
pharmaceutical web sites since the WHI. Given this, further research on the
construction of menopause on contemporary web sites for hormone therapies
sponsored by pharmaceutical companies eight years following the decision to
stop the WHI clinical trial was warranted.

Significance of the Study

By analyzing how menopause is portrayed on web sites for hormone
therapies sponsored by pharmaceutical companies, this study provides a missing
piece in the understanding of representations of menopause in various media. In
particular, my analysis addressed how menopause was constructed on
pharmaceutical web sites in order to address the knowledge gap in relation to
online representations of menopause. In examining these web sites, I was
particularly interested in the messages that pharmaceutical companies were
constructing and conveying about women and menopause. As Hust and
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Andsager (2003) note, although media are only one venue for information, they
are a “powerful means of transmitting ideas and shaping thought” (p. 116).
Conrad and Leiter (2008) further state, DTCA establishes a direct and
independent relationship between drug companies and consumers “encouraging
self-diagnosis and requests for specific drugs” (p. 825).
DTCA on the Internet has been called “one of the largest single threats to
global healthcare safety” (Lorence and Churchill, 2007, p. 551). In fact, the
advertising of prescription drugs to the general public is illegal in most countries.
Legal DTCA is exclusive to New Zealand and the United States (Woodlock,
2005). As online DTCA becomes increasing prevalent, a discussion of the
implications of the broad reach of DTCA of hormone therapies on the World Wide
Web was also warranted. Hence, both the growth and magnitude of DTCA
prescription drug advertising on the Internet and its potential consequences for
public health overall add to the importance of understanding its far-reaching
influence.
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CHAPTER 2
LITERATURE REVIEW

Introduction

Menopause has been theorized over the years by a range of medical,
social science, and feminist researchers. In fact, a variety of differing
perspectives on menopause exist and the paradigms through which menopause
has been represented varies considerably (Lyons and Griffin, 2003). While the
biomedical model views menopause as a “disease” that can be treated medically,
other models have emerged offering alternate frameworks for understanding
menopausal experiences. First, various models of menopausal research found in
the literature will be discussed. Then, the rise in popularity of hormone therapies
as a treatment for menopause is traced. Next, a brief history of the Women’s
Health Initiative, the first major study to examine the effects of hormone
therapies, is provided. Finally, federal regulations of direct-to-consumer
advertising in the United States and the pharmaceutical industry’s involvement in
marketing hormone therapies to physicians and consumers are discussed.

Biomedical Model of Menopause

According to Lyons and Griffin (2003), several paradigms of menopause
research exist, of which the biomedical paradigm is the most dominant model.
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Promoting a woman’s natural change of life as a medical condition of “estrogen
loss” has a history dating back several decades (Moynihan and Cassels, 2005).
In fact, the social construction of menopause as a “deficiency disease” has been
well-documented in the sociological literature (for example, see: Bell, 1987;
McCrea, 1983; Riessman, 1983; Posner, 1979). Negative biomedical definitions
of menopause include portraying menopause as the “end of fertility, ovarian
failure, or the loss of womanhood” (Dillaway, 2005, p. 400). Thus, meanings
around the aging feminine body cemented in a biomedical approach to
menopause center on “the loss of attractiveness, fertility, and function” (Lupton,
1996, p. 92).
Basically, the biomedical model assumes that menopause is “best understood
in terms of the biology of disease mechanisms” (Derry, 2002, p. 20). In this
prevalent model, menopause is considered to be pathological and abnormal
(Bell, 1987). As noted above, the biomedical model regards menopause as an
“estrogen deficiency disease for which estrogen replacement is the therapy of
choice” (Kaufert and Gilbert, 1986, p. 8). Therefore, a biomedical perspective has
constructed menopause as a negative event requiring medical intervention. As
Derry (2008) notes, postmenopausal women “do produce estrogen in their
bodies [and] these lower levels of hormone were assumed to be negligible” (p.
722).
Early medical reports suggested that estrogen could “reduce menopausal
symptoms” (Conrad, 2007, p. 121). Articles in the scientific and medical literature
also claimed the preventive benefits of estrogen, such as preventing breast
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cancer (McCrea, 1983). Furthermore, Robert Wilson’s bestselling book entitled
Feminine Forever (1966) declared a revolutionary breakthrough claiming that
hormones would “cure” the disease of menopause and reverse signs of aging.
Notably, the idea of menopause as a disease requiring medical treatment was
popularized in a book entitled Feminine Forever (1966) by Robert Wilson, a New
York physician and gynecologist. A central claim of the book was that
menopause was a condition that required management by a medical
professional. In this book, Wilson (1966) described menopausal women as
diseased and proclaimed that their ovaries were dead. Wilson (1966) further
asserted that menopause was an estrogen deficiency disease treatable with
estrogen replacement therapy.
Essentially, Wilson (1966) solidified the idea of “menopause as a disease,”
employed terms which were primarily negative about women and aging, and
focused on deficiency and deterioration which he claimed could be treated by the
beneficial effects of estrogen. As a result, Wilson (1966) defined menopause as a
biomedical event thereby laying the groundwork for treating menopause with
hormones (Lyons and Griffin, 2003). Thus, the idea that menopausal women had
an estrogen deficiency became widely accepted in society and established the
foundation for a pharmaceutical “treatment” for menopause.
The view of menopause as a disease necessitating medical treatment has
been a dominate discourse in the scientific and medical literature (Voda, 1992).
Rostosky and Travis (1996) also noted the predominance of articles in the
scientific literature about menopause based on the biomedical paradigm.
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According to Dickson (1993), menopause is frequently depicted by metaphors of
disease or breakdown in the biomedical research. Additionally, Kaufert and Lock
(1997) reported how the medical-scientific literature uses “graphs, tables, and
histograms to demonstrate that women who take hormones are at a lower risk of
coronary heart disease, hip and spinal fracture, vaginal atrophy, urinary
incontinence, and, possibly, Alzheimer’s disease” (p. 84). Thus, advertisements
and articles in the medical literature actively promote and disseminate a medical
model of menopause.
The biomedical perspective has also been dominant in popular media
accounts of menopause (Lyons and Griffin, 2003). Interestingly, research
indicates that women obtain much of their information about menopause from the
media and other forms of popular culture, most notably a primary source of
information is from women’s magazines (Clinkingbeard et al., 1999). Therefore,
investigations into representations of menopause in the popular media are
valuable.
The growing interest in menopause is illustrated by the increasing number
of articles published in the popular press (Carlson, Li, and Holm, 1997). An
analysis of the “lay” literature on menopause over a 10-year period showed that
most of the magazine articles blended opinion with fact, many of the authors of
the articles did not state their credentials, and physicians were often quoted as
experts about midlife women’s health (Carlson, Li, and Holm, 1997). Gannon and
Stevens (1998) examined the portrayal of menopause in the British media over a
15-year time period and found the articles emphasized this time of life as a

12
negative experience or as a disease needing medical treatment. Similarly, Hust
and Andsager (2003) found that photos of women shown in magazines over a
20-year period were predominately white and the coverage was narrowly focused
on scientific developments related to fertility. Shoebridge and Steed (1999) also
examined the print media in Australia. In particular, they assessed articles
relating to menopause over a 10-year period in two daily newspapers and four
women’s magazines finding that articles drew on and reinforced the biological
nature and disease management aspects. Moreover, Lyons and Griffin (2003)
analyzed four self-help texts and found that terms such as “symptoms,
deficiency, and atrophy” were employed across all four of the texts about
menopause (p. 1634).
In sum, the biomedical model of menopause as a deficiency disease
requiring medical treatment has dominated “both the popular and clinical
domains” (Lyons and Griffin, 2003, p. 1631). The literature cited above
demonstrates that the prevailing biomedical model is one that portrays
menopause as a disease and offers a negative view of menopause. In addition, a
biomedical approach has further been associated with the emergence of
hormone therapies that can be prescribed to “treat” menopause.

Socio-cultural and Feminist Models of Menopause

One critique of the biomedical approach to menopause is that this perspective
largely ignores “social and cultural aspects of the passage into menopause for
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women in American society” (Bell, 1987, p. 539). Given this, some researchers
have moved away from the biomedical perspective of menopause. In contrast,
the socio-cultural paradigm views the experiences of menopause as a natural
event in which social and cultural contexts and meanings are significant (Lyons
and Griffin, 2003). The socio-cultural perspective of menopause was developed
by sociologists, anthropologists, and others partly in response to the growing
dominance of the biomedical model (Hunter and O’Dea, 1997). Arguing that
women are “not diseased, defective, or disabled at menopause,” the sociocultural perspective considers menopause to be a natural process and normal
event (Voda, 1992, p. 923). Essentially, the socio-cultural paradigm views
menopause as a normal process and offers an alternative to the biomedical
model. From this perspective, menopause is conceptualized as a natural part of
the aging process, rather than an event that limits women’s psychological or
physical capacities (McCrea, 1983).
Another approach to understanding menopause found in the literature is a
feminist paradigm which refutes the disease model. A feminist approach views
menopause as a natural process and universal event for all women (Bell, 1987;
Lyons and Griffin, 2003; Voda, 1992). According to this model, menopause is a
significant landmark for women marking the normal “closure of menstrual life”
(Voda, 1992, p. 923). Simply put, menopause is largely regarded in this model as
a “natural life transition” (Zita, 1993, p. 61). Moreover, a feminist model considers
menopause to be the point at which a woman ceases to menstruate and signifies
the end of fertility (Lyons and Griffin, 2003). Some feminist researchers have also
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highlighted positive aspects of menopause. For example, Zita (1993) notes while
some women may experience this transition with difficulty, others may find it to
be a positive and easy experience. Voda (1997) further elaborates that
menopausal transition can be a time of personal growth and productivity.
A feminist approach to understanding menopausal experiences offers a
critique of the biomedical model of menopause. Bell (1987) argues that the
biomedical model and negative constructions of menopause reinforce traditional
ideas “of women as biologically different and inferior” (p. 538). In fact, the
feminist model views menopause as “yet another biological experience [that has]
been used to suppress women’s positions” in society (Lyons and Griffin, 2003, p.
1630). As noted, the biomedical model suggests that menopausal symptoms are
caused by a biological breakdown or malfunction, namely the lack of estrogen.
As such, the definition of menopause as a disease derived from the biomedical
model has “its origins in patriarchal views and beliefs of women as defective and
imperfect” (Voda, 1992, p. 923). Derry (2004) further asserts a biomedical model
of menopause directs attention to a simple variable, in this case estrogen, which
can be modified in straightforward ways. Specifically, a biomedical model
reduces the “problem [to] having the right amount of estrogen” (Derry, 2004, p.
15). The basic reasoning, according to a biomedical model, remains that some
kind of biological breakdown or malfunction can be altered with effective medical
intervention.
A feminist perspective also contends that the medical profession has helped
to transform the “meaning of menopause and defined it as a medical problem
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with a medical solution” (Bell, 1987, p. 539). According to medical reasoning, if a
health care provider believed that menopausal symptoms resulted from a lack of
estrogen, then estrogen replacement therapy was promoted as the logical
solution (Bell, 1987). If the disease definition of menopause is accepted, then
women should report any change or symptom to their physician to be medically
managed. Thus, physicians (usually male) reinforced their dominant social status
as they also reinforced the subordination of women by “giving expert advice
about how to grow old gracefully” (Bell, 1987, p. 540). As a result, a feminist
model regards this as one way in which the medical profession has been able to
assert control over women’s experiences of menopause (Coney, 1994; Kaufert
and Gilbert, 1986).
For these reasons, feminist researchers and women’s health advocates
contend that medicine does not have the right to “alter, manipulate, and control
the life course of women” (Voda, 1992, p. 931). As Derry (2002) states,
“menopause is larger than a medical event” (p. 22). Feminist approaches to
menopause may also give voice to female experiences of menopause that have
either been “silenced or erased by the medical gaze that sets it sights on the
horrifying dangers” of menopause (Zita, 1993, p. 66). As such, a feminist view of
menopause attempts to offer a broader model exploring the “social, cultural, and
psychological variables that influence the experiences of menopausal women”
(Derry, 2002, p. 21).
Overall, various models of menopausal research exist in the literature. These
models provide a framework through which we can begin to understand how
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menopause has largely been defined and promoted as a medical problem
requiring a medical solution. Clearly, the biomedical model of menopause has
been the dominant discourse surrounding menopause and has permeated the
scientific and popular literature. However, other models of menopause have
emerged, such as the socio-cultural and feminist paradigms, seeking to refute
the biomedical model by offering alternative perspectives through which
menopause experiences can be understood. Nevertheless, the dominant
discourse remains to be “menopause as a deficiency and disease” which is
based on a biomedical paradigm firmly grounded in a medical approach to
menopause.

History of Hormone Therapies

As noted above, the prevailing biomedical notion that menopausal symptoms
are caused by a lack of estrogen helped to set the stage for a medical treatment
for menopause. Accordingly, estrogen therapy could replace this biological
deficiency. To fully appreciate the widespread use and acceptance of hormone
therapies for the “treatment” of menopause, a brief history of the rise in popularity
of hormone therapies in the last few decades is provided. The term hormone
therapies (HT) refers to when a woman takes supplements of hormones, such as
estrogen alone or estrogen with another hormone called progesterone (progestin
in its synthetic form) (FDA, 2008b). It was presumed that “women who take
hormones are at lower risk of coronary heart disease, hip and spinal fracture,
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vaginal atrophy, urinary incontinence and, possibly, Alzheimer’s disease”
(Kaufert and Lock, 1997, p. 84). It is also important to note that these hormone
therapies come in many forms and dosages, including skin patches, vaginal
tablets or creams, and prescription pills. In addition, implants, shots, or vaginal
ring inserts are also available (National Institute on Aging, 2009).
As Conrad (2007) points out, early medical articles reported that estrogen
could “reduce menopausal symptoms” (p. 121). In addition, some medical
articles also claimed the preventive benefits of estrogen, such as preventing
breast cancer (McCrea, 1983). Furthermore, Robert Wilson’s bestselling book
entitled Feminine Forever (1966), which was discussed above, declared that
hormones would “cure” the disease of menopause and reverse signs of aging.
Although some of the proclaimed benefits of HT lacked scientific evidence, two
symptoms in particular appear “to be related to declining levels of estrogen
during the menopausal transition” (Mansfield and Voda, 1997, p. 59). Therefore,
HT may be effective in helping to moderate hot flashes and vaginal dryness.
As Derry (2004) noted, the “enthusiasm for hormone use” probably had many
roots (p. 214). In the 1930s and 1940s, American medical professionals started
using DES, a synthetic estrogen, to treat menopause (Bell, 1987). During this
time period, medical professionals started investigating the use of this synthetic
estrogen, raising the possibility of treating so-called hormone deficiencies in
women with hormone therapies. Subsequently, this became the first widely used
estrogen replacement therapy and it was approved for marketing in 1941 (Bell,
1987).
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Treatment with estrogen replacement therapy continued to grow. In the
1960s, there was a surge of interest in estrogen therapy and estrogen sales
soared. As previously noted, Dr. Wilson (1966) first popularized the notion that a
wonder drug (estrogen) could prevent the aging process in women in the book
Feminine Forever (Worcester and Whatley, 1992). In this book, the idea that
estrogen could keep women young forever and prevent the “decaying” process of
aging was promoted (Worcester and Whatley, 1992). As a result, idea of
menopause as an “estrogen deficiency disease” became widely accepted in our
society and laid the foundation for a medical “treatment” of menopause with
hormone therapies (HT).
By the mid-1970s, a series of research papers confirmed a link between
estrogen and endometrial cancer (Mansfield and Voda, 1997). In reaction to this
news, sales of estrogen dropped drastically. Yet, this did not deter
pharmaceutical marketing efforts to promote hormones. This was followed by
research attempts to find a way to protect a woman’s uterus from developing
cancer. In the 1980s, this research paid off and estrogens were re-introduced to
consumers in combination with a progestin (Voda and Ashton, 2006). By adding
a progestin to estrogen, the medical thought was that the uterine lining would be
protected. The new combination treatment, in which a woman was given both an
estrogen and a progestin hormone, meant that women would need to take
hormones every day (Voda and Ashton, 2006). Needless to say, menopausal
and postmenopausal women represented a huge potential market for the drug
industry.
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Also in the 1980s, a new marketing strategy focused on the prevention of
heart disease and osteoporosis. In particular, pharmaceutical manufacturers
aggressively advertised the preventative benefits of hormones to both health
care providers and consumers. This was evident in mass marketing efforts that
“encouraged all women over thirty-five years to consider taking estrogens to
prevent osteoporosis” (Worcester and Whatley, 1992, p. 4, italics in the original).
By linking osteoporosis with menopause, the implication was that “osteoporosis
practically [became] identified as a symptom of menopause” (Worcester and
Whatley, 1992, p. 9). As a result of this marketing campaign, women not only
heard about osteoporosis but they were also “frightened by the seeming
inevitability of postmenopausal hip fractures or of becoming like the elderly
woman with the severely bent spine” they saw in drug advertisements (Worcester
and Whatley, 1992, p. 4).
The use of HT for protection against heart disease in women was another
strategy employed by pharmaceutical companies to further generate interest in
hormones. Despite solid clinical evidence supporting the preventative benefits of
HT related to heart disease, this technique aimed to raise anxiety “to the point at
which a new group of women [would] actively seek” hormone prescriptions
(Worcester and Whatley, 1992, p. 4). As a consequence, HT became symbolic of
“the pattern of untested, unneeded products being marketed to healthy women
for pharmaceutical-company inspired ‘medical conditions’” (Worcester, 2004, p.
57).
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According to Worcester (2004), when drug companies started promoting HT
for the prevention of heart disease and osteoporosis, “they hoped to hook women
into a product they would stay on for the rest of their lives” (p. 63). Obviously, this
strategy had consequences for women. A major ramification was that women
would be using hormones “for the rest of their lives and dependent upon
expensive medical services to monitor how their bodies adjust to these products”
(Worcester and Whatley, 1992, p. 16).
In the 1990s, researchers explored the possibility that estrogen loss may
contribute to the development of Alzheimer's disease. As such, this fostered the
idea that estrogen replacement therapy may be useful for preventing or delaying
the onset of this dementia (Paganini-Hill and Henderson, 1994). At the same
time, there was a growing awareness of a variety of health risks associated with
hormone use, including gallbladder disease, elevated blood pressure, and blood
clots (Mansfield and Voda, 1997). In addition, evidence began to surface about
the relationship between estrogens and breast cancer. Not surprisingly, many
women became reluctant about using hormones and had concerns regarding the
long-term safety and effectiveness of hormone therapies.
Given the growing concerns about the side effects and risks associated with
hormones, women began questioning the benefits of using hormones. According
to Mansfield and Voda (1994), the control of hot flashes and sleep disturbances
were cited by women as primary reasons for continuing to use hormones. In
addition, women also stated that they decided to take hormones because their
health care provider recommended hormone therapy. Yet, some women cited

21
reasons for not using hormones which included that they did not perceive
menopause as a condition needing treatment, as well as their ongoing concerns
about risks or unpleasant side effects (Mansfield and Voda, 1994).
Attitudes towards menopause and hormone use also vary between women in
different social groups. For example, research has demonstrated that rates of
hormone use are typically lower among African-American and Hispanic women in
the United States (Kaufert and Lock, 1997). This pattern of hormone use is
reflective of previous research also showing that attitudes towards menopause
and aging differed across ethnic groups, with African American women having
more positive views than those expressed by Caucasian women (Sommer et al.,
1999). In fact, healthy, white middle-class women have typically been the usual
subjects of hormone-related menopausal research (Kaufert and Lock, 1997).
In light of the growing concerns over the potential risks associating with using
hormones, the U.S. National Institutes of Health began a set of clinical trials in
1997 to test hormone therapies known as the Women’s Health Initiative (WHI).
Although the WHI study began in 1997 and was expected to run at least 10
years, the National Institutes of Health halted a major clinical trial in June 2002
when unexpected results indicated increased risks for heart disease, stokes,
blood clots, and breast cancer for those using HT. Next, I turn to a discussion of
the history of the WHI.

History of the Women’s Health Initiative (WHI)
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A large set of clinical trials known as the Women's Health Initiative (WHI)
began in 1997. The WHI was a massive initiative of the U.S. National Institutes of
Health (NIH) pertaining to the health of postmenopausal women and included
several studies designed to evaluate the effects of prescribed hormone therapies
(HT) on the incidence of heart disease. The first study evaluated the effects of
daily use of a combination therapy consisting of estrogen plus progestin and this
arm of the study became known as the Combination Hormone Therapy Study
(Voda and Ashton, 2006). The second arm of the study, known as the Estrogen
Hormone-only Study, evaluated the effect of Estrogen on heart disease (Voda
and Ashton, 2006). Taken together, these large multi-center trials were part of
the largest coordinated study of women's health ever undertaken by the National
Institutes of Health.
One component of the WHI was a clinical trial designed to test whether the
combined therapy of estrogen plus progestin was safe and effective for the
primary prevention of coronary heart disease and was ended prematurely in July
2002 (Derry, 2004). As originally designed, subjects involved in this clinical trial
were to be followed for 8.5 years. However, WHI researchers announced that the
study was going to be halted after an average of 5.2 years of follow-up after an
excess number of subjects developed breast cancer (Derry, 2004).
As Voda and Ashton (2006) have pointed out, the “theoretical underpinning of
the WHI” was embedded in a biomedical model that defined menopause as a
state of estrogen deficiency that could lead to disease (p. 402). To help further
illustrate this point, a separate clinical trial of the WHI examined whether
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estrogen alone was safe and effective for heart disease prevention. This second
arm of the WHI was also halted earlier than originally planned, in 2004, when
study participants had an increased risk of stroke (Derry, 2004). Thus, the WHI
clinical trials provided “strong clinical trial evidence that postmenopausal HT does
not prevent heart problems” (Derry, 2008, p. 731).
As a result of the WHI findings, the FDA concluded that HT should be used
only for treatment of hot flashes, vaginal dryness, and possible osteoporosis at
the lowest dose and for the shortest period of time (FDA, 2003). In brief, risks to
health such as stroke and breast cancer were found, the studies were
prematurely discontinued, and acclaimed benefits of hormone use were not
supported (Voda and Ashton, 2006). Indeed, the WHI findings had a “seismic
effect on menopausal women’s health care in the U.S. and the rest of the
Westernized world” (Voda and Ashton, 2006, p. 402).
Yet, the idea that hormone therapy is “a valuable and powerful agent” to treat
menopausal symptoms has not subsided resulting in campaigns from
pharmaceutical companies to resurrect hormone therapies (Voda and Ashton,
2006). As a result, HT are being strategically re-introduced to health care
providers and consumers with an emphasis on improving the “quality of life” of
menopausal women (Voda and Ashton, 2006, p. 410). Presently, women are
again encouraged to take hormones, only now it is for symptom relief. This
“resurrection” is being witnessed in the promotion of HT as a viable treatment for
“debilitating” menopausal symptoms, such as hot flashes, burning, itching, and
painful urination (Derry, 2006, p. 406). Still implicit in this approach in the belief
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that women are “hormone deficient [and…] the right combination of hormones
can be found to prescribe” for any so-called menopausal symptom (Derry, 2004,
p. 408). Ultimately, this thinking continues past practices and beliefs of
menopause as a deficiency disease treatable with hormone therapies. In
particular, direct-to-consumer advertising is one way that pharmaceutical
companies

are

aggressively

marketing

hormone

therapies

to

potential

consumers for their products.

Direct-to-Consumer Advertising

Direct-to-consumer advertising (DTCA) is a growing area of pharmaceutical
marketing activity (Berger et al., 2001). DTCA is defined as “any promotional
effort by a pharmaceutical company to present prescription drug information to
the general public through the lay media” such as popular magazines and
television (Bradley and Zito, 1997, p. 86). The FDA further states that direct-toconsumer advertisements are “published in magazines and newspapers that are
distributed to a general audience rather than to healthcare providers such as
doctors, nurses, and pharmacists [and] can also be broadcast through television
or

radio”

(FDA

web

site:

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdverti
sing/ucm072025.htm. Retrieved: August 22, 2010). Currently, DTCA is only
permitted in the United States and New Zealand (Conrad and Leiter, 2008). In
the United States, DTCA is unique because prescription pharmaceutical products
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cannot be purchased without a physician's prescription and DTCA is also
regulated by the FDA (Huh and Langteau, 2007).
In light of increasing direct-to-consumer advertising efforts, it is helpful to
understand several advertising principles involved in the naming, labeling, and
packaging of pharmaceuticals. Drug companies use several criteria for selecting
a brand name. First and foremost, the name of the drug “must be easy to
remember” (Kenagy and Stein, 2001, p. 2036). The name of the drug should
also be easy to spell (Gundersen, 1998). Ideally, the drug name should be one
that physicians and consumers will not confuse with another product. The use of
color in the product packaging may help to differentiate the pharmaceutical
product from other competitors (Kenagy and Stein, 2001). In addition, drug labels
should be easy to read and the name of the drug should be the most prominent
feature (Kenagy and Stein, 2001). Taken together, these key principles constitute
the common practices involved in the naming and marketing of prescription drug
products.

FDA Regulations of DTCA

Between the years of 1906-1980 in the United States, advertising of
prescription medications was restricted to physicians only (Conrad and Leiter,
2008). Specifically, the pharmaceutical industry promoted HT to physicians in
multiple ways. First, the pharmaceutical industry purchased advertising space in
medical journals. Although prescription drug advertising is not a new
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phenomenon with the medical community, advertisements in medical journals
functioned as a way to introduce HT to physicians. Advertisements for HT, which
were placed in these journals specifically to influence doctors and their
prescribing patterns, contain “concepts and ideas that are prevalent across the
history of medical journals ads” (Richter, 2002, p. 16). For instance, advertising
messages in medical journals portrayed menopause as an illness and reinforced
the authority and patriarchal role of physicians (Richter, 2002).
In addition, the ads also reinforced the prescribing of estrogen products to
midlife and older women. In particular, ads for HT emphasized the physician’s
ability to help women (Watkins, 2007). For instance, ads showed images of both
distraught women and cheerful women signifying before medication and after
medication (Watkins, 2007). Furthermore, these portraits contributed to the
negative images of midlife and older women in American society (Whittaker,
1998).
Moreover, HT advertisements in medical journals expanded from focusing
on short-term “symptoms” of menopause to include indications for long-term use.
By promoting HT for the prevention of the “long-term ravages of aging,”
pharmaceutical companies tapped into the potentially enormous market of older
women in America (Watkins, 2007, p. 54). In fact, some advertisements in
medical journals approached the length of journal articles, including four-page
spreads offering references and results of clinical studies to help make the case
for the efficacy of HT (Watkins, 2007).
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Forging alliances with physicians in preventing diseases was another
strategy employed by pharmaceutical companies to create a potential captive
market. In particular, Dukes (1997) states “osteoporosis was clearly a central
target if the physicians were to be won” (p. 185). Therefore, pharmaceutical
company-funded patient booklets were produced and distributed to physicians.
These patient booklets and leaflets emphasized the benefits of HT, such as relief
from hot flashes, night sweats, and the reversal of bone loss, and were readily
available to women in waiting rooms at doctors’ offices. As a result, HT was
constructed by the pharmaceutical industry as a “preventive measure” for
osteoporosis (Worcester and Whatley, 1992). In fact, Moynihan and Cassels
(2005) refer to this alliance between parts of the medical profession and
pharmaceutical companies as the “menopause industry” (p. 48).
The promotion of drugs to physicians has been “one of the reasons for the
success” of HT (Katz, 2004, p. 931). Existing research has elucidated how
pharmaceutical companies embarked on a crusade through an array of
marketing techniques to promote HT to physicians. Through several strategies,
the pharmaceutical companies effectively promoted HT as a “blanket therapy for
all women” (Dukes, 1997, p. 185). Strategies used by the pharmaceutical
industry to shape medical opinion included purchasing advertisement space in
medical journals, forging alliances with physicians in preventing osteoporosis,
and producing patient information booklets to be distributed to women in waiting
rooms. Indeed, the pharmaceutical industry’s campaign to convey messages to
physicians in order to expand the market for HT has been strategic and
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calculated. From these advertisements, physicians received the message that
unflattering and undesirable “symptoms” of menopause, as well as aging in
general, were treatable by HT.

DTCA and Print Media

In the 1980s, pharmaceutical companies started expanding DTCA to the
general public in magazines and newspapers. The dramatic growth in DTCA can
be traced to 1985 when the FDA lifted restrictions on advertisements of
prescription medications aimed at consumers. In 1985, the FDA determined that
existing regulations in place for advertisements to physicians were sufficient to
cover print advertisements aimed at consumers (Perri, Shinde, & Banavali,
1999). As a result, the FDA permitted the pharmaceutical industry “sufficient
latitude to allow a broader engagement with print ads for prescription drugs”
(Conrad and Leiter, 2008, p. 834). Since then, the growth of DTCA of prescription
drugs has “grown exponentially” (Cline and Young, 2004, p. 132).
In addition to strategies used by pharmaceutical companies to shape medical
opinion about HT, the drug industry also employed a number of DTCA tactics to
shape public opinion. These DTCA strategies included consumer awareness
campaigns designed to “build a collective consciousness regarding estrogen
therapy for menopausal and postmenopausal women” (Palmlund, 1997, p. 159).
As a result, a new brand of DTCA was witnessed in the form of consumer
awareness education programs. Frequently, newspaper ads failed to mention
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that drug companies were funding the campaigns (Moynihan and Cassels, 2005).
The hidden company sponsorship of such consumer awareness campaigns has
been criticized as “marketing masquerading as education” (Moynihan and
Cassels, 2005, p. 55). Nonetheless, “consumer education” efforts saturated
advertisements in newspapers and popular magazines informing women that
they should demand their doctors prescribe HT for menopausal symptoms
(Cimons, 2008).
Whittaker (1998) also conducted an analysis of HT advertisements in
magazines and found that information in popular magazines relied heavily on the
importance of doctors prescribing HT for the woes of menopause and aging.
Interestingly, Whittaker (1998) found that women in the HT advertisements were
generally portrayed with “naked or near naked bodies that were in most
instances impossibly youthful for the age group they were representing” (p. 78).
Moreover, the images implied that women taking HT would “not succumb to
exhaustion, diminution, deficiency or decay” as a result of menopause
(Whittaker, 1998, p. 80). Thus, traditional definitions and idealized notions of
femininity, youth, and beauty prevailed in the DTCA advertisements for HT. The
advertisements cemented the idea that “menopause is an inevitable but
unnatural and undesirable process” (Richter, 2002, p. 2).
In addition, DTCA in popular women’s magazines conveyed the
“consistent message of the necessity” of hormone therapies (Watkins, 2007, p.
70). Women were advised to seek medical counsel, even if they did not have any
symptoms (Watkins, 2007). Thus, popular information about menopause and HT
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in newspapers and magazine DTCA followed the medical model and echoed
what women were hearing from the medical establishment (Watkins, 2007). This
is troubling given the fact that previous research has reported women cited
popular magazines as a primary source of information they consulted for
information about menopause (Clinkingbeard et al., 1999). Consequently,
advertisements for HT in popular magazines aimed at women perpetuated
messages that menopause was “difficult to come to terms with because [women]
are supposedly physically, sexually and emotionally in decline” (Whittaker, 1998,
p. 80).
The use of high-profile celebrities was another means used by
pharmaceutical companies to promote HT directly to women. Widely recognized
celebrities, such as Lauren Hutton, singer Patti LaBelle, and actress Cheryl Ladd
appeared in magazine advertisements as health advocates on an important
mission to educate the public about menopause and the “medical condition of
estrogen loss” (Moynihan and Cassels, 2005, p. 45). By reinforcing public fears
about menopause and aging, celebrity campaigns promoting the use of HT were
effective in helping to transform the way the general public viewed common
ailments. After all, the goal of these company-funded celebrity campaigns was to
“drive patients into doctors’ offices to seek treatment” (Moynihan and Cassels,
2005, p. 44).
In order to further expand markets for their products, pharmaceutical
companies also created DTCA capitalizing on fear. Another DTCA strategy to
promote HT to women was the promotion of fear and anxiety about “future ill-
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health in healthy individuals” (Mintzes, 2006, p. 0461). For many years, drug
companies actively marketed HT for the prevention of heart disease (Katz, 2003).
As seen with the marketing of HT to physicians to prevent osteoporosis, selling
HT directly to women also linked osteoporosis as a “symptom” of menopause in
such a way to create fear. Specifically, Wyeth-Ayerst advertisements featured
postmenopausal hip fractures and images of older women with severely bent
spines (Worcester and Whatley, 1992).

Furthermore, HT advertisements

encouraged all women over thirty-five years to consider taking hormones for
osteoporosis as a “preventive measure” (Worcester and Whatley, 1992, p. 9).
Thus, defining menopause as a risk for other conditions further illustrated how
pharmaceutical companies were able to target menopausal and postmenopausal
women intentionally with a manufactured idea intended to create a “social
demand” for hormone products (Palmlund, 1997, p. 162).
Consequently, the information women received from DTCA in newspapers
and magazines was biased towards the use of hormones. As a result, women
“learned to view menopause in terms of increased health risks that could be
prevented” with HT (Mintzes, 2006, p. 0462). By redefining the use of HT for
menopause in terms of prevention, osteoporosis became a mechanism for the
pharmaceutical industry to provoke undue anxiety in order to expand their
marketing of HT as a preventive measure (Mintzes, 2006).
A review of the literature helps to establish a picture of how
pharmaceutical companies utilized DTCA to promote HT to women. The selling
of HT directly to women was accomplished through pharmaceutical company-
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based

“consumer

awareness

programs,”

which

largely

consisted

of

advertisements in newspapers and popular magazines informing women to ask
their doctors about HT. Furthermore, the use of celebrity spokespeople helped to
transform the way the general public viewed menopause. Thus, women learned
about the existence of HT and the claims made for the potential benefits,
including its anti-aging effects (Watkins, 2007). In addition, information in popular
magazines depicted negative images of menopause and supported following the
advice of a medical expert. In particular, DTCA in newspapers and magazines
transmitted the notion that menopause was best navigated and “managed” with
guidance of a physician. Through the use of celebrities and advertisements in
print media, the pharmaceutical industry presented women with a positive image
of hormone therapies, made claims for its potential healing effects, and
supported physicians as the experts in “treating” women’s reproductive health
experiences.

Revised DTCA Regulations and Implications

In 1997, the FDA published revised guidelines that had major implications for
direct-to-consumer advertising beyond print ads. Pharmaceutical companies
could now market product-specific prescription medications, allowing both the
name and use of a medication to be mentioned, directly to consumers through
broadcast advertisements on television and radio. Essentially, this policy change
made it easier for pharmaceutical companies to advertise via broadcast media,
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such as television and radio, because it eased the type of risk disclosure needed.
Previously, regulations required drug companies to furnish a summary of the
product label, including all of the risk-related information in a product’s package
labeling, in any promotional materials (Gellad and Lyles, 2007). Under these new
guidelines, the drug companies were no longer required to provide all of the riskrelated information in their promotional materials. The FDA would allow productspecific DTCA if “adequate provision” was provided regarding information on the
manufacturer’s safety and efficacy claims (Gellad and Lyles, 2007). Since this
change in 1997, pharmaceutical companies could now tell consumers where to
find additional information, such as by referring them to an Internet web site or
providing a toll free telephone number.
Consequently, the updated 1997 FDA guidelines led to widespread print and
broadcast DTCA (Conrad and Leiter, 2008). In fact, spending on advertising in
medical journals to physicians decreased while DTCA spending for prescription
drugs increased rapidly (Berger et al., 2001). Since the FDA’s relaxation of its
regulation in 1997, pharmaceutical industry spending on DTCA has more than
tripled reaching $4.2 billion in 2005 for American broadcast DTCA efforts
(Conrad and Leiter, 2008). In 2004, the FDA further announced that print
advertisements no longer had to include full prescribing information thereby
raising important questions about the consistency and completeness of
information contained in DTCA (Hollon, 2005, p. 2030). Ultimately, DTCA has
provided pharmaceutical manufacturers with “a new avenue for increasing the
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rate of diffusion and adoption of new drugs” (Perri, Shinde, & Banavali, 1999, p.
1806).
To further complicate matters surrounding DTCA, the Internet has become
“another direct avenue from pharmaceutical companies to consumers, and one
that is not limited to national boundaries” (Conrad and Leiter, 2008, p. 834). As
researchers have noted, the pharmaceutical industry is in a position to “benefit
commercially from environmental changes such as the Internet” (Fox, Ward, and
O’Rourke, 2006, p. 323). For instance, the Internet may provide access to
individuals and new opportunities for information retrieval, pharmaceutical
marketing, and consumption (Fox, Ward, and O’Rourke, 2006). Indeed, the
Internet has further expanded the potential to reach specific audiences for
pharmaceutical products. According to Khim (2009), web sites are another way
that DTCA can reach consumers. Yet, there are no specific regulations for
Internet marketing in the United States and pharmaceutical web sites are
expected to adhere to the same guidelines set for any DTCA (Woodlock, 2005).
Therefore, the role of direct-to-consumer advertising of pharmaceuticals in a
global information environment warrants further investigation.
To date, no research exists on the representation of menopause and
information content on DTCA pharmaceutical web sites for hormone therapies.
However, a few studies of Internet web sites of pharmaceutical products exist in
the literature. Such examples provide direction for future research exploring
DTCA pharmaceutical web sites for HT.
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In a study examining several antidepressant web sites, Woodlock (2005)
found that depression, anxiety, eating disorders, and low self-esteem, were
classified as “illnesses” and the information on the web sites was based on
biological models with little attention to possible social reasons for the disorders.
Additionally, a vast majority of the images on the antidepressant web sites were
of young to middle aged, white women (Woodlock, 2005). Similarly, another
study of the portrayal of depression on Selective Serotonin Reuptake Inhibitors
(SSRIs) web sites found that the symptoms of depression listed on the
pharmaceutical web sites conveyed that the disorder was likely to be permanent
without treatment (Gawley, 2007). Specifically, the likelihood of depression being
a chronic condition and the danger of leaving any mental disorder untreated were
emphasized in the depression web sites sponsored by pharmaceutical
companies (Gawley, 2007). These two studies demonstrated the ways in which
prescription medications for mental health issues, such as depression, were
being marketed to consumers on the Internet and highlight the need for further
studies to look at how drug companies are marketing their drugs to women
(Woodlock, 2005). As noted, there is a lack of research on the representation of
menopause and information content on DTCA pharmaceutical web sites for
hormone therapies. According to Worcester and Whatley (1992), evaluating and
critiquing the mass marketing of hormones is of great importance.

Summary
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In this chapter, several theoretical perspectives were described, including
biomedical, socio-cultural, and feminist models. Although a biomedical view of
menopause tends to be the dominant discourse found in the scientific literature
and popular media accounts, other models have emerged offering alternatives to
the biomedical model. Yet, the biomedical model persists. Thus, the dominant
biomedical discourse of menopause as a “disease” caused by an estrogen
deficiency has resulted in menopause being largely regarded as a biomedical
breakdown of malfunction in need of medical treatment (Lyons and Griffin, 2003).
Despite the pervasiveness of the biomedical model found in the scientific
literature and popular media accounts, a biomedical approach does not
adequately reflect social and cultural aspects which can have an influence on
women’s complex menopausal experiences.
A review of the existing literature also provided possible explanations for the
rise in popularity of HT. From early proclaimed benefits of protection against
heart disease to the re-introduction of HT for symptoms relief, reasons for
hormone use had many origins. Within this context, a large set of clinical trials
known as the Women's Health Initiative (WHI) began in 1997 to evaluate the
effects of prescribed hormone therapies (HT) on the incidence of heart disease.
In short, the WHI studies were prematurely discontinued, risks to health such as
stroke and breast cancer were found, and proclaimed benefits of hormone use
were not supported (Voda and Ashton, 2006). Yet, the pharmaceutical industry
continues to strategically find ways to re-introduce HT as a viable option. Indeed,
“post-WHI risks to women’s health persist” (Voda and Ashton, 2006, p. 410)
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This chapter also examined regulations of DTCA in the United States and
characterized the pharmaceutical industry’s involvement in DTCA of hormone
therapies to physicians and consumers. A central focus of the existing research
is on how the pharmaceutical industry has promoted HT to physicians through
professional

publications.

Furthermore,

research

has

examined

how

pharmaceutical companies have targeted women directly through DTCA in
newspapers and magazines promoting the widespread use of HT as a universal
remedy for menopause and aging.
Lorence and Churchill (2007) state the growth of direct-to-consumer
marketing of pharmaceuticals in the United States has “spawned the generation
of web sites for consumer information” (p. 551). Despite this, little is known
about DTCA on pharmaceutical web sites for HT. As the Internet presents
pharmaceutical companies with a way to expand their advertising to potential
audiences for their prescription medications, a key concern is the ongoing
“invisible and unregulated attempts to change public perceptions about health
and illness to widen markets for new drugs” (Moynihan et al., 2002, p. 890).
Future research needs to explore online DTCA aiming to stimulate profits from
women’s reproductive experiences. Therefore, this study examined how
menopause was being portrayed on pharmaceutical web site advertisements for
hormone therapies to address this void in the literature. The following set of
research questions helped to address the gaps in the existing literature:
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1. What is the prominent discourse about menopause on the
pharmaceutical web sites? Did it vary across the web sites? If the
biomedical perspective is used in the portrayal of menopause, then
menopause will be presented as a medical event to be medically
managed. Furthermore, “deficiency” will be a common theme if the
biomedical perspective is accepted. If a feminist perspective is
used in the portrayal of menopause, I would expect to see an
alternative discourse that rejects the medical construction of
menopause as requiring medical treatment and supervision by a
health care professional. In addition, I will explore how symptoms
are presented and if the symptoms are the same across the web
sites.
2. How is the Women’s Health Initiative (WHI) framed on the
pharmaceutical web sites? Likewise, I will also examine if evidence
of actual clinical studies, such as the WHI or others, are referenced
on the pharmaceutical web sites.
3. Who is/are the intended target audience(s) of the web sites? To
help determine if the web sites are geared towards a specific
audience, I will examine the language and/or visual cues employed
on the pharmaceutical web sites.
4. Is the information presented differently for various audiences, and if
so, how? (i.e. health professionals, consumers, etc.). For example,
I will investigate if the advertising slogans differ depending on the
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target audience. In addition, I will examine what (if anything) is
absent or lacking on the web sites.
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CHAPTER 3
THEORETICAL FRAMEWORK

Overall, the concept of medicalization has been widely used by social
scientists to examine how processes come to be perceived and treated as
illnesses. Essentially, medicalization is a process that entails the transformation
of human conditions into treatable disorders (Zola, 1991). Thus, the existing
literature has tended to focus on “how diagnostic categories emerge, evolve, and
are phenomenologically experienced in particular health contexts” (Timmermans
and Haas, 2008, p. 663). Notable examples of medicalization described by
sociologists include hyperactivity in children (Conrad, 1975), aging and disability
(Zola, 1991), pregnancy (Oakley, 1984; Riessman, 1983), and menopause
(McCrea, 1983). Next, I describe the process of medicalization and take a closer
look at the specific social contexts in which the different dimensions of
medicalization arise.

Medicalization

Conrad (2007) defines medicalization as the process by which nonmedical problems are defined and treated as medical problems. For Conrad, the
“key to medicalization is definition” (2007, p. 5). In particular, medicalization
occurs “when human problems or experiences become defined as medical
problems, usually in terms of illnesses, diseases, or syndromes” (Conrad and
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Barker, 2010, in press). Hence, the process of medicalization includes defining a
problem in medical terms, adopting a medical framework, and treating a problem
with medical interventions (Conrad, 2007).
Originally, the concept of medicalization was associated with the notion of
professional dominance (Freidson, 1970). Early sociological studies focused on
the creation of “new medical categories with the subsequent expansion of
medical jurisdiction” (Conrad, 2007, p. 8). In this context, the power and authority
of the medical profession was “evident in the medicalization” of hyperactivity in
children and childbirth (Conrad, 2007, p. 9). In addition, “deviant” behaviors, such
excessive alcohol consumption and homosexual behavior, also came to be
regarded and treated as medical conditions (Conrad and Schneider, 1992). As
noted by Zola (1991), several natural processes, including aging, have also been
transformed into diseases. As such, the increasing trend of medicalization of
natural processes and “deviant” behaviors were linked to the growing authority of
the medical profession. Beginning with the extension of medicine’s jurisdiction,
medicalization was viewed as a process whereby natural occurrences in
everyday life came “under medical domination, influence, and supervision” (Zola,
1983, p. 295).
Conrad and Schneider (1980) further suggest that there are three levels to
medicalization. First, the conceptual level entails the use of medical language to
define a problem. Second, the institutional level consists of medical collaboration
with authorities to gain legitimacy over management of the problem. The third
level consists of the interaction between physicians and the patient where the
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problem is defined and managed with medical treatments (Conrad and
Schneider, 1980). Thus, these various levels of medicalization illustrate how the
medical profession has been able to assert social control over natural processes
and “deviant” behaviors.
As noted, early formulations of the concept of medicalization considered
the extension of medicine’s jurisdiction over “normal” life events as the major
catalyst driving this phenomenon. However, Conrad (2007) elaborated and
identified three emerging forces also contributing to medicalization. These forces
are the pharmaceutical industry, consumers, and managed care. Thus, several
new forces are seen as providing momentum for further medicalization.
Specifically, the rise of pharmaceutical advertisements “marketing diseases and
then promoting drugs to treat those diseases” is now common practice (Conrad,
2007, p. 135). Given these changes in the health care landscape, Conrad argues
that the physicians’ role in medicalization in decreasing while the role of
pharmaceutical companies is increasing (Conrad, 2007). As Conrad states,
“while physicians are still the gatekeepers for many drugs, the pharmaceutical
companies have become a major player in medicalization” (Conrad, 2007, p.
134). As Riessman notes, this process has had “far-reaching consequences” for
women (1983, p. 3). As a result, the process of medicalization has transformed
several reproductive experiences, such as childbirth and menopause, into
medical-technical problems necessitating medical intervention.

Medicalization of Women’s Reproductive Experiences
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According to Riessman (1983), a “plethora of female conditions” have
been re-conceptualized as illnesses (p. 9). In fact, research on medicalization
has shown that women’s issues have been disproportionately medicalized
(Conrad, 2007; Lorber, 1997; Riessman, 1983; Riska, 2003). For example,
childbirth has been medicalized (Barker, 1998; Brubaker and Dillaway, 2009;
Riessman, 1983). With childbirth, there has been an increase in the use of
medical technology (Williams and Umberson, 1999). As such, women are
admitted as patients to a hospital and hooked up to monitors (Riessman, 1983).
As a result, one consequence is the expectation of women to be under medical
supervision during childbirth and to relinquish some control over the childbirth
process.
Furthermore, menstruation has also been medicalized (Chrisler and Levy,
1990). Negative consequences of medicalizing menstruation include that women
are seen as angry, moody, irritable, and irrational during menstruation (Chrisler
and Levy, 1990). Such labels have implications and suggest that women are
unable to fulfill their social roles and obligations. As such, the transformation and
labeling of these natural processes into diseases has severe consequences for
women.
Indeed, childbirth and menstruation are two examples of natural
processes and reproductive experiences that have been medicalized. Through
this widespread medicalization of gendered reproductive experiences, women
have received messages that their bodies are a “burden, particularly during the
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hormonal and physiological changes associated with menstruation, pregnancy,
and menopause” (Whittaker,

1998,

p. 80).

Consequently,

reproductive

experiences among women have been medicalized resulting in the expansion of
medical jurisdiction over women’s bodies.

Medicalization of Menopause

In addition to menstruation and childbirth, menopause has also been
medicalized further illustrating how definitions “of health and illness are socially
constructed” (McCrea, 1983, p. 111). As noted, although menopause is a part of
the natural aging process, it has been socially constructed by clinical
communities and pharmaceutical companies as a pathological and abnormal
“condition” in need of medical intervention (Dillaway, 2005; Ferguson and Parry,
1998; McCrea, 1983; Riessman 1983). This standpoint stems from the
widespread acceptance and adoption of a biomedical model of menopause
which regards menopause as an “estrogen deficiency disease for which estrogen
replacement is the therapy of choice” (Kaufert and Gilbert, 1986, p. 8). Hence, a
biomedical perspective has constructed menopause as a negative event
requiring medical intervention. As Derry (2008) notes, postmenopausal women
“do produce estrogen in their bodies [and] these lower levels of hormone were
assumed to be negligible” (p. 722). Moreover, McCrea (1983) suggests such
medical definitions of menopause as a “deficiency disease” have resulted in
many women to feel morally obligated to accept medical intervention. Thus, all
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midlife and older women are being defined as “hormonally deficient” and in need
of medical intervention (Meyer, 2001, p. 770). As a result, the medicalization of
menopause allows for the “widespread acceptance of hormone use as a primary
prevention strategy” for menopause (Meyer, 2001, p. 779). Furthermore, the
medical label of “hormone deficiency” decreases the status and autonomy of
women while increasing the status and power of the physician (Bell, 1990;
Coney, 1994; Lupton, 1996; McCrea, 1983). In summary, the reproductive aging
experiences of women have been particularly susceptible to medicalization in our
society.

Importance of Framework

The process of medicalization allows for a researcher to recognize and
understand the levels of medicalization operating within the constructions of
menopause in online drug advertisements. Within this study, medicalization
provides a useful framework for understanding the degree to which any process
of medicalization is present in portrayals of menopause on the web sites for
hormone therapies. Conrad (2007) identifies “diagnostic expansion” as one way
in which medicalization can occur (p. 47). Hence, the expansion of established
diagnosis and definitional boundaries to include new problems or new markets
beyond what something was originally designated for provides an opportunity to
investigate how this aspect of medicalization operates (Conrad, 2007).
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Additionally,

Kaufert

and

Gilbert

(1986)

describe

several

tests

for

medicalization that can be used to determine if the process of medicalization is
occurring. One sign is when the decline of estrogen production has become a
central theme. When menopause becomes defined exclusively as an estrogen
deficiency or disease-like requiring medical management, proposed treatment
options for menopause will involve the use of hormone therapies to supplement
or balance this loss of hormones. Another indication is when women are told that
they should depend on a physician to have their menopausal status recognized
and defined, rather than relying on their own judgment (Kaufert and Gilbert,
1986). Taken together, these “tests for medicalization” will be helpful to help
ascertain if the process of medicalization is occurring or advanced across the
DTCA web sites for HT. Furthermore, this theoretical grounding allows for greater
insight and understanding of the wider social processes shaping the
medicalization of menopause, such as the availability of new technologies and
pharmaceutical
medicalization.

products

for

profit

which

provide

further

potential

for
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CHAPTER 4
METHODOLOGY

The primary focus of this qualitative investigation was on how menopause
was portrayed on web sites for hormone therapies sponsored by pharmaceutical
companies. Because of this focus, a qualitative and interpretive approach was
most appropriate. In particular, qualitative content analysis focuses on the
content and contextual meaning of text (Creswell, 2007).

Furthermore, a

qualitative content analysis also emphasizes the interaction among the
researcher and the data to “develop a theory or pattern of meaning” (Creswell,
2007, p. 21). Within this tradition, I employed an interactive and reflexive
approach to data collection and analysis in order to develop a fuller
understanding of the phenomenon under investigation.
By exploring the constructions of menopause in online advertisements for
hormone therapies, I sought to generate rich insight into subjective meanings
that are negotiated and situated both socially and historically. As stated earlier,
exploring the online messages that pharmaceutical companies were conveying
about women and menopause was of particular interest in this study. As a result,
this qualitative investigation contributes to the “critical analysis of social texts”
(Denzin and Lincoln, 1994, p. 101).
Within my review of the existing literature, I identified several key issues that
were relevant for developing an understanding of how menopause is constructed
in online DTC advertisements for hormone therapies. These key issues included:
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understanding how menopause is portrayed on web sites for hormone therapies
sponsored by pharmaceutical companies, identifying intended target audiences
of the web sites, determining whether the information is presented differently for
these various target audiences, and assessing if anything is silent or missing on
the web sites. As such, the core research questions were generated with these
issues in mind to allow for exploration of these key dimensions.
As noted, previous research of DTC advertising on the Internet provided a
useful foundation for this study of web sites for hormone therapies. In particular,
Gawley (2007) examined the medicalization of depression on Selective Serotonin
Reuptake Inhibitors (SSRIs) web sites and found that medicalization had a strong
impact on the portrayal of depression on the web sites. In particular, the
likelihood of depression being a chronic condition and the danger of leaving any
mental disorder untreated were emphasized in the depression web sites
sponsored by pharmaceutical companies. Furthermore, symptoms of depression
listed on the pharmaceutical web sites conveyed that the disorder was likely to
be permanent without treatment (Gawley, 2007). Specifically, the dataset for the
study by Gawley (2007) was comprised of online DTC advertisement web sites
for SSRI antidepressants. Modeled after this study, I used a list of FDA-approved
drug products for treating postmenopausal symptoms and identified relevant web
sites sponsored by pharmaceutical companies for analysis to explore how
menopause was portrayed in the online advertisements.

The Sample
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This study was a cross-sectional observation and the dataset was comprised
of a sample of online DTC advertisement web sites for hormone therapies.
Specifically, the web sites marketed prescription “treatments” for menopause as
a primary focus and acknowledged a sponsorship or affiliation with a
pharmaceutical company. The sampling frame consisted of web sites for
Estrogen and Estrogen-Progestin products approved by the U.S. Food and Drug
Administration (FDA). In particular, the web sites were identified by using a list of
FDA-approved estrogen- and progestin-containing drug products used for
treating postmenopausal symptoms as of January 16, 2008 (see Table 1). Thus,
the sample of English-language web sites were selected because of their wide
circulation on the World Wide Web, accessibility to the researcher, authorship
(i.e. created by a pharmaceutical company), FDA-approved products, and target
audience or audiences. The units of analysis were the printed textual web pages.
In accordance with University policies, I applied for exemption from the Wayne
State University Human Investigation Committee since this study entailed
analyzing data available from publically available web sites and human subjects
were not involved in the research. In June 2009, exemption was granted (see
Appendix B) from the Wayne State University Human Investigation Committee
for this study.
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Table 1: FDA-Approved Estrogen and Estrogen-Progestin Products*
HT Web Site

Date of Last Update on
Web Site

1. Alora (N/A)

1.

N/A

2. Angeliq (http://www.angeliq-us.com)

2.

Not Stated

3. Climara (N/A)

3.

N/A

4. Climara Pro (N/A)

4.

N/A

5. Combipatch (http://www.combipatch.com)

5.

2006

6. Delestrogen (N/A)

6.

N/A

7. Enjuvia (http://www.enjuvia.com)

7.

2008

8. Estraderm (N/A)

8.

N/A

9. Estrasorb (http://www.estrasorb.com)

9.

2008

10. femhrt

10.

Not Stated

11.

Not Stated

12. Prefest (N/A)

12.

N/A

13. Premarin (http://www.premarin.com)

13.

2006

14. PREMPRO (http://www.prempro.com)

14.

2006

15. Vivelle-Dot (N/A)

15.

N/A

(http://www.wcrx.com/products/femhrt)
11. Femring
(http://www.wcrx.com/products/femring)

(Source: FDA, 2008a.)
*Information current as of January 16, 2008.
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The criteria for the online DTC advertisement web sites for hormone therapies
were:

1. FDA-approved Estrogen and Estrogen-Progestin products as of January
2008 (presented in Table 1).
2. The FDA-approved prescription products (mentioned above) must have a
web site.
3. Web sites promoting alternatives for menopause, such as herbs,
supplements, and alternative therapies, were excluded.

In this study, menopause was defined as a natural part of the aging process,
rather than an event that limits women’s psychological or physical capacities
(McCrea, 1983). Furthermore, this study concentrated on advertisements for
hormone therapies for women who reached menopause naturally, as opposed to
those who had surgical menopause (i.e. removal of the ovaries or the uterus).
This study uses the term hormone therapies to refer to when a woman takes
supplements of hormones, such as estrogen alone or estrogen with another
hormone called progesterone (progestin in its synthetic form) (FDA, 2008b). It is
also important to note that these hormone therapies come in many forms and
dosages, including skin patches, vaginal tablets or creams, and prescription pills.
In addition, implants, shots, or vaginal ring inserts are also available (National
Institute on Aging, 2009). Thus, the overall focus of this study was on the directto-consumer online advertisements of various FDA-approved hormone therapies,
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defined as estrogen or estrogen plus progestin products, for menopausal and
postmenopausal women.
Initial data collection took place over a two-week period (July 11-25, 2009).
During this time, each pharmaceutical web site was printed out in its entirety over
the course of one day. I also went back to the web sites in January 2010 to use
the online symptom tools found on four of the pharmaceutical web sites
(ANGELIQ, ENJUVIA, PREMARIN, and PREMPRO) for an experiment, which is
described in Chapter 7. As indicated in Table 1, there were 15 FDA-approved
Estrogen and Estrogen-Progestin products but only eight had web sites active
during this time period and these comprised the study sample (N=8). I began on
the home page (or main page) and systematically followed each link and menu
item. Once printed, the pages were organized by the web site, labeled, and
numbered. For instance, each web page was printed out and labeled using the
following convention: Premarin1, Premarin2, and so forth. Moreover, each web
site was coded from beginning to end in order to develop a fuller understanding
of the overall content of each web site, tone, and key features. In addition, web
sites are constantly evolving and changing. To address this, the URL of each
web site and the date the data was retrieved was noted.
As Gawley (2007) notes, web sites are more than text. Often, web sites
include diagrams, cartoons, and photographs. As such, the full-text of the printed
web pages was analyzed with a focus on the content and contextual meaning of
the text and visual elements. In addition, content analysis involves subjective
judgments. In order to make the study as reproducible and systematic as
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possible, I developed a coding instrument to help characterize the online drug
advertisements.

Analysis Procedures

The advertising of hormone therapies by pharmaceutical companies via web
sites offered rich data for content analysis. For the analysis, I used a qualitative
content analysis approach for data analysis which is an ongoing process
involving continual reflection and asking analytic questions. The analysis was
guided by the core research questions. First, I answered the first research
question concerning the portrayal of menopause on web sites for hormone
therapies. I also examined the framing of the Women’s Health Initiative on the
pharmaceutical web sites. Next, I examined the apparent target audience or
audiences for the web sites. Further, I investigated if and how the information
was presented differently for various target audiences and addressed what, if
anything, was missing or silent on the web sites for hormone therapies.

My data analysis plan consisted of the following steps:

1. Look for broad themes (open coding)
2. Axial coding (recode #1, major categories emerged from data)
3. Relational / selective coding (recode #2, began to establish core
categories)
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4. Pattern analysis (conclusion, developed explanation, used relevant
theories in discussion section and compared with other findings of
similar studies)

When coding, I began by looking at several dimensions of the web sites
for hormone therapies. As I started analyzing, I examined the various features of
the web sites, such as online quizzes to test one’s knowledge, checklists or
guides for patients to talk with their physician, and self-diagnostic tools to assess
menopausal “symptoms.” I also looked at the words, meanings, metaphors, and
color schemes. Furthermore, features such as personal testimonials proved
fruitful for analysis.
The size and positioning of visual elements were also of particular interest,
such as how women were positioned in images (i.e. if the women were active or
passive). If a person was presenting a message, I also looked at the gender,
estimated age, and race of the person delivering the message. In addition, I was
also curious to discover if possible side effects of the hormone therapies were
highlighted and if the Women’s Health Initiative was mentioned. Although these
were some areas that I intended to consider whenever I began my coding and
analysis, I expected to expand the coding sheet and categories as new or
interesting aspects emerged during coding and analysis. Indeed, this was the
case as I added more categories to the coding sheet whenever I analyzed the
images of the characters in the online advertisements for HT. In this way, I
expanded the code sheet (Appendix A) to capture the primary location, primary
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behavior, and attire for the characters being depicted in the online
advertisements to help provide a richer context.

Analytic Approach

The analysis is divided into five chapters which include an overview of the
web site characteristics, textual and visual elements of the web sites, the
portrayal of menopause, and the presentation of benefits and side effects of
hormone therapies (HT). In particular, Chapters 5 and 6 focus on the
characteristics of the direct-to-consumer web sites for HT. In these chapters, I
examine the menu options, slogans, color schemes, and imagery employed on
the web sites for both consumers and health care professionals. Two questions
are explored in these chapters. In particular, I identify two main audiences for the
HT web sites and I also investigate how the online information is presented
differently for these two potential markets.
Chapter 7 explores the portrayal of menopause on the web sites for HT,
examining how menopause was being portrayed in the online advertisements by
analyzing the definitions of menopause, descriptions of menopausal “symptoms,”
and self-diagnosing symptom tools found across the HT web sites in the study
sample. Chapter 8 analyzes the presentation of benefits and side effects of HT.
This chapter also helps to illuminate what was deficient or missing in the online
drug advertisements for HT. Chapter 9 provides a discussion of the results and

56
compares key findings with other findings of similar studies. Finally, Chapter 10
discusses policy implications of my findings and ideas for future research.

57
CHAPTER 5
OVERVIEW OF PHARMACEUTICAL WEB SITES
FOR HORMONE THERAPIES

This chapter provides an overview of the direct-to-consumer (DTC)
pharmaceutical web sites for FDA-approved prescription hormone therapies and
is divided into several sections. First, the names of the various hormone
therapies (HT) and what these product names may symbolize are examined.
Next, the overall layout and organization of the web sites for HT are described to
help elucidate how the information content about the HT products was presented
to web site users. Finally, the chapter concludes with a comparison of menu
options for consumers and health care professionals observed on the web sites
for HT.

Description of HT Products

To provide a foundation for analyzing the HT products in the study sample, I
started by examining the name of the pharmaceutical manufacturer, the type of
the HT product (i.e. tablet, patch, or lotion form), and the brand name of the HT
products. Table 2 shows the name of the pharmaceutical manufacturer for each
of the HT products and the type of HT product in the sample (N=8). As seen in
Table 2, the study sample contained HT products from six different
pharmaceutical manufacturers. Two of the HT products in the sample (femhrt
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and Femring) were manufactured by Warner Chilcott. In addition, two of the HT
products (PREMARIN and PREMPRO) were from Wyeth Pharmaceuticals (now
part of Pfizer Inc.) Out of the four remaining HT products in the sample, one
each was from the following pharmaceutical manufacturers: Bayer HealthCare
Pharmaceuticals
Duramed

(ANGELIQ),

Pharmaceuticals

Novogyne

(ENJUVIA),

Pharmaceuticals
and

Graceway

(CombiPatch),
Pharmaceuticals

(Estrasorb).

Table 2: Description of HT Products
Name of HT Product

Manufacturer

Type of HT Product

ANGELIQ

Bayer HealthCare
Pharmaceuticals

Tablets

CombiPatch

Novogyne Pharmaceuticals

Patch

ENJUVIA

Duramed Pharmaceuticals

Tablets

Estrasorb

Graceway Pharmaceuticals

Lotion

femhrt

Warner Chilcott

Tablets

Femring

Warner Chilcott

Vaginal Ring

PREMARIN

Wyeth Pharmaceuticals
(now part of Pfizer Inc.)

Tablets

PREMPRO

Wyeth Pharmaceuticals
(now part of Pfizer Inc.)

Tablets

Table 2 further shows the type of the HT products in the sample. In most
cases (n=5), the HT product was available in tablet form. The HT products
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available in tablet form included ANGELIQ, ENJUVIA, femhrt, PREMARIN, and
PREMPRO. It should be noted that PREMARIN and PREMPRO were also
available as vaginal creams; however, the PREMARIN and PREMPRO web sites
reflected information about HT product in the tablet form. Therefore, information
about these two HT products in tablet form was included in the analyses.
Additionally, one of the HT products (CombiPatch) was available as a
combination patch containing both estrogen and a progestin. According to the
CombiPatch web site, the product is an alcohol-free patch that “releases both
estrogen and progestin continuously through your skin” (CombiPatch web site:
http://www.combipatch.com. Retrieved: July 13, 2009). The HT product known as
Estrasorb was available as a “topical estrogen delivered in a moisturizing, soybased lotion” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15,
2009). Furthermore, one of the HT products was provided as a vaginal ring. The
Femring web site described the product as “an off-white, soft, flexible vaginal ring
with

a

center

that

contains

an

estrogen”

(Femring

web

site:

http://www.wcrx.com/products/femring. Retrieved: July 17, 2009). As made
evident by the product name Femring, the form of the HT product was sometimes
embedded in the product name. Therefore, next I examined the names of the
various HT products.
As noted in an earlier chapter, there are several advertising principles
involved in the naming, labeling, and marketing of pharmaceutical prescription
products. According to Gundersen (1998), the brand name for a prescription drug
is “owned solely by the manufacturer […and] choice of the brand name is
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motivated by marketing considerations” (p. 678). Considerations that play a role
in a company’s decision include a brand name that is easy to spell and one that
consumers and health care providers will remember (Gundersen, 1998).
Among the HT product names, two brand names were unique in the sense
that the form of the HT product was incorporated directly into the product name.
For example, Femring can be viewed as a combination of “feminine” and “ring,”
or alternatively, “female” and “ring.” Another example was CombiPatch where
the name of the product captured the essence of the product which was a
combination patch containing both estrogen and a progestin. Here, it is likely that
the naming choices of these two HT products reflected a common advertising
technique of selecting a brand name for a drug that is easy to remember (Kenagy
and Stein, 2001).
For other drug names in the sample, interesting word associations were
embedded into the brand names of the HT product. The name ANGELIQ in and
of itself may suggest something being angelic, ethereal, celestial, or saintly. The
name ENJUVIA closely resembled the word rejuvenate and may imply the
possibility to make young again or restore to youthful vigor. Both the brand
names ANGELIQ and ENJUVIA are examples of how HT products may be
marketed by likening them to positive words and their possible associations.
Additionally, the name PREMARIN referred to origin of drug. According to
Vance (2007), the name PREMARIN was “coined from pregnant mare urine,
from which the estrogen complex was isolated” (p. 282). Furthermore, Estrasorb
could be viewed as a play on words suggesting that the HT product works by
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absorbing the estrogen cream into the skin. These are possible interpretations of
the brand names and what they may signify. Although these are interpretations,
an analysis of the brand names has been productive for understanding several
key points.
First, the brand names of the HT products reflected common DTCA
techniques. Two of the HT products, CombiPatch and Femring, incorporated the
form of the product into the name. This technique can help potential consumers
and health care providers to remember the drug name (Kenagy and Stein, 2001,
p. 2036). Additionally, such strategic naming choices for prescription products
may also help distinguish the product so that physicians and consumers will not
confuse

it

with

another

HT

product

on

the

market.

Second, certain words were embedded into the HT product names to evoke
positive associations and feelings about the HT products. In this sense, the
product name of ANGELIQ is an example used to connote particular qualities or
desires, such as suggesting something is angelic. Next, I examined the layout
and organization of the HT web sites to help demonstrate how information about
the HT products was presented to web site users.

Web Site Layout and Organization

To help understand the construction of menopause in online drug
advertisements for HT, an examination of the overall organization of the web
sites in the sample was warranted. Table 3 illustrates the layout of the HT web
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sites. There are many common elements on a web site; such as links, logos, and
textual content. Navigation systems, presented to web site visitors in the form of
menu options and links, are typically found on the left side or across the top of
web sites. As shown in Table 3, all of the web sites in the sample (N=8) provided
links for navigating content on the left side and across the top of the web sites.

Table 3: Layout of HT Web Sites
Name of HT
Product

Navigation
Links on
Left

Navigation
Links
Across Top

Logo in Top
Left Corner

Textual
Content
Centered

ANGELIQ

Yes

Yes

Yes

Yes

CombiPatch

Yes

Yes

Yes

Yes

ENJUVIA

Yes

Yes

Yes

Yes

Estrasorb

Yes

Yes

Yes

Yes

femhrt

Yes

Yes

Yes

Yes

Femring

Yes

Yes

Yes

Yes

PREMARIN

Yes

Yes

Yes

Yes

PREMPRO

Yes

Yes

Yes

Yes

Another common element of web site design includes the positioning of
logos in the upper left corner of web sites. Here again, logos were observed in
the upper left corner on each of the HT web sites (N=8). Furthermore, another
common web site design technique is to center or display the primary textual
content in the middle of the web page as a focal point. In the online

63
advertisements for HT, all of the web sites (N=8) adhered to these conventions.
Within these online advertisements, the placement of logos was in the top left
corner, navigation links were positioned on the left side and across the top, and
main textual content was centered on the web page.
Hence, this analysis is important for illustrating how the layout and
organization of the pharmaceutical web sites provided a structure to help guide
web site users through information about the HT products. These basic web site
design techniques offered a consistent way for the pharmaceutical companies to
present information about their HT products to potential markets. Next, I take a
closer look at the information content found across web site portals designed
specifically for two potential markets: consumers and health care providers.

Consumer and Health Care Provider Portals

In this study, all of the web sites for HT (N=8) provided information about
their products to two discernable yet distinct audiences, consumers and health
care providers. In fact, specific sections of the web sites were clearly labeled for
each intended audience. Specifically, Table 4 illustrates how the various web site
portals for health care providers were labeled. A total number of 608 printed
pages of web site content were analyzed in this study from the eight HT web
sites (N=8). As illustrated in Table 4, 134 of printed pages were geared towards
health care providers. In comparison, there were 474 of printed pages of web site
content for consumers demonstrating the amount of information aimed at
consumers.
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Table 4: Label for Section of Web Site and Number of Printed Pages of Web Site
Content for Health Care Providers

Name of HT Product

Label for Health Care
Provider Portal

Number of Printed
Pages of Web Site
Content for Health
Care Providers

ANGELIQ

Physician Information

1

CombiPatch

For Health Care
Professionals

37

ENJUVIA

Healthcare Professionals
Click Here

43

Estrasorb

Healthcare Professionals

11

femhrt

Full U.S. Prescribing
Information

1

Femring

Full U.S. Prescribing
Information

1

PREMARIN

Health Care Professionals’
Info

20

PREMPRO

Health Care Professionals’
Info

20

As shown in Table 4, five of the HT web sites (n=5) provided information
for health care providers in a section of the web site labeled with the words
“health care professionals.” Two of the HT web sites (femhrt and Femring) simply
provided “Full U.S. Prescribing Information” for health care professionals. In one
instance, the ANGELIQ web site used the label “physician information.”
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Interestingly, the ENJUVIA web site provided information for pharmacists in
addition to physicians. By including information aimed at pharmacists,
pharmaceutical manufacturers were able to extend their reach to other health
providers

thereby

widening

their

potential

market

for

their

products.

Nevertheless, a web site visitor was transported to an entirely different set of
content on all of the HT web sites (N=8) by selecting one of the web site portal
options intended for health care professionals. Next, a comparison of the type of
menu options provided for consumers and health care providers is discussed.

Menu Options for Consumers

Menu options were important indicators of how information about the HT
products was presented to web site visitors. In this section, I examine the type
and amount of menu options available on the web sites for consumers, which
were presumably female consumers. Table 5 shows the number of menu options
for consumers provided on each of the HT web sites. As shown in Table 5, the
number of menu items provided across all of the web sites for consumers totals
134. The number of menu items ranged from five menu items provided on the
femhrt web site to 24 menu items for consumers on the ANGELIQ web site.
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Table 5: The Number of Menu Options for Consumers
HT Web Site

Number of Menu Options for
Consumers

ANGELIQ

24

CombiPatch

22

ENJUVIA

22

Estrasorb

8

femhrt

5

Femring

8

PREMARIN

23

PREMPRO

22

Total

134

A variety of menu options were presented to consumers across the HT
web sites. Table 6 details the menu options observed for consumers across all of
the HT web sites in the sample. In every instance, information for consumers
about the HT product was located under a menu option entitled “About” followed
by name of the particular HT product (N=8). For example, information about
ANGELIQ was observed under the menu option entitled “About ANGELIQ” on
the HT web site (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July
13, 2009). Likewise, this trend was observed in another example in which web
site visitors could learn more about CombiPatch by following the link titled “About
CombiPatch” (CombiPatch web site: http://www.combipatch.com. Retrieved: July
13, 2009).
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Table 6: Menu Options for Consumers
HT Web Site

Menu Options for Consumers

ANGELIQ

About ANGELIQ
• The Difference in DRSP (DRSP
refers to drospirenone, a
synthetic progesterone and a
spironolactone analog)
• Is ANGELIQ Right for me?
• How do I Get ANGELIQ?
• Discussion Guides for Talking
with Your Health Care
Professional
Using ANGELIQ
• What to Expect
About Menopause
• Understanding Your Symptoms
• Treatment Options
• Healthy Lifestyle Changes
• Assess Your Symptoms
About Hormone Therapy
• Hormone Therapy in the News
FAQ
Tools
• Quiz How Much Do You Know
About Menopause
• Guide for Talking with Your
Health Care Provider
• Assess Your Symptoms
Patient Information
Safety Information
Refer a Friend
Contact Us
ANGELIQ Press Room

CombiPatch

New to CombiPatch?
Already Using CombiPatch?
About Menopause
• Menopausal Symptoms
• Natural vs. Surgical Menopause
• Menopause FAQs
• Menopause Resources
Living with Menopause
• Eating Right
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• Keeping Fit
• Sex After Menopause
About Hormone Therapy
• Risks/Benefits of Hormone
Therapy
• Myths About Hormone Therapy
About CombiPatch
• How It Works
• How to Use It
• Risks/Benefits of Using
CombiPatch
• Talking to Your Doctor
• CombiPatch FAQs
• Cyclic Therapy FAQs
Contact Us
ENJUVIA

A Stage of Life Called Menopause
• Surgical Menopause
• Natural Menopause
About ENJUVIA
• ENJUVIA Is Demonstrated to
Help
• Taking ENJUVIA
• Safety and Tolerability
• Frequently Asked Questions
Advice for Coping With Menopause
• Little Steps that Can Make a Big
Difference
• Tip of the Month
• Tips for Talking with Your
Healthcare Professional About
Menopause and Hormone
Therapy
Resources
• Glossary
• Assessing Your Symptoms: The
Menopause Impact Tool
• Mystified About Menopause?
Want to Talk About It?
• Related Web Sites
• ENJUVIA Coupon
Prescribing Information
Important Safety Information
Contact Us
Assess Your Symptoms
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Free Coupon for ENJUVIA
Estrasorb

About Estrasorb
How to use Estrasorb
About Menopause
Estrasorb Experiences
FAQ
Important Safety Information
Contact Us
Women’s Health Resources

femhrt

About FEMHRT
What is Menopause?
What Are the Recent Concerns
Regarding HRT?
Important Safety Information
Patient Product Information

Femring

About Femring
About Menopause
Hormone Therapy News
Important Safety Information
Femring Reminder Program
FAQ
Inserting Instructions
Patient Acceptability

PREMARIN

Understanding Menopause
• What is Menopause?
• What to Expect During
Menopause
• Common Symptoms of
Menopause
• Menopausal Symptom Assessor
About PREMARIN
• What is PREMARIN?
• Benefits of PREMARIN
• Dosing and Time on Therapy
• Side Effects and Safety
Wellness Plan
• Seeing Your Health Care
Professional During Menopause
• Taking Care of Yourself
Women’s Stories
• Connie
• Jeanne
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• Mary
• Maureen
• Rochelle
Prescribing Information
Important Safety Information
Tell a Friend
Contact Us
PREMPRO

Understanding Menopause
• What is Menopause?
• What to Expect During
Menopause
• Common Symptoms of
Menopause
• Menopausal Symptom Assessor
About PREMPRO
• What is PREMPRO?
• Benefits of PREMPRO
• Dosing and Time on Therapy
• Side Effects and Safety
Wellness Plan
• Seeing Your Health Care
Professional During Menopause
• Taking Care of Yourself
Women’s Stories
• Carol
• Debbie
• Penny
• Carolyn
Important Safety Information
Tell a Friend
New Packaging
Contact Us

Further analysis regarding the breakdown of broad categories for the menu
options for consumers is displayed in Table 7. In the online advertisements, all of
the HT web sites (N=8) provided information about menopause for consumers.
On four of the HT web sites, the menu option was labeled “About Menopause.”
These four web sites included ANGELIQ, CombiPatch, Estrasorb, and Femring.
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In addition, three of the HT web sites (femhrt, PREMARIN, and PREMPRO)
highlighted information about menopause under the menu option entitled “What
is Menopause.” Another example was found on the ENJUVIA web site and the
menu option was called “a Stage of Life Called Menopause.” Thus, all of the HT
web sites furnished information about menopause for web site visitors. Common
information under this menu option across all of the HT web sites (N=8) included
a definition of menopause and information about menopausal symptoms.
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Table 7: Breakdown of Categories of Menu Options for Consumers
Menu Option

Number of HT Web Sites
with Menu Option

HT Web Site

About [HT Product]

8

ANGELIQ, CombiPatch,
ENJUVIA, Estrasorb,
femhrt, Femring,
PREMARIN, PREMPRO

About Menopause

8

ANGELIQ, CombiPatch,
ENJUVIA, Estrasorb,
femhrt, Femring,
PREMARIN, PREMPRO

Advice for Talking with
Health Care Provider

5

ANGELIQ, CombiPatch,
ENJUVIA, PREMARIN,
PREMPRO

FAQs

4

ANGELIQ, CombiPatch,
Estrasorb, Femring

Women’s Stories

3

Estrasorb, PREMARIN,
PREMPRO

Refer a Friend

3

ANGELIQ, PREMARIN,
PREMPRO

Coupon

2

ANGELIQ, ENJUVIA

Glossary of Terms

1

ENJUVIA

Moreover, five of the HT web sites in the sample provided advice to
consumers for talking with their health care providers. These five web sites
included ANGELIQ, CombiPatch, ENJUVIA, PREMARIN, and PREMPRO.
Consumers could access the “Guide for Talking with Your Health Care Provider”
on the ANGELIQ web site (ANGELIQ web site: http://www.angeliq-us.com.
Retrieved: July 13, 2009). In addition, CombiPatch provided information for
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“Talking with Your Doctor” (CombiPatch web site: http://www.combipatch.com.
Retrieved: July 13, 2009). Visitors to the ENJUVIA web site could learn “Tips for
Talking with Your Healthcare Professional about Menopause and Hormone
Therapy” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009).
According to the ENJUVIA web site, consumers may “find that this simple form
will make it easier to talk with your healthcare professional [so] simply complete
the form, print it, and take it with you to your next appointment” (ENJUVIA web
site: http://www.enjuvia.com. Retrieved: July 14, 2009). Advice for what to expect
during your first visit with your health care professional was provided on both the
PREMARIN and PREMPRO web sites under the menu choices entitled “Seeing
your Health Care Professional during Menopause.”
On all five of the web sites that offered guidance to consumers, a list of
recommended questions that consumers could ask their health care provider was
presented. In these questions, consumers were first and foremost encouraged to
ask their health care provider about HT treatment options. Undeniably, the
positioning of this question implied the importance of inquiring about HT.
Interestingly, two of the web sites (ANGELIQ and CombiPatch) suggested that
consumers may also want to ask about non-medical options, such as diet
modifications for reducing symptoms. However, this question was positioned at
the very end of the recommended list of questions for consumers to ask their
health care provider. Obviously, by positioning non-medical options as last on the
list of questions to ask, the implication was that non-medical options were not as
important. In addition, the ENJUVIA web site told consumers to “talk with your
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health care professional before you begin any new exercise plan or diet”
(ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). In this
case, non-medical options were being referred to a health care provider for
medical supervision and guidance. As a result, the ENJUVIA web site implied
that all options, HT and non-medical options, should be discussed, approved,
and even supervised by a health care professional.
Also under the guise of providing “advice,” consumers were reminded to
see their physician on a regular basis and to obtain more medical tests.
Mammograms and bone density tests were examples of recommended medical
tests (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009).
Thus, the advice to consumers emphasized that continued medical monitoring
was important for staying healthy. The PREMARIN web site informed consumers
that “achieving the best possible health during menopause means seeing your
health care professional on a regular basis during this time of transition”
(PREMARIN web site: http://www.premarin.com. Retrieved: July 17, 2009). In
this statement, the role of the health care provider was linked to achieving
positive health outcomes thereby encouraging consumers to consult medical
treatment. Consumers were also told on the ENJUVIA web site that talking with
a health care professional was important because it “could lead to a more
accurate

assessment

of

your

symptoms”

(ENJUVIA

web

site:

http://www.enjuvia.com. Retrieved: July 14, 2009). As a result, the so-called
“advice” furnished to consumers on the pharmaceutical web sites privileged
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medical authority and the physician’s role in providing a diagnosis was
reinforced.
In comparison, physicians were also provided with information about
talking with patients. Yet here, information provided to health care professionals
for talking with their patients emphasized their medical expertise and authority in
“combating” misinformation about HT. One example was found on the
CombiPatch web site in which health care providers were told that consumers
will

“look

to

you

for

guidance”

(CombiPatch

web

site:

http://www.combipatch.com. Retrieved: July 13, 2009). Specifically, health care
providers were told they may need to help “combat the many misconceptions
about HT” (CombiPatch web site: http://www.combipatch.com. Retrieved: July
13, 2009). To help combat this confusion, the drug manufacturers supplied
information for health care providers in case they were asked to provide a
clarification for their patients.
Continuing with my analysis of the menu options for consumers, four of the
HT web sites provided Frequently Asked Questions (FAQs). These four web
sites were ANGELIQ, CombiPatch, Estrasorb, and Femring. In addition,
“Women’s Stories” were also observed as a menu option on three of the HT web
sites (Estrasorb, PREMARIN, and PREMPRO), which will be explored further in
Chapter 7. Also, three web sites (ANGELIQ, PREMARIN, and PREMPRO) had
a menu option where consumers could “Tell a friend” about the HT product. In
these three instances, web site visitors could type in the email address of a
“friend” and send them information about the HT product. Interestingly, this email

76
“Tell a Friend” option capitalized on technology to further disseminate information
about HT products to potential consumers.
In the menu options for consumers, coupons and a glossary were also
observed. Specifically, two of the HT web sites offered a coupon. A coupon found
on the ANGELIQ web site informed consumers that they could “save up to $50
on

your

first

3

prescriptions

of

ANGELIQ”

(ANGELIQ

web

site:

http://www.angeliq-us.com. Retrieved: July 13, 2009). Another coupon on the
ENJUVIA web site could be printed out “to receive 30 tablets of ENJUVIA –
Free!” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009).
Upon further scrutiny of the coupon, it stated ”once your healthcare professional
attaches this coupon to a completed, signed prescription form, you can take the
prescription to your pharmacy and receive up to 30 tablets of ENJUVIA at no
charge” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009).
Here again, the importance of the health care provider providing a prescription in
order to receive the “free” tablets was noted. Finally, the ENJUVIA web site
provided an alphabetical glossary of terms for consumers. Some examples of
terms found in the glossary include estrogen, hot flashes, night sweats, and
osteoporosis.
To summarize, the menu items provided for (female) consumers generally fell
into three leading categories: First, an “About” section described the various HT
products. Second, an “About Menopause” menu option identified several
menopausal symptoms for web site users. Next, information was provided to
consumers for talking with their health care provider. Taken together, the top
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menu categories emphasized information about the HT products, information
about menopause, and advice for talking with a physician focused on HT
treatment and the need to consult a health care professional. For comparison, I
examined the type of menu options available on the web sites for health care
providers, which is discussed further in the next section of this chapter.

Menu Options for Health Care Providers

In contrast, the number of menu items on the HT web sites geared
towards health care providers is shown in Table 8. In the online advertisements,
the number of menu options for health care providers totaled 51 menu items. In
particular, two of the HT web sites (Femring and ANGELIQ) provided only one
menu option for health care providers which led to detailed prescribing
instructions. On the other hand, 16 menu options were observed on both the
CombiPatch and ENJUVIA web sites for health care providers.
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Table 8: The Number of Menu Options for Health Care Providers
HT Web Site

Number of Menu Options for Health
Providers

ANGELIQ

1

CombiPatch

16

ENJUVIA

16

Estrasorb

3

femhrt

2

Femring

1

PREMARIN

6

PREMPRO

6

Total

51

As shown next in Table 9, a range of menu options were presented to
health care providers across the HT web sites. In every instance, prescribing
information was provided for health care professionals (N=8). While all of the HT
web sites provided prescribing information for health care providers, important
differences existed between the web sites. For example, four of the HT web sites
provided a menu option about dosage options. The four web sites providing a
menu option for health care providers to learn more about various dosage
strengths were CombiPatch, ENJUVIA, PREMARIN, and PREMPRO. In all four
instances, this menu option led to information about various dosage options and
was accompanied by colorful pictures of the HT products in their various dosage
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strengths. On the PREMARIN web site, a picture of five colored tablets
representing a “range of dosing options” was displayed (PREMARIN web site:
http://www.premarin.com. Retrieved: July 17, 2009). Likewise, a “variety of
dosage strengths for prescribing flexibility” was shown on the ENJUVIA web site
complimented with a picture of five colored tablets (ENJUVIA web site:
http://www.enjuvia.com. Retrieved: July 14, 2009). In addition, a picture of three
colored tablets was observed on the PREMPRO web site (PREMPRO web site:
http://www.prempro.com. Retrieved: July 17, 2009). Another example was
present on the CombiPatch web site. In this case, pictures of two different sized
patches were shown to depict the “two treatment regimens for CombiPatch”
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009).
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Table 9: Menu Options for Health Care Providers
HT Web Site

Menu Options for Health Providers

ANGELIQ

Physician Information

CombiPatch

About CombiPatch
• How It Works
• Why It’s Different
• Dosage and Regimen Options
• Choosing a Treatment Regimen
• Clinical Trial Information
• Transdermal Preference
Talking to Your Patients
• Risks/Benefits of Hormone
Therapy
• Myths about Hormone Therapy
• Women’s Health Initiative
Library
• Online Resources
• CME
• Events
CombiPatch Prescribing Information

ENJUVIA

Enjuvia Home
Discover the ENJUVIA Effect
• Discover the ENJUVIA Effect on
Moderate-to-Severe
Vasomotor Symptoms
• Discover the ENJUVIA Effect on
Moderate-to-Severe Vaginal
Dryness and Pain With Sex
• Low-Dose Efficacy with the
ENJUVIA Effect
• The ENJUVIA Delivery System
• ENJUVIA Dosage Strengths
• ENJUVIA Safety Profile
• Frequently Asked Questions
About ENJUVIA
Resources
Information for Pharmacists
Menopause Impact Tool
Prescribing Information
Important Safety Information
References
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Contact Us
Estrasorb

Symptoms and Therapy
Efficacy
Delivery and Safety

femhrt

Full Prescribing Information
Information for the Patient

Femring

Full Prescribing Information

PREMARIN

Premarin Home
Premarin Family Name
Practice Resources
Patient Materials
Important Safety Information
Prescribing Information

PREMPRO

Prempro Home
Practice Resources
Patient Materials
Important Safety Information
Prescribing Information
New Packaging for Prempro

Further analysis of the categories of menu options provided to health care
professionals across the HT web sites is shown in Table 10. As seen in Table 10,
the most frequently observed menu choice for health care providers was
prescribing instructions. As already noted, this menu option was provided across
all of the HT web sites (N=8). This was followed by a menu option about the
range of dosage options on four of the HT web sites (CombiPatch, ENJUVIA,
PREMARIN, and PREMPRO). Additionally, a menu option leading to information
that health care providers could distribute to their patients was also presented.
The four web sites providing information for patients were CombiPatch, femhrt,
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PREMARIN, and PREMPRO. Interestingly, a health care provider had to register
first for a free account in order to access the patient education materials from the
PREMARIN and PREMPRO web sites. However, information for patients was
available on the CombiPatch and femhrt web sites and health care providers
could easily print out the information from these two web sites and distribute it to
their patients.
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Table 10: Breakdown of Categories of Menu Options
for Health Care Professionals
Menu Option

Number of HT Web Sites
with Menu Option

HT Web Site

Prescribing Information

8

ANGELIQ, CombiPatch,
ENJUVIA, Estrasorb,
femhrt, Femring,
PREMARIN, PREMPRO

Dosage Options

4

CombiPatch, ENJUVIA,
PREMARIN, PREMPRO

Information for Patients

4

How it Works

3

CombiPatch, femhrt,
PREMARIN, PREMPRO
CombiPatch, ENJUVIA,
Estrasorb

Events Calendar

3

CombiPatch,
PREMARIN, PREMPRO

Efficacy

2

ENJUVIA, Estrasorb

CME

1

CombiPatch

To continue with my analysis of the main categories of menu options for
health care providers, next I observed a menu option about how the HT product
worked on three of the web sites (CombiPatch, ENJUVIA, and Estrasorb). For
example, health care providers could select the menu option labeled “How
CombiPatch Works” to learn more about how hormones were delivered to
patients using the product (CombiPatch web site: http://www.combipatch.com.
Retrieved: July 13, 2009). Health care providers could also click on the menu
choice titled “The ENJUVIA Delivery System” and watch an animated video that
shows how ENJUVIA was released (ENJUVIA web site: http://www.enjuvia.com.
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Retrieved: July 14, 2009). Likewise, a menu option entitled “Delivery and Safety”
was provided to health care professionals on the Estrasorb web site (Estrasorb
web site: http://www.estrasorb.com. Retrieved: July 15, 2009).
Next, an event calendar was observed on three of the HT web sites.
These event calendars were designed so that a health care provider could learn
more about upcoming events and stop by a pharmaceutical booth “to learn more
about [their] product portfolio or to speak with a representative” (PREMARIN web
site: http://www.premarin.com. Retrieved: July 17, 2009). Two of the HT web
sites also provided a menu option specifically discussing the efficacy of the HT
product (ENJUVIA and Estrasorb). In fact, the word “efficacy” was used in the
title of the menu option. For instance, health care providers were presented with
a menu option simply entitled “Efficacy” on the Estrasorb web site (Estrasorb web
site: http://www.estrasorb.com. Retrieved: July 15, 2009). Moreover, the menu
option on the ENJUVIA web site was called “low-dose efficacy with ENJUVIA”
(ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009).
Furthermore, the CombiPatch web site was unique in the study sample
because it was the only web site that provided continuing medical education
(CME) opportunities for health care providers. In this case, a list of five online
continuing education resources, “designed to meet the Continuing Medical
Education information needs of health care professionals” was provided
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009).
Interestingly, whenever a web site user would click on one of the online
resources for CME, they were informed “you are now leaving the CombiPatch
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web site and moving to an external web site independently operated and not
managed by Novogyne Pharmaceuticals. Novogyne assumes no responsibility
for the sites” (CombiPatch web site: http://www.combipatch.com. Retrieved: July
13, 2009). All of the five online resources for CME were commercially-produced
and anyone interested in obtain CME credits had to register and create an
account with the company. The inclusion of such resources on the CombiPatch
web site demonstrated that the pharmaceutical company recognized these online
continuing education opportunities might be of particular interest to this target
audience (i.e. health care professionals) visiting information about their HT
product.
In summary, menu options for health care professionals could be grouped
into four main categories. First, a menu option linking to full prescribing
information was observed on all of the HT web sites. Second, the next frequently
observed menu option for health care providers was for the range of available
dosage strengths. In all four instances, colorful pictures of the HT product were
included to help illustrate the range of dosage options. As noted, the language
used in the menu options was biomedical in nature and used easily recognizable
language by the intended audience, such as prescribing information and dosage
and regimen options.

Health care professionals were also supplied with

information that could be distributed to their patients. In the information that
health care provider could supply to patients, the physician’s medical authority
and clinical expertise were reinforced. Hence, a comparison of menu options for
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consumers and health care providers illustrated how information was presented
to targeted web site audiences for the HT products.

Summary

In this chapter, I presented an analysis of the overall layout and
organization of the web site for HT. My analysis included an examination of the
names of the HT products and I found that brand names either indicated the form
that the product was available or played with word associations, such as
rejuvenation and angelic, to link HT products with certain feelings or desires. In
addition, I observed the presence of two web site portals on the HT web sites for
different audiences. This analysis was valuable because it helped to demonstrate
how information content on the pharmaceutical web sites was being presented to
these two potential markets for HT products. As evident in the creation of distinct
web portals for consumers and health care providers, this enabled the drug
manufacturers to organize and present information to two potential markets for
their products. By also utilizing web portals for distinct audiences and then
labeling these sections for consumers and health care providers, drug companies
were further able to furnish certain types of information tailored for different
audiences.
My analysis also revealed that the menu options presented to consumers
varied from the content provided to health care providers. Leading menu options
for consumers included an “About” menu option describing the HT products (i.e.
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About ANGELIQ), an “About Menopause” menu option, and a menu option
providing information to assist consumers in talking with their health care
provider. Thus, the order of the menu options for consumers created a context
where consumers first learned about a particular HT product, then they learned
about menopause, and next they were given advice for talking with their health
care provider. Within the advice provided on the web sites, consumers were
encouraged to first ask about HT treatment options and were also told that
seeing a health care provider on a regular basis during menopause was
important to a healthy outcome.
On the other hand, health care providers were presented with different
menu options. Of these menu options, prescribing information, the range of
available dosage strengths, and information for patients were prominent.
Correspondingly, the menu options for health care providers utilized biomedical
rhetoric, such as dosage and regimen options, likely because it was familiar to
the target audience. Health care providers were told that patients would look to
them for guidance thereby reinforcing their medical authority and expertise in
helping combat misconceptions about HT that consumers may have. By
presenting information to health care providers that emphasized their medical
authority, and by also providing “advice” for consumers that clearly reinforced the
importance of medical supervision and routine medical tests during menopause,
we begin to see how a biomedical perspective of menopause was being adopted
and articulated on the web sites for HT.
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This chapter provided a foundation for understanding how information
about the HT products was presented differently on the web sites depending on
the target audience. As made evident by the menu options provided to
consumers, information about the HT products, information about menopause,
and advice for talking with a physician were prominent. When taken together, the
menu options for consumers focused on HT treatment and the need for
consumers to consult a health care professional.
In sum, the pharmaceutical web sites introduced consumers to the
importance of consulting with a health care provider about HT treatment options.
In contrast, common menu options for health care providers utilized biomedical
rhetoric, such as dosage and regimen options. Additionally, the information for
physicians to distribute to their patients reinforced their medical authority and
expertise in helping to combat consumer “misconceptions” about HT.
In the next chapter, I delve more into the textual and visual elements
observed on the web sites for HT. In particular, the advertising slogans found on
the web sites are examined. In addition, an analysis of the color schemes and
imagery observed across the HT web sites is presented.
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CHAPTER 6
TEXTUAL AND VISUAL ELEMENTS OF THE
WEB SITES FOR HORMONE THERAPIES

This chapter examines the textual and visual elements present on the
direct-to-consumer (DTC) web sites for hormone therapies. First, the advertising
slogans found on the web sites are analyzed. In particular, a comparison of
advertising slogans aimed at consumers and health care professionals is
presented. Next, an analysis of the color schemes and imagery observed across
the HT web sites is provided. Finally, the chapter concludes with a discussion of
multimedia elements present on several of the HT web sites.

Advertising Slogans

In general, corporations depend on a variety of advertising strategies to
help achieve their marketing success. Pharmaceutical manufacturers of HT
products are no exception and use carefully constructed online advertising
slogans to promote a product and to generate interest in their products. In this
study, advertising slogans are defined as those few words beneath, below, or
beside the HT product name often found in the upper left corner on the web sites.
These slogans appeared in the largest font on the HT web sites and were
separated from the rest of the web site content for easy recognition. Therefore,
their prominent placement on the web sites helped to draw attention to these
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advertising slogans. In fact, these slogans were among the first words a web site
visitor would likely see, following the product name and product logo, and were
some of the most repeated words throughout the HT web sites. This key
placement is in agreement with a key direct-to-consumer advertising principle in
which the brand name of a drug should be the most prominent feature in
advertisements (Kenagy and Stein, 2001).
On seven of the HT web sites in this study (n=7), the main advertising
slogan was repeated on subsequent web pages. Repetition of the advertising
slogans from web page to page helped to unify a drug manufacturer’s message
about its HT product. Hence, advertising slogans can help form an initial
impression for web site visitors and assist with product name recognition. Next, I
examined the advertising slogans aimed at consumers observed on the web
sites for HT.

Advertising Slogans for Consumers

From a sociological perspective, advertising slogans are a useful data
source that can be used to investigate the messages and meanings embedded in
a drug company’s communications. As Table 11 indicates, seven of the HT web
sites (n=7) presented advertising slogans aimed at consumers. Out of the seven
slogans, a number of recurring key phrases or words were observed. In the
online advertisements, the words “discover,” “relief,” and “treat” were repeated
within the slogans.
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Table 11: Advertising Slogans for Consumers on the HT web sites
HT Web Site

Advertising Slogans for Consumers

ANGELIQ

•
•
•
•

Focus on You
Discover the Difference
Ask for ANGELIQ
Relief may be a once-a-day
tablet away

CombiPatch

•

The New Menopause

ENJUVIA

•
•
•

Great Expectations
Discover ENJUVIA
ENJUVIA is Demonstrated to
Help

Estrasorb

•
•
•

Feel Good Again
Treat Yourself
Get Relief

femhrt

N/A

Femring

•

Change Your Menopause Not
Your Life

PREMARIN

•

Treat Your Menopausal
Symptoms

PREMPRO

•

Relief from Hot Flashes, Night
Sweats, and Vaginal Symptoms

In particular, the word “relief” was noted in three of the slogans on the web
sites (ANGELIQ, Estrasorb, and PREMPRO). The ANGELIQ web site proclaimed
“Relief

may

be

a

once-a-day

tablet

away”

(ANGELIQ

web

site:

http://www.angeliq-us.com. Retrieved: July 13, 2009). The slogan suggesting that
“relief may be once a-day tablet away,” introduced the idea that well-being is just
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a pill away and depended on the assumption that potential consumers will desire
the convenience of a daily tablet to treat their “symptoms” all day, every day.
With the possibility that “relief may be once a-day tablet away,” the advertising
slogan further suggested to consumers what can be expected from using their
product. By pairing up the words “relief” and “once a-day tablet” in the same
slogan, the message was clear. The slogan conveyed that medical intervention
would lead to some type of “relief.”
Another example was found on the Estrasorb web site which stated “Get
Relief” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15, 2009).
Visitors to the PREMPRO web site were greeted by the slogan “Relief from Hot
Flashes, Night Sweats, and Vaginal Symptoms” (PREMPRO web site:
http://www.prempro.com. Retrieved: July 17, 2009). Thus, the most frequently
observed word in the slogans aimed at consumers was the word “relief.” Here
again, by pairing up the words “relief” alongside hot flashes, night sweats, and
vaginal symptoms, the slogan conveyed that medical intervention would lead to
“relief” from such symptoms. Moreover, the use of the specific word “relief”
implied that something was unfavorable and was treatable with HT. By proposing
to consumers that they could get “relief” from various symptoms, the language in
the slogans helped to present symptoms as “problematic” and could be medically
managed.
As seen in Table 11, the use of the word “”relief” was followed by the use
of the words “discover” and “treat” in the slogans which were observed two times
each. For example, the ANGELIQ web site stated “Discover the Difference”
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(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). By
encouraging web site visitors to “Discover the Difference,” this slogan provided a
structure for the pharmaceutical company to make a convincing case that there
was a significant difference to be discovered when consumers learned more
about their HT product. Similarly, web site visitors were presented with the
slogan “Discover ENJUVIA” (ENJUVIA web site: http://www.enjuvia.com.
Retrieved: July 14, 2009).
As noted, the word “treat” was also found in several of the advertising
slogans. The slogan on the Estrasorb web site tells consumers to “Treat
Yourself” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15,
2009). Likewise, the slogan “Treat Your Menopausal Symptoms” was found on
the PREMARIN web site (PREMARIN web site: http://www.premarin.com.
Retrieved: July 17, 2009).
Upon further analysis, the advertising slogans also demonstrated how the
use of language could assist pharmaceutical companies in conveying messages
about their products directly to consumers. In particular, the slogans “Treat
yourself,” “Focus on you,” and “Find your comfort zone” caught my attention. In
these instances, the three advertising slogans made a personal appeal by
directly addressing the potential consumer by using the words “you,” “yourself”
and “your” in the advertising slogans.
To summarize, the use of the word “relief” was the most frequently used
word in the advertising slogans aimed at consumers. By proposing to consumers
that they could get “relief” by using HT, the slogans helped to introduce the idea
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to consumers that menopause could be medically managed. Meanwhile, this was
followed by the use of the words “discover” and “treat” in the slogans. All of these
examples clearly illustrated the deliberate use of certain words to help set the
stage for using HT products to get “relief” from problematic menopausal
symptoms. Additionally, I observed the use of the words “you,” “yourself” and
“your” in the advertising slogans which spoke directly to consumers. As made
evident in the slogans across the web sites, the language employed articulated a
biomedical perspective and treatment for menopause. For comparison, I then
investigated the slogans employed on the web sites for HT aimed at health care
providers.

Advertising Slogans for Health Care Providers

Four of the HT web sites (n=4) in the study sample utilized different
advertising slogans when targeting health care providers. As such, each of these
four advertising slogans is discussed in this section of the chapter. Table 12 lists
the advertising slogans aimed at health care providers found on the HT web
sites.
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Table 12: Advertising Slogans for Health Care Providers
on the HT Web Sites
HT Web Site

Advertising Slogans for Health Care
Providers

ANGELIQ

N/A

CombiPatch

N/A

ENJUVIA

•

Have You Discovered the
ENJUVIA Effect?

Estrasorb

•

A Novel, Effective Delivery
System

femhrt

N/A

Femring

N/A

PREMARIN

•

A Blend of Estrogens with
Extensive Evidence to Support
Your Recommendation

PREMPRO

•

More Dosing Options than Any
Other Single-Tablet
Combination Hormone Therapy

As seen in Table 12, the first advertising slogan aimed at health care
providers was observed on the ENJUVIA web site. The slogan “Have You
Discovered the ENJUVIA Effect?” posed a question to health care providers
(ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). Similar to
the advertising slogan used for consumers on the same web site, which simply
stated “Discover ENJUVIA,” this slogan utilized the word “discover” to encourage
health care providers to also learn more about their product.
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A second advertising slogan was found on the Estrasorb web site. The slogan
“A Novel, Effective Delivery System” attempted to distinguish the HT product,
which is a topical estrogen lotion, from other available HT products on the market
(Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15, 2009). In this
case, the advertising slogan emphasized the “novel” delivery system of the
product as being unique and different from its competitors.
The third advertising slogan, “A Blend of Estrogens with Extensive
Evidence to Support Your Recommendation,” was presented to health care
professionals

on

the

PREMARIN

web

site

(PREMARIN

web

site:

http://www.premarin.com. Retrieved: July 17, 2009). In this slogan, the reference
to “evidence” was noticeable. Thus, the advertising slogan assured health care
providers about the scientific merit of the HT product.
Finally, a fourth advertising slogan was found on the PREMPRO web site.
Health care providers were told that PREMPRO provided “More Dosing Options
than Any Other Single-Tablet Combination Hormone Therapy” (PREMPRO web
site: http://www.prempro.com. Retrieved: July 17, 2009). From this slogan it was
evident that a range of dosage options was viewed as an attractive feature to
advertise to health care professionals. Thus, my analysis indicates that the
advertising slogans for health care professionals emphasized “discovering” a
particular product, a “novel” delivery system, evidence of scientific merit, and a
range of available dosage options. Clearly, the advertising slogans for health
care providers relied on medical rhetoric that would be familiar to the target
audience. Correspondingly, the language used in the slogans for health care
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providers mentioned a “novel delivery system,” “more dosing options, and
“scientific evidence to support your recommendation.” In this sense, the slogans
for health care providers conveyed that menopause and symptoms could be
medically managed with their HT products while also reinforcing the physician’s
role in medically managing menopause.
Overall, advertising slogans for consumers and health care providers
appeared in larger font sizes on the HT web sites and attracted attention to
messages about a product’s attributes. My analysis suggests that consumers
were informed about what can be expected from using the HT products from the
repeated use of the words “relief,” “discover,” and “treat” observed in the
advertising slogans. In addition, health care providers were informed about the
range of available “treatment options” and dosage strengths. In other words, the
advertising slogans differed depending on the potential market. Given this, the
advertising slogans illustrated an important distinction between the information
content being presented to health care providers and potential consumers. The
slogans further demonstrated the role of language as an effective means of
introducing the idea that menopause and menopausal symptoms could be
medically managed with HT products. In the next section of the chapter, I take a
closer look at the various color schemes and imagery found on the web sites for
HT products.

Color Schemes
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As noted earlier, the use of color to help differentiate pharmaceutical
products from other competitors is a fundamental DTCA marketing strategy
(Kenagy and Stein, 2001). Importantly, color is an integral part of products,
packaging, and logos and can be an effective means of “creating and sustaining
brand and corporate images in customers’ minds” (Madden, Hewett, and Roth,
1999, p. 90). Colors used on the various HT web sites ranged from purple, pink,
green, blue, to yellow. Table 13 illustrates the colors found across the web sites
for HT in the study sample.
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Table 13: Colors used on the HT Web Sites
HT Web Site

Colors

ANGELIQ

Pink, purple, white

CombiPatch

Yellow, green, blue

ENJUVIA

Green, white, purple

Estrasorb

Purple, white, green

femhrt

Blue, purple, white

Femring

Pink, purple, white

PREMARIN

Blue, white

PREMPRO

Purple, white, green

The most popular color scheme observed on the web sites for HT was the
combination of purple, white, green. Three of the web sites utilized this color
scheme (ENJUVIA, Estrasorb, and PREMPRO). This color combination was
followed by the use of pink, purple, and white on two of the web sites (ANGELIQ
and Femring). However, some differences across the HT web sites existed. One
instance of the combination of yellow, green, and blue was observed
(CombiPatch). Another color scheme was evident on the femhrt web site in which
blue, purple, and white was present. Finally, one instance of the use of blue and
white was found on the PREMARIN web site. Given this, the most popular color
scheme observed on the HT web sites was the combination of purple, white,
green and this was followed by the color combination of pink, purple, and white.
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Notably, seven of the HT web sites utilized the color white. According to
Kress and Van Leeuwen (2002), the color white has long been associated with
the idea of “purity” (p. 348). Additionally, the color white mostly has positive
connotations (Allan, 2009). On the pharmaceutical web sites, the color white was
used heavily as a background color on seven of the web sites. In addition, white
flowers were observed on the PREMPRO and PREMARIN web sites. Since color
can symbolize ideas that help convey meaning, the white flowers assisted in
making an association with purity, cleanliness, and serenity. In these cases, the
color white was tied to particular HT products and assisted consumers in the
interpretation of product attributes. Here, the visual image of the white flowers
made a connection with cleanliness and purity. As also seen in Table 13, six of
the HT web sites used the color purple as a background color. Once again, the
use of certain colors can express or reproduce ideas about femininity (Kress and
Van Leeuwen, 2002). Given the prevalent use of white and purple on the HT web
sites, I speculate that the pharmaceutical companies were making associations
with femininity in order to appeal to potential female consumers.

Organic and Nature Imagery

In the online advertisements for HT, the use of arcs, circles, ribbons, and
rounded edges were observed. Table 14 shows the use of this imagery across
the web sites for HT. Next, I further examine these visual elements.
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Table 14: Imagery used on the HT Web Sites
HT Web Site
ANGELIQ

Imagery
•
•
•

Circles (pink and purple)
Swirly, scrolls that resemble
flowers and stems (pink)
Ribbons (purple)

CombiPatch

•
•

Ribbons (green and blue)
Circles (green and blue)

ENJUVIA

•

Ribbons (green)

Estrasorb

•
•
•
•

Leaves (green)
Ribbons (cream-colored)
Curves (purple)
Flowers (pink)

femhrt

•

Circle (blue)

Femring

•

Flowers (pink)

PREMARIN*

•

Flowers (white)

PREMPRO*

•

Flowers (white)

(* HT web sites also used interactive web site banners)

As Table 14 indicates, the use of ribbons was observed on four of the HT
web sites (ANGELIQ, CombiPatch, ENJUVIA, and Estrasorb). An example of a
curly or wavy green “ribbon” was observed on the ENJUVIA web site. This visual
element was repeated whenever a woman was pictured wearing a green scarf
closely resembling the green ribbon found in the web site banner. In fact, the
green ribbon was reminiscent of a holiday ribbon or decoration on a package.
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These repetitive elements, such as the soft “curves” of the green ribbon and
green scarf, helped to create a visual coherence about the HT product. Hence,
the use of such feminine imagery on the HT web sites, such as the curves and
ribbons, were used as a way to make connections with femininity in order to
appeal to and attract attention of potential female consumers.
Soft “curves” or “ribbons” were also used to underline an advertising
slogan. In particular, one example was observed on the Estrasorb web site,
which is a topical estrogen lotion available by prescription. In this case, a creamcolored “ribbon” (similar to the actual HT product in its white color and cream-like
texture) was used to underscore the advertising slogan for the HT product. To
this end, the curvy ribbon underscoring the Estrasorb advertising slogan “Feel
Good Again” intentionally resembled the actual HT product which is an estrogen
lotion.
Circle shapes were also present on three of the web sites (ANGELIQ,
CombiPatch, and femhrt). For example, CombiPatch web site had a blue circle in
product logo which closely resembled the HT product (i.e. patch). Similarly, the
femhrt and Femring web sites had blue circles incorporated into their logos which
also resembled the shape of the HT product (tablets). In all three cases, the
circles found in the HT product logos were blue in color.
The presence of nature imagery was also observed on several of the HT
web sites. As seen in Table 14, pictures of flowers and leaves were noted.
Flowers were observed on five of the HT web sites. In three instances, the
flowers were pink (ANGELIQ, Estrasorb, and Femring). The use of green leaves
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was noted on the Estrasorb web site. Hence, the use of ribbons was the most
popular image found across the web sites and this was followed by the use of
flowers and circles. Therefore, the ribbons, flowers, and circles in the online
advertisements for HT drew upon traditional symbols of feminine imagery.
Certainly, the use of a particular image in concert with a specific color, such as
the pink flowers or green leaves, was a noticeable pattern in the online
advertisements. As is evident, these were strategic marketing attempts to
“package” information about the HT products in a way that would appeal or
resonate with potential female consumers.

Images of HT Products

In addition, pictures of the various HT products were observed on seven of
the HT web sites (n=7). Table 15 shows which of the web sites provided pictures
of the various HT products. As seen in Table 15, pictures related to the HT
products found on the web sites included images of the actual prescription
tablets or pictures of the packaging for the HT product, such as lotion packets or
the cardboard box.
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Table 15: Web Sites with Pictures of HT Products
HT Web Site

Pictures of HT Product

ANGELIQ

•
•

Tablets (pink)
Packaging (purple and pink box)

CombiPatch

•
•

Patch
Packaging/Box

ENJUVIA

•

Tablets (5 dosage strengths, 5
different colored pills)

Estrasorb

•

Lotion packets

femhrt

N/A

Femring

•

Picture of product (ring)

PREMARIN

•

Tablets (5 dosage strengths, 5
different colored pills)

PREMPRO

•

Tablets (3 dosage strengths, 3
different colored pills)
Packaging/Box

•

As noted, seven web sites had pictures of the actual HT products. Of these
seven, the most popular images were pictures of the tablets. Four of the web
sites for HT presented colorful pictures of the tablets (ANGELIQ, ENJUVIA,
PREMARIN, and PREMPRO). One web site had a picture of the patch
(CombiPatch). Another web site provided a picture of lotion packets (Estrasorb).
In addition, one web site displayed a picture of the ring (Femring). Thus, seven of
the web sites included pictures of the HT products.
In addition, three of the web sites provided pictures of the packaging of the
product (ANGELIQ, CombiPatch, and PREMPRO). Certainly, the product
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packaging is an effective communication tool and the intention behind the
inclusion of such product pictures can be viewed as two-fold. First, featuring
pictures of the HT product may aid in easier consumer identification of the
product. As I witnessed with the three instances from the study sample, the
product packaging clearly displayed the product name and colorful logo.
Secondly, product packaging also plays a crucial role in explaining to consumers
how to use the HT product. With names such as the “EZ Dispenser,” the product
packaging for PREMPRO enables the drug manufacturer to speak to the
consumers directly with claims of how their product is easy to use by simply
pushing the “tablets through the sealed foil to obtain your daily dose” (PREMPRO
web site: http://www.prempro.com. Retrieved: July 17, 2009). Thus, pictures of
various HT products and their packaging found on the web sites achieved
several purposes. Pictures of the actual HT products or their packaging may
assist with easier brand recognition, speak to consumers directly, and also help
to differentiate among the various products on the markets with company logos.
Accordingly, these are direct-to-consumer advertising strategies commonly used
to ensure that a product is easy to remember (Kenagy and Stein, 2001).
Yet, some marked differences across HT web sites were noted. In particular,
only two of the pharmaceutical web sites for HT showed the product being used.
The first instance was found on the Estrasrob web site in which a woman was
shown applying the estrogen cream to her thigh. The second instance was
observed on the Femring web site. In this case, a drawing depicted a woman
demonstrating how to insert the feminine ring. Again, these were the only two
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web sites in the sample that showed the HT products being used. None of the
pharmaceutical web sites in the sample pictured women taking prescription pills.

Portraits of Characters in the Online Advertisements

This study also investigated the representation of female and male
characters in the online advertisements, including depictions of health care
professionals. Table 16 shows the range of the characters found across the web
sites for HT. As seen in Table 16, characters were observed on six of the HT
web sites. Within these six web sites, a total of 25 images of characters were
observed throughout the web sites. These twenty-five images depicted 28
different characters. Therefore, in some instances, there were two characters
present within one image.

107
Table 16: Portrayal of Characters on the HT Web Sites
HT Web
Site

Primary
Setting

Primary
Behavior

ANGELIQ
(Three
images)

1. work
1. work
2. recreational 2. walking
3. residential
3. talking

Appearance (estimated age
range, race, and attire)
1. Middle-aged Caucasian
woman in business attire
(jacket and scarf)
2. Two Middle-aged Caucasian
women in active wear (jogging
suits)
3. Picture of Middle-aged
Caucasian woman in casual
attire, Caucasian man, and a
dog

CombiPatch 1. not known
(Five
2. recreational
images)
3. recreational
4. recreational
5. not known

1. headshot,
looking at
audience
2. walking/hiking
3. yoga/stretches
4. on exercise
bike
5. headshot,
looking at
audience

1. Middle-aged Caucasian
woman in casual attire
(sweater)
2. Middle-aged Caucasian
woman in active wear (shirt,
shorts, and hiking boots)
3. Middle-aged Caucasian
woman in active wear (sweat
shirt and sweat pants)
4. Middle-aged Caucasian
woman in active wear (tank top,
shorts, and sneakers)
5. Middle-aged Caucasian
woman in casual attire (shirt
and vest)

ENJUVIA
(Three
images)

1. work
2. headshot,
looking at
audience
3. sitting in exam
room

1. Middle-aged Caucasian
woman in business attire (suit,
scarf, and brief case)
2. Middle-aged African
American woman in casual
attire (sweater)
3. Middle-aged Caucasian
woman sitting in exam room
with female health care
professional who is middleaged and Caucasian (wearing
a white coat and stethoscope)

1. work
2. not known
3. health care
environment
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Estrasorb
(Three
images)

1. not known
2. not known
3. not known

1. headshot,
looking at
audience
2. headshot,
looking at
audience
3. headshot,
looking at
audience

1. Middle-aged Caucasian
woman in casual attire
(sweater)
2. Middle-aged Caucasian
woman in casual attire
(sweater)
3. Middle-aged African
American woman in casual
attire (sweater)

Femhrt
(no images)

N/A

N/A

N/A

Femring
(no images)

N/A

N/A

N/A

PREMARIN
(Six
images)

1. residential
2. residential
3. residential
4. residential
5. residential
6. residential

1. talking to
audience,
“greeted” web site
visitors
2. headshot,
looking at
audience
3. headshot,
looking at
audience
4. headshot,
looking at
audience
5. headshot,
looking at
audience
6. headshot,
looking at
audience

1. Middle-aged Caucasian
woman in business attire
(jacket and scarf)
2. Middle-aged Caucasian
woman in business attire
(jacket and scarf)
3. Middle-aged African
American woman in business
attire (jacket)
4. Middle-aged Caucasian
woman in casual attire
(sweater)
5. Middle-aged Caucasian
woman in casual attire
(sweater)
6. Middle-aged Caucasian
woman in casual attire
(sweater)

PREMPRO
(Five
images)

1. residential
2. residential
3. residential
4. residential
5. residential

1. talking to
audience,
“greeted” web site
visitors
2. headshot,
looking at
audience
3. headshot,
looking at
audience

1. Middle-aged Caucasian
woman in casual attire
(sweater)
2. Middle-aged Caucasian
woman in casual attire
(sweater)
3. Middle-aged Caucasian
woman in casual attire
(sweater)
4. Middle-aged Caucasian
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4. headshot,
looking at
audience
5. headshot,
looking at
audience

woman in casual attire
(sweater)
5. Middle-aged Caucasian
woman in casual attire
(sweater)

Notably, all of the images depicted smiling people. Researchers have
reported that direct-to-consumer advertisements are likely to be successful
whenever they “establish positive identification with the depicted models” (Cline
and Young, 2004, p. 137). Similarly, Kaufert and Lock (1997) found pictures of
bright, healthy, and beautiful women appearing in pharmaceutical brochures.
Here, the smiling people depicted in the images on the pharmaceutical web sites
helped to develop a positive link between the HT products and happiness.
Furthermore, the smiling people in the pictures could be conceived as adding
their approval of the product.
In my analysis, I also examined the primary setting of the images to help
provide context. As such, I coded the primary setting depicted in the images as
either “work,” “residential,” “recreational,” “health care environment,” or “not
known.” Female characters appeared in a residential space more than any other
setting. Therefore, a domestic or residential space was the most popular setting
and served as the primary setting for 12 of the images. For example, five female
characters were observed on the PREMARIN web site sitting on a couch, looking
at photo albums, and having beverages in coffee mugs (PREMARIN web site:
http://www.premarin.com. Retrieved: July 17, 2009). Although PREMARIN and
PREMPRO are both products of Wyeth Pharmaceuticals, four different female
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characters were observed on the PREMPRO web site sitting around a dining
room table and having beverages in coffee mugs (PREMPRO web site:
http://www.prempro.com. Retrieved: July 17, 2009). Here, the images depicted
women in a social context in which they were shown smiling, interacting, and
socializing. In this way, the images choreographed a “scene” that could be
familiar to potential female consumers. As a result, such images may attract
attention or identification with the people being depicted.
I coded the primary setting as “not known” for six of the images. In these
six cases, the images were headshots and the focus was on the woman’s face.
With the characters’ faces being the focal point of the pictures, these images
contained minimal or no surroundings. Interestingly, these character portraits
showed the woman looking directly out at the web site audience, perhaps in
order to engage with the viewer. In four other instances, the primary setting was
recreational. By and large, a domestic setting the most popular setting for the
images, followed by images grouped into the “not known” category, and then
images in a recreational setting.
As also seen in Table 16, I noted the primary behavior, or activity, of the
characters being depicted in the advertisements. Instances of female characters
looking directly at the web site audiences were observed 15 times in the images.
As stated earlier, these images consisted of “headshots” which focused
exclusively on the women’s faces as they looked directly at web site visitors.
Therefore, the presence of female characters “looking at the web site audience”
was clearly the most popular behavior (or activity) being performed in the
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images. In effect, the female characters on the pharmaceutical web sites were
looking back at our gaze. Goffman (1979) has also noted how magazine
advertisements show women looking back at the viewer.
In four other cases, examples of “physical activity” were observed.
Specifically, two female characters were walking in an image found on the
ANGELIQ web site (ANGELIQ web site: http://www.angeliq-us.com. Retrieved:
July 13, 2009). In addition, a female character was shown performing yoga
stretches

on

the

CombiPatch

web

site

(CombiPatch

web

site:

http://www.combipatch.com. Retrieved: July 13, 2009). Another example was
also present on the CombiPatch web site in which a female character was riding
an exercise bike (CombiPatch web site: http://www.combipatch.com. Retrieved:
July 13, 2009).
My analysis suggests that these depictions are meaningful in terms of the
degree of physical activity being portrayed. As discussed above, the majority of
images showed female characters passively looking out at web site audiences.
Also among the portrayal of female characters, some of the images depicted
women as being active in a very limited fashion. While such lifestyle factors, such
as exercising were depicted, the web sites did not state that these activities could
help to reduce symptoms. Rather, the Femring web site stated “You do not want
to take ‘time out’ to deal with symptoms of menopause… [and] Femring offers a
convenient and discreet approach to estrogen therapy allowing you to get on with
the

things

that

are

really

important”

(Femring

web

site:

http://www.wcrx.com/products/femring. Retrieved: July 17, 2009). Here, women
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were told that they would not have to spend their time worrying about the
symptoms of menopause if they used HT. Another example was found on the
ANGELIQ web site where a woman was shown jogging and yet the web site
stated “HT is one of the most effective options to help manage menopausal
symptoms such as hot flashes, night sweats, vaginal dryness, and potential bone
loss” (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).
One more example was found in which a woman was shown walking in hiking
boots and the statement on the web site said: “CombiPatch is designed to stay
on during activities… [and] you can get back to enjoying an active lifestyle while
wearing

the

patch”

(CombiPatch

web

site:

http://www.combipatch.com.

Retrieved: July 13, 2009). Therefore, as illustrated by these examples, the
underlying premise was that hormones could help to achieve the activity that was
being presented. To be sure, these visual images conveyed health, activity, and
vitality that could be achieved through the use of HT. According to the online
advertisements, the “treated” woman was healthy, active, and happy.
Additionally,

the

appearance

of

the

characters

in

the

online

advertisements, such as their estimated age, race, and attire (or dress), was
included in my analysis. In the online advertisements for HT, 24 of the female
characters were Caucasian, including one picture of a health care provider on the
ENJUVIA web site.

As Coney (1994) states, hormone therapy has been

“predominantly used by white, middle-class women” (p. 224). Therefore, the
depictions of female characters on the pharmaceutical web sites reflected
hormone use patterns reported in the literature. Cortese (2008) further notes that
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target advertising assumes a particular group or groups have money to spend.
Conversely, non-representation suggests the powerless status of groups that do
not “possess significant material or political power” (Cortese, 2008, p. 15). In
comparison, only three of the female characters in the images were African
American (ENJUVIA, Estrasorb, and PREMARIN web sites).
Since the majority of the female characters featured in the online
advertisements were Caucasian women, this closely mirrored the demographic
characteristics of the typical users of hormone therapies. This demographic
pattern is also true of users of the Internet. Research reports that 79% of adult
women use the Internet and 80% of Internet users are Caucasian, highlighting
the fact that some groups lack access to the Internet (Pew Research Center
Internet & American Life Project web site: http://www.pewinternet.org/TrendData/Whos-Online.aspx. Retrieved: September 29, 2010). As a result, the
pharmaceutical web sites were likely trying to appeal to this target audience for
their products.
With regards to the type of attire, 16 of the female characters wore causal
attire such as sweaters. Unique among the sample, women were shown in
business attire in only six of the images. Thus, women were portrayed in a
professional role in limited manner. Images coded with the category of “business
attire” were identified by various symbols such as business suits or brief cases.
For example, one female character was observed on the ENJUVIA web site
wearing a business suit (jacket and pants) and carrying a brief case (ENJUVIA
web site: http://www.enjuvia.com. Retrieved: July 14, 2009). Finally, female
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characters in active wear, such as jogging suits, were found in four of the
images.
Another unique finding was that only one image of a health care
professional was depicted in the online advertisements for HT. As Table 16
shows, a Caucasian female health care provider was depicted on the ENJUVIA
web site (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009).
To this end, the image portrayed the health care provider talking with a patient in
what is presumably an exam room. Not surprisingly, I found that the use of such
iconic imagery, such as the white coat and stethoscope, reflected symbols
commonly associated with the health care environment making the health care
provider easy to identify in the image.
Furthermore, one Caucasian male character was present on the
ANGELIQ web site. In this image, the male character was shown talking with a
female character. In addition, a dog was also present in the picture. This image
was worth noting due to the fact that it was the only image of a male character
observed in the online advertisements for HT.
To briefly summarize, an analysis of the characters appearing in the online
advertisements for HT was conducted. Among the online advertisements for HT,
female characters were portrayed largely as passive and relegated to a
residential space. This pattern persisted with the inclusion of “headshots” in the
images where women were shown passively looking back at web site visitors. All
of the images depicted people smiling. By also depicting women as participating
in recreational activities, the images further presented “healthy” appearing
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people. Since the web sites did not say that lifestyle modifications, such as
exercise, could help alleviate symptoms, the images implied that the activity
being depicted could be achieved through the use of HT. Overall, the online
advertisements for HT positioned women within the domestic or residential realm
while also conveying that health, activity, and vitality could be achieved through
the use of HT.

Multimedia Elements

As discussed above with the portraits of characters in the online
advertisements, pharmaceutical companies may employ visual strategies to
convey messages about their products. For instance, a web site banner allows a
drug manufacturer to customize their web site for their intended audiences. A
traditional web site banner, sometimes referred to as a web site header, is a
graphic commonly found at the top of a web site and displays the company
name, logo, and advertising slogan. Six of the HT web sites (n=6) in the study
sample made use of a traditional web site banner. However, two instances in
which web site banners were further enhanced by audio and animation were
observed. In the online advertisements for HT, web site banners with multimedia
were present on the PREMARIN and PREMPRO web sites (both are products
from Wyeth Pharmaceuticals). With the use of audio and Macromedia flash
animations, these audio-driven web site banner advertisements introduced their
HT products to potential markets by basically functioning as mini-presentations.
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The PREMARIN web site featured a presumably middle-aged Caucasian
woman in a business suit welcoming visitors to the web site with an introduction
that begins “Hi. I am Kathy. Menopause can be a very confusing time for many
women” (PREMARIN web site: http://www.premarin.com. Retrieved: July 17,
2009). The female character “Kathy” goes on to state “I am here to tell you that
you are not alone. I will be your guide and together we will talk about some of the
common

symptoms

of

menopause”

(PREMARIN

web

site:

http://www.premarin.com. Retrieved: July 17, 2009).
Likewise, the PREMPRO web site featured a middle-aged Caucasian
woman named “Joanne” in casual attire greeting web site visitors. The character
“Joanne” greeted web site visitors with the following: “Hi. I am Joanne. We all
experience menopause differently, for some women it can be a confusing time…
but you are not alone. Follow me and together we talk about some of the
common

symptoms

of

menopause”

(PREMPRO

web

site:

http://www.prempro.com. Retrieved: July 17, 2009). The female character
“Joanne” continued with “we are in it together and we will find some of the
answers you may be looking for” (PREMPRO web site: http://www.prempro.com.
Retrieved: July 17, 2009).
As previously noted, both PREMARIN and PREMPRO are products of
Wyeth Pharmaceuticals. In both of these cases, the audio introductions are
accompanied by captions which may be turned off or on at the discretion of the
web site visitor. Nevertheless, both the PREMARIN and PREMPRO web sites
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utilized web site banners enhanced with multimedia to welcome visitors to their
web sites.
In brief, the multimedia banners on the two HT web sites entice
consumers to view much more information than can typically fit into a traditional
banner (without audio or animation). These mini-commercials introduce the idea
to consumers that menopause can be a “difficult time,” whereby reinforcing the
notion that a physician can help navigate this difficult and confusing time. As
such, the mini-commercials served as an introduction articulating a biomedical
conceptualization of menopause as being “problematic.”

In doing so, the

multimedia web site banners helped to advance the idea that menopause should
be medically treated and managed. By harnessing such technologies, the
manufacturer of these two HT products (Wyeth Pharmaceuticals) was further
able to personalize an introduction to their web sites by having a female
character speak directly to web site visitors. In light of this, the multimedia web
site banners provided more information for potential consumers about the HT
products in comparison to the text-only web sites in the sample.

Summary

In this chapter, I was particularly concerned with textual and visual
elements observed on the web sites and how these elements helped to construct
messages about the HT products for potential markets. To address this issue
more fully, I investigated the advertising slogans presented to consumers. For
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consumers, the advertising slogans included the repeated use of the words
“”relief,” “discover,” and “treat” to inform consumers what can be expected from
using the HT products. The ability of the slogans to conceptualize menopause as
needing “relief” effectively introduced consumers to the idea that their HT
products could provide some type of “relief.”
For comparison, I then analyzed the advertising slogans aimed at health
care providers. Slogans for health care providers were crafted with the busy
practitioner in mind and utilized biomedical rhetoric familiar to the target
audience. The promise of flexibility in HT treatment options, such as the range of
available dosing options, and “evidence” of scientific data supporting the use of
the HT product served as “selling points” in the advertising slogans aimed at
health care professionals. Such an analysis contributes to our understanding of
how the information content across the DTCA web sites for HT differed in its
presentation depending on the target audience. Although the slogans differed
depending on the target market for the HT products, the slogans demonstrated
the importance of language used in the advertising slogans in articulating
menopause as medically problematic.
I also examined the color schemes and imagery utilized in the online
advertisements for HT. The use of color was a fundamental advertising technique
to help distinguish HT products from other competitors. Notably, the use of the
colors white and purple on the HT web sites made associations with femininity.
Further, feminine shapes were used on web sites, such as circles, curves, wavy
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lines. Together, the gender specific nature of many of these strategies was an
attempt to attract and appeal to potential female consumers for the HT products.
Pictures of HT products and their packaging were also included on the
web sites to aid in easier consumer identification of the product. Only two web
sites actually pictured the HT product being used. Additionally, I analyzed the
images of characters in the online advertisements. My findings suggest that
female characters were mostly depicted as passive and shown in domestic
settings. Given that the majority of the female characters in the online
advertisements were Caucasian women this mirrored the demographic
characteristics of both the common users of hormone therapies and typical users
of the Internet. Moreover, only one image of a health care provider was
presented as well as one image of a male character.
Certainly, drug manufacturers of hormone therapies (HT) have capitalized
on a range of advertising slogans, color schemes, and imagery to form the
foundation for “selling” their products online directly to consumers and health
care providers. In the next chapter, I take a closer look at how menopause was
portrayed on the web sites for HT. In particular, the nature of the representation
of menopause and the means used to construct this portrayal will be examined.
Features found on web sites for HT, such as online tools for assessing
menopausal symptoms, will also be investigated to help elucidate how
menopause is constructed by drug manufacturers in online advertisements for
HT.
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CHAPTER 7
THE PORTRAYAL OF MENOPAUSE

Direct-to-consumer (DTC) web sites for hormone therapies allow for an
examination of medicalization and pharmaceuticals by raising questions about
the presentation of menopause. In particular, what are the web sites for hormone
therapies representing about menopause? Likewise, how are messages about
menopause constructed? To unravel these questions, this chapter examines how
menopause is portrayed on the DTC web sites for hormone therapies (HT).
First, textual descriptions of menopause found on the web sites for HT
were examined. This examination included how menopause was defined on the
HT web sites with particular attention to the language being used to describe
menopause. Second, I explored the various explanations presented on the HT
web sites for the “causes” of menopause. Next, the variety of menopausal
“symptoms” identified on the HT web sites was analyzed. As I will demonstrate,
when taken together these elements played an important role in how menopause
was being portrayed in the online advertisements for HT.

Description of Menopause

In the online advertisements for HT, three main phrases were used to
describe menopause. Table 17 illustrates how menopause was described on the
various HT web sites. Firstly, menopause was described as a “change of life” on
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four of the HT web sites (CombiPatch, femhrt, Femring, and PREMARIN).
Secondly, menopause was described as “three phases.” These three phases
were perimenopause, menopause, and postmenopause. The description of
menopause as “three phases” was found on three of the HT web sites
(ANGELIQ, PREMARIN, and PREMPRO). Meanwhile, the ENJUVIA web site
referred to menopause as a “stage of life.”

Table 17: Description of Menopause on HT Web Sites
Name of HT Product
ANGELIQ

Description of Menopause
The end of regular
menstruation, can be
explained in three phases

Key Phrases/Words
Three phases

CombiPatch

Change of life, reproductive
system slowly shuts down

Change of life

ENJUVIA

Stage of life, a change that all
women eventually experience

Stage of Life

Estrasorb

Period has stopped for one
year

Period has stopped

femhrt

Change of life, sooner or later
all women go through it

Change of life

Femring

Change of life, your body is
adjusting to lower levels of
hormones

Change of life

PREMARIN

Change of life, a transition in
three stages

Change of life, three
stages

PREMPRO

Transition in three stages

Three stages
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As noted, my analysis found that menopause was described on four of the
HT web sites (CombiPatch, femhrt, Femring, and PREMARIN) as a “change of
life.” However, the language used on the HT web sites clearly indicated that this
“change of life” was not a welcomed or positive one. For example, the
CombiPatch web site proclaimed to consumers that “you don't have to suffer
through moderate to severe flashes and night sweats. You have options”
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009). In
this example, there were several important messages implied. First, women were
introduced to the idea that they did not have to “suffer” from menopause.
Second, women were told that they did not have to needlessly suffer because
there were medical treatment options available. As evident in the language used
in this example from the CombiPatch web site, menopause was introduced to
consumers as problematic. According to the CombiPatch web site, women could
learn

to

“adjust

to

http://www.combipatch.com.

this

change”

Retrieved:

July

(CombiPatch
13,

2009).

web

Undeniably,

site:
this

“adjustment” involved the use of hormone therapies. As Derry (2008) notes,
postmenopausal women “do produce estrogen in their bodies [but] these lower
levels of hormones were assumed to be negligible” (p. 722). Therefore, the
language on the CombiPatch web site echoed this sentiment, namely that
hormone levels were deficient and women could use HT products to adjust to this
so-called decline.
Moreover, the PREMARIN web site advocated that managing this “change
of life” was best accomplished by conferring with a health care provider.
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Specifically, consumers were told “it’s important to talk to your doctor or other
health care professional about the best ways to keep healthy during this time of
change” (PREMARIN web site: http://www.premarin.com. Retrieved: July 17,
2009). From the description of menopause presented on the PREMARIN web
site, women were informed that menopause should be medically managed.
Previous research has also noted women are often told they should depend on a
physician’s medical expertise rather than on their own judgment (Kaufert and
Gilbert, 1986). Here, the PREMARIN web site also articulated the idea that
physicians should be regarded as the main source for determining whether or not
a woman is “menopausal.”
Thus, not only was this “change of life” portrayed as unwelcomed
specifically on the CombiPatch and PREMARIN web sites, it was also presented
as being best managed by a health care expert for an optimal health outcome.
Indeed, such representations of menopause as a medical event to be medically
managed by an “expert” suggested that women should go to their physicians for
information and advice. For these reasons, the language found on the
CombiPatch and PREMARIN web sites reinforced the long-standing idea of
physicians as experts over women’s experiences as “someone with power to
define and categorize their experience” which are signs pointing towards a
biomedical understanding of menopause (Kaufert and Gilbert, 1986, p. 14).
Meanwhile, my analysis shows that three of the HT web sites (ANGELIQ,
PREMARIN, and PREMPRO) portrayed menopause as “three stages.” The three
phases that these web sites are referring to were perimenopause, menopause,

124
and postmenopause. Research has shown that menopause is not a universal
experience and women experience menopause differently (Mansfield and Voda,
1997). Coney also states that apart from menstruation stopping, there is nothing
universal about menopause and there are as many “menopauses as there are
cultures” (p. 95). Yet, the three stages listed on the HT web sites can be viewed
as an attempt to medically “measure” when menopause begins and when it ends.
Here again, the definitions of menopause found on the ANGELIQ, PREMARIN,
and PREMPRO web sites suggested menopause was an event that could be
defined and measured medically.
Furthermore, the ENJUVIA web site referred to menopause as a “stage of
life.” In fact, the ENJUVIA web site stated this stage was one that “all women
eventually experience” (ENJUVIA web site: http://www.enjuvia.com. Retrieved:
July 14, 2009). As I have expressed, language and word choice were important
to the overall context of the descriptions of menopause being used by the
pharmaceutical companies in their online advertisements for HT. By suggesting
that menopause was a stage that “all women eventually experience,” the
ENJUVIA web site was associating menopause with something that was “natural”
and “inevitable.”
Ironically, this paradoxical definition presented menopause to female
consumers as both normal and abnormal. The ENJUVIA web site stated “if you
can't explain how you feel, often your healthcare professional can” (ENJUVIA
web site: http://www.enjuvia.com. Retrieved: July 14, 2009). This description
seems contradictory; although the online advertisement for ENJUVIA suggested
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this was a natural and inevitable stage of life, women were told it may also be a
time of confusion and best understood with the help of a health care provider. As
seen in the above quote, the diagnostic role of the physician in distinguishing
what is “normal” from “abnormal” was implied. Therefore, the ability of the
ENJUVIA web site to simultaneously represent menopause as natural and
disease-like through such language effectively placed menopause under the
rubric of medical supervision.
One more description of menopause was noted on the HT web sites. One
instance of menopause being described as when a woman’s “reproductive
system slowly shuts down” was observed on CombiPatch web site (CombiPatch
web site: http://www.combipatch.com. Retrieved: July 13, 2009). By describing a
woman’s reproductive system as “slowly shutting down,” the mechanical
language in this example was reminiscent of the biomedical model in which the
body is viewed as a machine breaking down. An emphasis on how the “aging
ovaries stop working” have resulted in menopause being regarded as a
malfunction (Derry, 2002, p. 14). Here, the online advertisement likened the
aging female body to a machine “breaking down,” which in turn, helps to illustrate
how menopause was being articulated as a declining biological function.
To summarize, menopause was described as either “three stages,” “a
change of life,” or “a stage of life” on the HT web sites. From these examples, the
language on the HT web sites introduced menopause as a medical event
needing to be medically managed. Accordingly, statements found on several web
sites (CombiPatch and PREMARIN) articulated a biomedical perspective by
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presenting menopause as problematic thereby further solidifying the idea that
menopause belongs under the domain of medicine. The PREMARIN web site
also told women that this “change of life” was best managed by a medical
professional thus reinforcing the physician’s role and expertise in offering a
diagnosis. Overall, my analysis indicated the descriptions of menopause on the
HT web sites introduced menopause to consumers as a “problematic” biomedical
event best managed by HT under the supervision of a health care provider. Next,
I explored explanations for the “causes” of menopause provided on the HT web
sites to further understand how menopause was portrayed in the online
advertisements.

Explanations for Menopause

Explanations for menopause on the HT web sites further contributed to the
overall portrayal of menopause. Table 18 illustrates how an explanation for
menopause was represented on the various HT web sites. As noted in previous
chapters, menopause was defined in this study as a natural part of the aging
process, rather than an event that limits women’s psychological or physical
capacities (McCrea, 1983). By contrast, my analysis showed that main
explanations for menopause in the online advertisements were described
through the prism of biological or physiological causes to account for these
changes. The two main explanations, or “causes,” for menopause found on the
HT web sites were the loss of hormones and the end of regular menstruation.
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Table 18: Explanations for Menopause
Name of HT Product

Explanations for Menopause

ANGELIQ

End of regular menstruation, occurs when
your body stops producing estrogen

CombiPatch

Ovaries taper off from producing estrogen
and progesterone to the extent where
menstruation stops

ENJUVIA

Decrease in the production of certain
hormones

Estrasorb

Once your period has stopped for one year,
loss of estrogen

femhrt

Your body is adjusting to lower levels of the
hormones estrogen and progesterone

Femring

Loss of estradiol

PREMARIN

Once you have not had a period for 12
consecutive months, ovaries stop producing
estrogen and fertility ends

PREMPRO

Ovaries stop production of hormones and no
menstrual periods for 12 consecutive months

In the online advertisements, all of HT web sites (N=8) referred to menopause
as the result of the loss of hormones. The ENJUVIA and PREMPRO web sites
stated the decrease in production of hormones in general, while the other web
sites for HT mentioned the loss of a specific hormone (i.e. estrogen,
progesterone, and estradiol). Nevertheless, all of the HT web sites in the sample
used the loss of hormones to explain menopause.
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Specifically, the femhrt web sites stated that the “body is adjusting to
lower levels of the hormones estrogen and progesterone” (femhrt web site:
http://www.wcrx.com/products/femhrt. Retrieved: July 25, 2009). The femhrt web
site goes on to state “HT is a way of providing your body with the estrogen that
you no longer produce naturally after menopause” (femhrt web site:
http://www.wcrx.com/products/femhrt. Retrieved: July 25, 2009). Here, an
emphasis was placed on the “loss” of estrogen.
A focus on the loss of hormones was also evident on the CombiPatch
web site which further explained that HT products work by “balancing the
hormone levels in your body” (CombiPatch web site: http://www.combipatch.com.
Retrieved: July 13, 2009). Here again, an emphasis on “balancing” hormone
levels to make up for some loss of hormone production was clear. In addition, the
ANGELIQ web site referred to menopause as a “balancing act” since a woman’s
“reproductive cycle is based on a delicate balance of 2 hormones: estrogen and
progesterone” (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July
13, 2009). Further, the ANGELIQ web site stated “HT with ANGELIQ tablets can
help bring back the balance” (ANGELIQ web site: http://www.angeliq-us.com.
Retrieved: July 13, 2009). Once more, the importance of balancing hormones
was emphasized in order to “restore” or “get back” to an adequate level. Given
this, three of the HT web sites (ANGELIQ, CombiPatch, and femhrt) suggested
that the loss of hormones should be supplemented with HT products to help
restore this “balance.” From the above examples found on the HT web sites, it
was assumed the lower estrogen levels were considered to be negligible. Such
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explanations for menopause direct attention to the simple variable of estrogen
(Derry, 2002). Another example was particularly evident on the PREMARIN web
site which stated menopause begins when “estrogen production from your
ovaries starts to decline” (PREMARIN web site: http://www.premarin.com.
Retrieved: July 17, 2009). With such words as adjusting, balance, and decline
found on the HT web sites, I found that “deficiency” and “loss” were common
themes on the web sites. The implication was that women need to “balance” or
“make up” for the loss of estrogen production. Importantly, these words set the
stage for the idea of using prescription HT products to restore this balance.
At the same time, five of the HT web sites cited the end of regular
menstruation (ANGELIQ, CombiPatch, Estrasorb, PREMARIN, and PREMPRO).
Here, a clinical definition (i.e. end of regular menstruation) was adopted to
explain menopause. Even though changes in the menstrual cycle are a common
condition of the menopausal transition, women may interpret these changes as
“signs of disease and experience unnecessary fear” (Mansfield and Voda, 1997,
p. 62). Thus, the explanations for menopause on the HT web sites were defined
exclusively as the loss of estrogen production and the end of regular
menstruation firmly grounded in a biomedical discourse of menopause.
This analysis was instrumental for beginning to illustrate the ways in which
biomedical rhetoric was being used to explain menopause on the HT web sites.
By emphasizing menstrual cycle changes and declining estrogen production, the
HT web sites drew on biomedical definitions of menopause. As such, menopause
was portrayed on the pharmaceutical web sites for HT as some type of physical
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problem related to biological functioning. In light of this, women were informed by
the online advertisements that they could learn to adjust to these changes and
restore the balance of hormone levels by using HT.
As noted in earlier chapters, print advertisements found in popular magazines
and medical journals have tended to also heavily draw on biomedical
explanations of menopause as a hormone deficiency disease that can be easily
“fixed” with drugs (Cimons, 2008; Richter, 2002; Whittaker, 1998). Similarly, my
analysis also indicated that online advertisements continued to utilize biomedical
rhetoric to emphasize a loss of hormones and implied that this transition was a
state of biological decline. Indeed, all of the web sites in the sample emphasized
the loss of hormones as a “reason” or explanation for menopause. While an
emphasis on change was clear, only one web site (PREMARIN) actually used
the word “decline.” Other web sites, such as ANGELIQ, CombiPatch, and femhrt,
employed the terms “adjustment” and “balance.” When taken together, the
language used on the web sites, helped to set the stage for using the HT
products in order to restore or balance hormone levels. As a result, according to
the web sites for HT, menopause could be viewed as a biomedical phenomenon
and treated accordingly with HT.

Variety of Menopausal Symptoms

In addition to the definitions of menopause that accompanied the online
advertisements, the HT web sites also prompted potential consumers to identify
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with specific emotional or physical conditions. Table 19 indicates the type of
menopausal symptoms that were found across the various HT web sites.
Analysis of the data indicated that often these conditions were portrayed as
problematic. In this way, by suggesting that these conditions were “symptoms”
best addressed through medical avenues, potential consumers were prompted to
identify with a particular HT product to alleviate the so-called symptoms. Hence,
the variety of symptoms that were identified and the language used to describe
these symptoms contributed to the representation of menopause in the online
advertisements. As a consequence, the portrayal of symptoms and the language
used to present these symptoms helped to constitute for female audiences what
it means to be “menopausal.”
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Table 19: Symptoms of Menopause on the HT Web Sites
Name of HT Product

Symptoms Listed on Web Site

ANGELIQ

Hot flashes, night sweats, vaginal dryness

CombiPatch

Hot flashes, night sweats, vaginal dryness,
sleep disturbances, tiredness,
postmenopausal osteoporosis, mood
changes

ENJUVIA

Vasomotor symptoms, vaginal atrophy, hot
flashes, night sweats, vaginal dryness, pain
with sex, irregular periods, weight gain,
problems sleeping, dry skin, mood swings,
irritability

Estrasorb

Hot flashes, night sweats

femhrt

Hot flashes, night sweats, insomnia, vaginal
changes, postmenopausal osteoporosis

Femring

Hot flashes, night sweats, vaginal dryness

PREMARIN

Hot flashes, night sweats, vaginal
symptoms, postmenopausal symptoms such
as increased risk of cardiovascular disease,
weight gain, and bone loss

PREMPRO

Hot flashes, night sweats, vaginal symptoms

Analysis of the data indicates that two “symptoms” of menopause in
particular were common across all of the HT web sites (N=8). In the online
advertisements, hot flashes and night sweats were mentioned as menopausal
symptoms on all of the HT web sites. A further analysis of the online
advertisements indicated that seven of the HT web sites (n=7) listed the same
three symptoms (hot flashes, night sweats, and vaginal changes/dryness).
Therefore, the symptoms that were identified largely as “common” symptoms of
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menopause across the web sites included hot flashes, night sweats, and vaginal
changes/dryness.
Interestingly, the ENJUVIA web site was unique among the study sample
for its use of biomedical rhetoric for describing symptoms. In this case, the terms
“vasomotor symptoms” and “vaginal atrophy” were used on the ENJUVIA web
site (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). By
using biomedical nomenclature, this particular advertisement in my data set
placed these “symptoms” within a medical context thereby suggesting to
consumers that menopause was “disease-like.”
While the “common” three symptoms of hot flashes, night sweats, and
vaginal changes were presented across all of the HT web sites, some important
differences existed between the web sites. That is to say, instances of “other”
menopausal symptoms were also observed. To provide some more context for
this discussion, Coney (1994) says despite the claims of some health care
providers that produce lengthy menu of menopausal symptoms, there are “only
three signs [that] can be directly attributed to the physiological event of
menopause” (p. 102). These are menstrual changes, vasomotor effects (hot
flashes and night sweats), and loss of moisture and elasticity in the vagina
(Coney, 1994). Despite this, menopause continues to be defined by a long list of
symptoms (Rostosky and Travis, 1996). Indeed, the HT web sites did not create
the lists of symptoms rather they incorporated lists of symptoms already created
by biomedical research (Mansfield and Voda, 1997). Therefore, further insight
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into the portrayal of menopause was gained after examining these “other”
menopausal symptoms presented on the HT web sites.
One of the most telling differences across the various the HT web sites
were the additional symptoms listed on the CombiPatch and ENJUVIA web sites.
In particular, mood changes, mood swings, and irritability were also observed on
the CombiPatch and ENJUVIA web sites. Moreover, the ENJUVIA web site
further listed irregular periods, weight gain, and dry skin as “other” symptoms of
menopause (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14,
2009). These changes are not necessarily related to menopause and just
because a woman may experience mood changes or irritability during the
menopausal transition “does not mean that menopause caused the condition”
(Mansfield and Voda, 1997, p. 60, italics in the original). Yet, by having these
listed as so-called symptoms of menopause on the CombiPatch and ENJUVIA
web sites suggested a possible link or association.
Additionally, the CombiPatch and femhrt web sites listed “postmenopausal
osteoporosis”

as

a

symptom

of

menopause

(CombiPatch

web

site:

http://www.combipatch.com. Retrieved: July 13, 2009). The PERMARIN web site
also identified an increased risk of cardiovascular disease, weight gain, and bone
loss

as

“postmenopausal”

symptoms

(PREMARIN

web

site:

http://www.premarin.com. Retrieved: July 17, 2009). Therefore, these three web
sites in the sample (CombiPatch, femhrt, and PREMARIN) illustrated a technique
described in previous research of linking osteoporosis with menopause in such a
way that “osteoporosis practically becomes identified as a symptom of

135
menopause” (Worcester and Whatley, 1992). Again, such a technique has been
seen as a way to expand the list of symptoms to include conditions that have not
been traditionally associated with menopause. The U.S. Department of Health
and Human Services has noted that estrogen should not be used as a first-line of
treatment for osteoporosis (U.S. Department of Health and Human Services web
site:

http://www.womenshealth.gov/faq/menopause-treatment.cfm.

Retrieved:

January 24, 2010).
In all of this an especially crucial area was illuminated. One of the key
ways in which these “other” symptoms have been instrumental is in their ability to
encompass emotional or physical conditions that may not be related to
menopause. For example, weight gain, dry skin, and mood changes may be
explained by a host of other reasons than menopause and could be easily
viewed as unrelated. Yet, having such symptoms listed on the web sites implied
to consumers that they were important and implied they could be treated with HT.
The pharmaceutical web sites were incorporating lists of so-called menopausal
symptoms that already existed in the biomedical literature; however, the online
advertisements for HT were effectively able to imply a connection by listing them
as possible symptoms and linking them with menopause. At the present,
menopausal hormone therapy is recommended only as a short-term treatment of
moderate to severe symptoms such as hot flashes or night sweats (U.S.
Department

of

Health

and

Human

Services

web

site:

http://www.womenshealth.gov/menopause/treatment. Retrieved: January 24,
2010). Through the alignment of such emotional and physical issues and
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presenting them to consumers as so-called symptoms of menopause, drug
manufacturers were able to further promote the widespread use of HT for an
extended range of menopausal “symptoms.”
In brief, groups of “common” and “other” symptoms emerged. A
comparison of “common” and “other symptoms” brought into focus a technique to
incorporate an expansive list of so-called menopausal “symptoms” into the HT
web sites. Hence, my analysis demonstrated an array of menopausal
“symptoms” was presented to consumers on the web sites as treatable with HT.
By suggesting to potential consumers that their physical and emotional issues
might fit medical models of menopause, the online advertisements capitalized on
already existing lists of symptoms found in the biomedical literature and linked
these symptoms with menopause to include emotional changes and the
prevention of osteoporosis. Consequently, such sweeping claims of menopausalrelated symptoms could be used to further propose the use of HT products for
emotional and physical conditions beyond the “commonly” regarded symptoms of
hot flashes, night sweats, and vaginal changes. Next, I take a closer look at the
language used to describe the symptoms of menopause.

Portrayal of Symptoms

This section of the chapter analyzes the language used to describe the
various menopausal symptoms listed on the HT web sites. Table 20 illustrates
the language used to describe symptoms of menopause presented across the
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HT web sites in the study sample. Here, I was most interested in the way
language was used by the pharmaceutical companies to describe symptoms in
either a positive or negative light.
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Table 20: Portrayal of Symptoms
Name of HT Product

Portrayal of Symptoms

Key Phrases/Words

ANGELIQ

Disruptive and inconvenient
hot flashes, night sweat can
lead to poor sleep quality
and a reduced sense of self

Disruptive
Inconvenience
Poor sleep quality
Reduce sense of self

CombiPatch

Hot flashes may interrupt
your sleep, causing
tiredness and possibly
mood changes

Interrupt sleep
Tired
Mood Changes

ENJUVIA

Hot flashes may be easily
tolerated or range from
embarrassing to debilitating

Easily Tolerated
Embarrassing
Debilitating

Estrasorb

Moderate to severe hot
flashes, can be severe
enough to interrupt your
sleep and make you feel
miserable

Severe
Interrupt sleep
Miserable

femhrt

Night sweats are often
severe enough to wake
you, many women going
through menopause
experience insomnia

Severe
Insomnia

Femring

Hot flashes intruding on
your day, night sweats
interrupting your sleep,
unpredictable hot flashes
throughout the day

Intruding on day
Interrupting sleep
Unpredictable hot
flashes

PREMARIN

Unpredictable hot flashes,
may also feel irritated,
annoyed, or frustrated
during a hot flash

Unpredictable hot
flashes
Irritated
Annoyed
Frustrated

PREMPRO

Unpredictable hot flashes,
may also feel irritated,
annoyed, or frustrated
during a hot flash,

Unpredictable hot
flashes
Irritated
Annoyed
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uncomfortable or painful
intimacy, hampered sex
lives

Frustrated
Uncomfortable
Painful intimacy
Hampered sexual
relations

As Table 20 indicates, menopausal symptoms were represented by a
number of recurring key phrases or words. In the online advertisements,
menopausal

symptoms

were

described

as

unpredictable,

inconvenient,

embarrassing, and portrayed as an interruption or intrusion. For example, the
ANGELIQ web site described hot flashes as “disruptive and inconvenient”
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).
Furthermore, unpredictable hot flashes may also leave one feeling “irritated,
annoyed, or frustrated” (PREMARIN web site: http://www.premarin.com.
Retrieved: July 17, 2009).
Another example was found on the ENJUVIA web site which stated hot
flashes may range from “embarrassing to debilitating” (ENJUVIA web site:
http://www.enjuvia.com. Retrieved: July 14, 2009). In addition, night sweats could
“lead to poor sleep quality and a reduced sense of self” (ANGELIQ web site:
http://www.angeliq-us.com. Retrieved: July 13, 2009). On one hand, the
ANGELIQ web site claimed night sweats and poor sleep could lead to a reduced
sense of self, and yet, one might argue, how do we know that an individual has
no sense of self? Unfortunately, neither an explanation nor description was
offered to provide further context. Moreover, the negative impact that
menopausal symptoms could have on sexual relations was implied on the
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PREMPRO web site which stated vaginal changes can result in uncomfortable or
painful intimacy leading to “hampered sex lives” (PREMARIN web site:
http://www.premarin.com. Retrieved: July 17, 2009).
One of the most sweeping aspects of the HT web sites was the overall
portrayal of symptoms in a negative light. This was accomplished by presenting
symptoms in terms of physical symptoms, such as night sweats and vaginal
dryness. The physical symptoms were then associated with having a negative
impact on social and personal relations. Notably, the PREMPRO associated
vaginal changes with hampered sex lives. Similarly, the ENJUVIA web site
proclaimed that poor sleep quality resulting from night sweats could lead to a
“reduced sense of self.” Furthermore, instances of “disruptive hot flashes” found
on the ANGELIQ, PREMARIN, and PREMPRO web sites portrayed menopausal
symptoms as unpredictable, a disruption to daily life, and even something that
was out-of-control.
By portraying such symptoms as “disruptive,” symptoms were presented
as problematic to consumers thereby positioning them within a disease-like
model requiring medical treatment. Certainly, the language used to portray the
symptoms in these instances helped to set the stage for using the HT products. If
left untreated, extremes were presented to consumers, namely that symptoms
could become debilitating, lead to a reduced sense of sense, and result in
hampered sex lives. It is also noteworthy that the use of positive language, such
as describing menopause as a “beginning” or “freedom,” was not observed on
any of the web sites for HT.
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Under further scrutiny, I observed a technique in which the web sites
attempted to convey that other women were also “suffering” similar menopausal
symptoms. For example, the Estrasorb web site asked consumers the question
“Hot

Flashes?

You’re

In

Good

Company!”

http://www.estrasorb.com. Retrieved: July 15, 2009).

(Estrasorb

web

site:

Such advertisements

favorably shape consumers’ impressions about a particular product because
“consumers are led to believe that the use of such a product is done en masse”
(Arney and Rafalovich, 2007, p. 54). The use of the specific phrase “You are not
alone” can help create what Arney and Rafalovich (2007) refer to as a
“Community of Sufferers” in which potential consumers are encouraged to join
the bandwagon to use a particular product (p. 54).
The notion that menopausal symptoms were common to a large number
of women was also promoted through the use of numbers and statistics on the
HT web sites. For instance, the CombiPatch web site asserted that hot flashes
were common during menopause and “eighty-five percent of women experience
this undesirable symptom” (CombiPatch web site: http://www.combipatch.com.
Retrieved: July 13, 2009). Unfortunately, no reference or citation was provided to
put this claim into context for the web site user. This finding is in agreement with
previous research also reporting that claims were not supported in magazine
advertisements for HT (Carlson, Li, and Holm, 1997).
A similar example was found on the ENJUVIA web site which stated
“nearly three out of four women have hot flashes during menopause” (ENJUVIA
web site: http://www.enjuvia.com. Retrieved: July 14, 2009). Here again, a
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reference to this claim was not provided; however, we were assured by this
statement that large numbers of women experience hot flashes. Therefore,
assuming that web users may identify with the symptoms described on the HT
web sites, a potential consumer may feel that she belongs to the group of
“sufferers” because the symptoms in the advertisements were portrayed as
common to a large group of women (Arney and Rafalovich, 2007).
In sum, lists of symptoms taken from the biomedical literature were
capitalized and incorporated on the HT web sites. Indeed, the term “symptoms” is
commonly associated with problems and illness (Rostosky and Travis, 1996).
The web sites linked menopause with a long list of “symptoms” and treatments
for these symptoms, as if it were a disease. Perhaps most striking about the
portrayal of symptoms on the pharmaceutical web sites for HT was the way in
which a connection was implied between the physical symptoms and the impact
on social and personal relations. Symptoms such as hot flashes and vaginal
changes were presented to consumers as “problematic” using such language as
debilitating, reduced sense of self, and hampered sex lives. In short, symptoms
presented across the HT web sites were grounded in a biomedical perspective
which further articulated a disease-like model of menopause necessitating
medical intervention.

Prescription of Action
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Conrad and Leiter (2008) expressed concerns over the ability of DTCA to
encourage consumers to self-diagnosis and influence requests for prescription
medications. Statements on the HT web sites that encouraged women to seek
medical treatment and advice were also evident. To investigate this phenomenon
further, I analyzed the language used on the HT web sites that encouraged
consumers to perform some kind of behavior or activity. To illustrate this
argument, Table 21 describes the various statements found across the HT web
sites.
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Table 21: Prescription of Action
Name of HT Product

Prescription of Action

ANGELIQ

Ask to your health care professional if
ANGELIQ is right for you

CombiPatch

Talk to your doctor or pharmacist for
more information

ENJUVIA

Ask your healthcare professional if
ENJUVIA is right for you

Estrasorb

Talk to your healthcare provider about
Estrasorb for the relief of hot flashes
and night sweats

femhrt

Talk to your doctor about what
treatment option is right for you

Femring

Talk to your doctor about what
treatment option is right for you

PREMARIN

Discuss the level of relief you can
expect with PREMARIN with your
health care professional

PREMPRO

Discuss the level of relief you can
expect with PREMPRO with your
health care professional

As seen in Table 21, all of the HT web sites in the sample (N=8) exhibited
statements encouraging prospective consumers to inquire about medical
treatment with a health care professional. In fact, all of the statements started
with action verbs, such as “talk,” “ask,” and “discuss.” In this way, all of the HT
web sites clearly suggested that consumers should do something. To further
understand the action or behavior that was being advocated, I examined the
actual language presented to consumers on the web sites.
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Out of the eight web sites, four of the HT web sites used the word “talk” in
their statements (CombiPatch, Estrasorb, femhrt, and Femring). For example, the
CombiPatch web site stated “talk to your doctor or pharmacist for more
information” (CombiPatch web site: http://www.combipatch.com. Retrieved: July
13, 2009). Another example was found on the Estrasorb site which stated “talk to
your healthcare provider about Estrasorb for the relief of hot flashes and night
sweats” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15,
2009). In addition, both the femhrt and Femring web sites encouraged
consumers to “talk to your doctor about what treatment option is right for you”
(femhrt web site: http://www.wcrx.com/products/femhrt. Retrieved: July 25,
2009).
Two of the HT web sites (ANGELIQ and ENJUVIA) used the word “ask” in
their statements. For example, visitors to the ANGELIQ web site were prompted
to “ask to your health care professional if ANGELIQ is right for you” (ANGELIQ
web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). Similarly, the
ENJUVIA web site promoted “ask your healthcare professional if ENJUVIA is
right for you” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14,
2009). By encouraging consumers to “ask” a health care provider about HT, the
statements in question on ANGELIQ and ENJUVIA web sites were prescriptive.
In this sense, these two web sites recommended a particular behavior or action
for consumers (i.e. ask about HT) while also reinforcing that notion that a health
care provider could determine “what is right for you.” Not only was a consumer
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behavior being advocated, but the expert role of medical authority was
reinforced.
In comparison, the word “discuss” was observed on two other HT web
sites (PREMARIN and PREMPRO). The PREMARIN web site urged consumers
to “discuss the level of relief you can expect with PREMARIN with your health
care professional” (PREMARIN web site: http://www.premarin.com. Retrieved:
July 17, 2009). Likewise, the PREMPRO web site suggested consumers should
“discuss the level of relief you can expect with PREMPRO with your health care
professional” (PREMPRO web site: http://www.prempro.com. Retrieved: July 17,
2009).

Here, the pairing of the words “discuss” and “relief” in both of the

statements associated discussing HT options with a health care provider and
some form of relief that could be expected from the HT products. Therefore,
when you “discuss” HT options, you will learn about the “relief” you can expect.
Although all of the web sites encouraged women to follow-up with health
care providers, some differences across the web sites were detected.
Interestingly, five of the HT web sites (n=5) encouraged consumers to inquire
about a specific HT product. These five web sites were ANGELIQ, ENJUVIA,
Estrasorb, PREMARIN, and PREMPRO. To illustrate this point, the ANGELIQ
web site stated “ask to your health care professional if ANGELIQ is right for you”
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).
On the other hand, three of the HT web sites (CombiPatch, femhrt, and
Femring) encouraged consumers to inquire about general treatment options but
they did not explicitly mention the name of an HT product. For instance, the
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Estrasorb web site encouraged consumers to “talk to your doctor about what
treatment option is right for you” (Estrasorb web site: http://www.estrasorb.com.
Retrieved: July 15, 2009). Thus, more of the HT web sites in the study sample
encouraged consumers to inquire about a particular HT product than asking
about general treatment options. Nevertheless, all of the HT web sites
encouraged women to follow-up with a health care professional regarding HT
treatment options. As witnessed from the language used on the HT web sites,
consumers were encouraged to contact a health care professional and inquire
about medical treatment options. Overall, statements found across all of the
pharmaceutical web sites prescribed a behavior or course of action for
consumers.

Self-Diagnostic Symptom Tools

Up to this point, I have considered the textual representation of menopause
on the HT web sites by examining the descriptions for menopause and how the
various “symptoms” were portrayed through the use of language. In addition, half
of the HT web sites in the sample (n=4) provided online self-diagnosing symptom
tools for web site consumers. Table 22 indicates which of the HT web sites had
symptom tools.
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Table 22: HT Web Sites with Symptom Tools
Name of HT Product

Symptom Tools

ANGELIQ

Yes

CombiPatch

No

ENJUVIA

Yes

Estrasorb

No

femhrt

No

Femring

No

PREMARIN

Yes

PREMPRO

Yes

Concerning self-diagnosis, Conrad and Potter (2000) contend that adults who
self-diagnose disorders might have become familiar with the condition through
the media. Indeed, this concern illustrates the public’s reliance on the media for
information and poses interesting questions about media portrayals of
menopause and the role of media in shaping the public’s perception of health
and illness. Since media outlets, including online advertisements, are an effective
means of disseminating information about drugs and medical “conditions,” an
examination of how menopause was portrayed through the online self-diagnosing
symptom tools was warranted.
Specifically, the ANGELIQ, ENJUVIA, PREMARIN, and PREMPRO web sites
(n=4) provided symptom tools for web site users to assess the type and degree
of severity of their menopausal symptoms. The self-diagnosing symptom tools
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were an example of an interactive component found on the HT web sites. With
these online symptom tools, consumers were presented with a series of
questions and response categories to select from. The web site user then
proceeded through the series of questions by clicking (or advancing) to the next
question in the series until the web site visitor reached the end of the questions.
At this point, a customized “report” of menopausal symptoms was provided to the
web site user. I posit that these interactive self-diagnosing tools were yet another
vehicle through which the pharmaceutical companies could construct and convey
messages about menopause, symptoms, and their HT products. As such, they
are an interesting subject for sociological analysis. Next, I examined the selfdiagnosing symptom tools found on the HT web sites.
Out of curiosity, I performed an experiment with the PREMARIN symptom
tool. In this experiment, I completed the PREMARIN symptom tool three different
times. For each of my attempts, I indicated a different degree of “severity,” for my
so-called menopausal symptoms. At first, I selected that my symptoms “rarely”
affected my life. Then, I indicated that my (hypothetical) symptoms “moderately”
affected my life. Finally, I checked the response options expressing that my
symptoms were “severely” affecting my life. With all three attempts at answering
the PREMARIN symptom tool questions, the recommendation on my customized
symptom “reports” was the same. In essence, all three reports recommended
printing and sharing the “results” about my symptoms with a health care provider.
Additionally, all three reports linked back to the PREMARIN web site to learn
more about treatment options. From this experiment, I can reasonably conclude
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that this online symptom tool in particular was not sophisticated enough to
discern my responses, especially given the fact that I clearly indicated various
degrees of “severity.” Thus, the tool primarily functioned to encourage contact
with a health care provider while also referring me back to the HT web site for
more information about HT treatment options.
The symptom tool located on the ANGELIQ web site was labeled “Assess
Your Symptoms.” The front page of the symptom tool declared that the “first step
to help you manage your menopausal symptoms is to be aware of what your
body is telling you” (ANGELIQ web site: http://www.angeliq-us.com. Retrieved:
January 18, 2010). As seen in this statement, web site users were informed from
the beginning that this tool could help them gain new knowledge about their
bodies so that they can become more aware of what their bodies were telling
them. Furthermore, a disclaimer in smaller font was also provided stating that the
symptom tool could not offer a diagnosis; therefore, one should “schedule an
appointment with a health care provider” (ANGELIQ web site: http://www.angeliqus.com. Retrieved: January 29, 2010). Not only did the legal disclaimer function
to protect the pharmaceutical companies so they would not appear to be giving a
diagnosis, but it also deferred to medical authority for a diagnosis thereby further
encouraging potential consumers to contact a health care provider.
In general, symptom tools are designed as a quick and easy way for
consumers to assess their experiences and determine when to seek medical
attention. Once an ANGELIQ web site user clicked on the symptom tool they
were greeted by the message “Menopause. It’s a natural part of life, but these
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symptoms don’t have to be” (ANGELIQ web site: http://www.angeliq-us.com.
Retrieved: January 18, 2010). From this statement, consumers were told that
menopause was natural. However, the statement further implied that symptoms
were “unnatural.” Here, the tension between “natural” (in this case, menopause)
and “unnatural” (menopausal symptoms) was conveyed and created a context for
consumers to learn how to “treat” such undesirable symptoms with HT products.
In this sense, it encouraged women to regard any changes as unacceptable
symptoms.
Next, the web site user would proceed through a series of eleven questions
designed to provide “new insight” into how the consumer feels (ANGELIQ web
site: http://www.angeliq-us.com. Retrieved: January 18, 2010). Presumably,
consumers would learn more about their symptoms, which were framed as
unnatural and unhealthy from the very beginning of their interaction with the
online tool. Table 23 indicates the types of questions and response options that
were presented to web site users on the ANGELIQ “Assess Your Symptoms”
Tool.
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Table 23: Questions from the ANGELIQ “Assess Your Symptoms” Tool
Symptoms Questions

Response Categories

How old are you?

Consumer types in response

How long has it been since your last
period?

Two response options:
1. Less than one year
2. More than one year

Are you experiencing menopausal
symptoms, such as hot flashes, night
sweats, and vaginal dryness?

Three response options:
1. Yes
2. No
3. Not sure

Have you had your ovaries surgically
removed?

Two response options:
1. Yes
2. No

How often do you experience hot
flashes?

Three response options:
1. Rarely (very little or not at all)
2. Frequently (often enough that I
find it to be irritating and
embarrassing)
3. Severely (so often that it
severely interferes with my daily
activities)

On average, how many hot flashes do
you experience each day?

Consumer types in response

How often do you experience night
sweats?

Three response options:
1. Rarely (very little or not at all)
2. Frequently (often enough that I
find it to be annoying and
uncomfortable)
3. Severely (so often that it
severely interferes with my sleep
patterns)

On average, how many times do night
sweats disrupt your sleep per night?

Consumer types in response

Are vaginal symptoms causing you
discomfort?
• Dryness

On a scale of 1 to 5 ( 1 being not at all,
5 being most severe)
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•
•
•

Itching
Burning
Discomfort during sex

Are you considering using or currently
using a combination (estrogen and
progestin) therapy?

Two response options:
1. Yes
2. No
(If yes, what are you current using?
Consumer types in response)

Would you consider using a once-aday combination pill to help manage
your symptoms?

Two response options:
1. Yes
2. No

The ANGELIQ “Assess Your Symptoms” Tool entailed eleven questions
about hot flashes, night sweats, and vaginal dryness. In this online symptom tool,
symptoms were also presented in terms of physical symptoms. Specifically, two
questions asked about hot flashes. As seen in Table 23, a web site visitor was
asked “how often do you experience hot flashes?” The physical symptoms were
then associated with having a negative affect on social and personal situations.
For instance, consumers were asked to indicate how often they experienced hot
flashes and they could select a response from three options (rarely, frequently,
and severely). Interestingly, the response option “severely” was defined as “so
often that it severely interferes with my daily activities” (ANGELIQ web site:
http://www.angeliq-us.com. Retrieved: January 29, 2010). Unfortunately, such
“daily activities” referred to in the response option were not further defined for
consumers. Moreover, since the mention of “daily activities” was undefined, there
was no way for women working outside of the home to indicate if they
experienced different “daily” concerns. Another two questions centered on
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physical symptoms, including night sweats and one more question about vaginal
symptoms. The remaining six questions that comprised the ANGELIQ “Assess
Your Symptoms” Tool asked about age, how long it had been since
menstruation, if the woman’s ovaries had been surgically removed, and if the
consumer was currently using any combination of hormone therapies.
At the completion of the ANGELIQ “Assess Your Symptoms” Tool, the web
site user would be presented with a customized report entitled “My Symptom
Report” which could be printed out and shared with their health care provider.
Consumers were told to “use what you learn to talk to your healthcare
professional and explore what treatment options may be right for you” (ANGELIQ
web site: http://www.angeliq-us.com. Retrieved: January 27, 2010). Based on
this statement, I speculate one function of the symptom tools was to facilitate
communication between the potential consumer and a health care provider. In
brief, the pattern of presenting symptoms to consumers as “unnatural” was clear
in this online tool. Through the response options, the online tool then implied that
these physical symptoms could have a negative impact on social and personal
dimensions. As a result, consumers were encouraged to print out and share their
customized “symptom report” with their health care provider to learn more about
HT options.
The pattern of presenting symptoms as “problematic” continued in the next
online symptom tool. Secondly, the ENJUVIA web site provided the “Menopause
Impact Tool” for web site users. Just as the name suggests, this tool could be
used by consumers to assess the “impact” menopausal symptoms were having
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on their lives. Clearly, the name of the online tool implied that symptoms would
have an impact, it was just a matter of using their tool in order to assess how
much of an impact. Obviously, there was a built-in assumption about the nature
of menopausal symptoms and in this case symptoms were conceptualized and
articulated as capable of having an “impact.” Therefore, the question becomes,
how can women lessen this impact? Table 24 shows the types of questions and
response options from the ENJUVIA “The Menopause Impact Tool.”
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Table 24: Questions from the ENJUVIA “The Menopause Impact Tool”

Symptoms Questions

Response Categories

In the last month, to what extent have
you been bothered by the following
symptoms?
• Hot flashes
• Night sweats or chills
• Sleep disturbance
• Joint pain or stiffness
• Fatigue

Three response options:
1. Not at all or rarely
2. A little or moderately
3. Regularly or frequently

To what extent have these symptoms
negatively impacted the following?
• Feelings about yourself
• Relationships
• Work

Three response options:
1. Not at all or rarely
2. A little or moderately
3. Regularly or frequently

In the last month, to what extent have
you been bothered by the following
symptoms?
• Genital dryness, pain, and/or
burning
• Pain during sexual activity
• Decreased sexual desire
• Decreased sexual frequency

Three response options:
1. Not at all or rarely
2. A little or moderately
3. Regularly or frequently

To what extent have these symptoms
negatively impacted the following?
• Feelings about yourself
• Relationships
• Work

Three response options:
1. Not at all or rarely
2. A little or moderately
3. Regularly or frequently

In the last month, to what extent have
you been bothered by the following
symptoms?
• Anxiety
• Irritability
• Sadness
• Difficulty concentrating

Three response options:
1. Not at all or rarely
2. A little or moderately
3. Regularly or frequently

To what extent have these symptoms
negatively impacted the following?

Three response options:
1. Not at all or rarely
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•
•
•

Feelings about yourself
Relationships
Work

2. A little or moderately
3. Regularly or frequently

The ENJUVIA web site stated the symptom tool “provides information that
your health care professional can use to determine which treatment might be
right for you” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: January 18,
2010). In this statement, the reoccurring theme of the role of health care
providers in providing a diagnosis and medically managing menopause was
conveyed. Similar to the ANGELIQ symptom tool, the importance of sharing the
“results” of the ENJUVIA symptom assessment was emphasized. Once again,
the importance of reporting symptoms to a health care professional was
stressed. As Kaufert and Gilbert (1986) noted, one indication that medicalization
is occurring is whenever women are told that they should depend on a physician
rather than their own judgment. Here, the ANGELIQ and ENJUVIA web sites
perpetuated the idea that menopause was a medical event to be medically
managed. Since only health care professionals “can determine which treatment
is right,” this statement reinforced the “expert” role of physicians in their ability to
define and categorize women’s experiences.
Likewise, consumers navigated through a series of six questions on the
ENJUVIA web site designed to assess how menopause symptoms impacted
their lives in four key areas. These areas were hot flashes, night sweats, sexual
health, and psychological symptoms. To help assess the impact of menopausal
symptoms, web site users were asked to indicate to what extent they were

158
“bothered” by symptoms, such as hot flashes, night sweats or chills, sleep
disturbance,

joint

pain

or

stiffness,

and

fatigue

(ENJUVIA

web

site:

http://www.enjuvia.com. Retrieved: January 29, 2010). The use of negative
language, such as being “bothered,” consistently conveyed the message that
symptoms were bothersome and problematic for which HT was a viable
treatment.
As seen in Table 24, consumers were asked in five of the questions to
speculate the extent to which these symptoms had “negatively impacted” various
aspects of their lives, such feelings about their own selves, relationships, and
work. The three response options that were provided for these five questions
included “not at all or rarely,” “a little or moderately,” and “regularly or frequently.”
Although the pattern of response options for these five questions was consistent,
it was not very helpful to consumers because definitions for the varying response
categories were not provided. Meanwhile, the repeated use of the words
“bothered” and “negatively impacted” in the questions observed on the ENJUVIA
“The Menopause Impact Tool” played an important role in portraying such
symptoms as bothersome while suggesting these had an undesirable or negative
effect on personal, relationships, and work aspects. Here again, symptoms were
linked to affecting social and personal situations. In doing this, the
pharmaceutical companies were able to directly propose to consumers a need
for their HT products to alleviate “bothersome” symptoms.
In comparison to the other online symptom tools in the sample, the ENJUVIA
symptom tool was the only one to include psychological symptoms among the list
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of possible menopausal symptoms. As Table 24 illustrates, the ENJUVIA
“Menopause Impact Tool” included psychological symptoms such as anxiety,
irritability, sadness, and difficulty concentrating. As I discussed earlier in this
chapter, these psychological “symptoms” may be explained by a host of other
reasons other than menopause. They could also be easily viewed as unrelated.
Yet, the inclusion of such psychological symptoms in the ENJUVIA online tool
implied to consumers that they were important and associated with menopause.
Finally, upon completion of the ENJUVIA symptom tool consumers received a
“Menopause Impact Analysis” report. Consumers were told they could “print the
results and share them with your healthcare professional” (ENJUVIA web site:
http://www.enjuvia.com. Retrieved: January 27, 2010).
Two more web sites (PREMARIN and PREMPRO) provided online selfdiagnosing symptom tools. Both symptom tools asked the same eleven
questions and also provided the same response categories to consumers. This
similarity is not surprising considering the fact that both PREMARIN and
PREMPRO are products of Wyeth Pharmaceuticals. Although both tools had the
same content, two differences were noted amongst the PREMARIN and
PREMPRO online symptom tools. First, the PREMARIN and PREMPRO online
symptom tools utilized different background colors. For instance, the PREMARIN
symptom tool was blue. In contrast, the PREMPRO symptom tool was purple. In
fact, these color choices were consistent with the color schemes found on each
corresponding HT web site. In addition, a different woman was pictured on each
of the symptom tools. On the left side of each symptom tool, a different picture of
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a woman was present. Again, different pictures of women on the PREMARIN and
PREMPRO online symptom tools helped to visually tie the specific symptom tool
to a particular HT web site. Essentially, I found that the content of the
PREMARIN and PREMPRO online symptom tools was the same but some visual
differences, such as the background color and images of two different women,
were employed to help tie the symptom tool to the particular HT web site. Given
this, next I analyzed the questions from the PREMARIN and PREMPRO
“Menopausal Symptoms Assessor” Tools.
Upon arriving at the PREMARIN and PREMPRO “Menopausal Symptoms
Assessor” tools, web site users were told that “tracking and assessing your
menopausal symptoms are important first steps in managing them” (PREMARIN
web site: http://www.premarin.com. Retrieved: January 18, 2010). This statement
reinforced the connection between assessing your symptoms and the ability to
“manage” them. The terms “tracking,” “assessing,” and “managing” are symbolic
medical terms that stem from the dominant biomedical view of menopause where
any changes are regarded as pathological. The PREMARIN and PREMPRO
symptom tools consisted of eleven questions for the consumer to answer. Table
25 shows the types of questions and response options from the PREMARIN and
PREMPRO “Menopausal Symptoms Assessor” Tools.
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Table 25: Questions from the PREMARIN and PREMPRO “Menopausal
Symptoms Assessor” Tool
Symptoms Questions

Response Categories

How old are you?

Consumer types in response

How would you describe your
menstrual status?

Four response options:
1. No change in frequency or flow
of my menstrual period
2. There seem to be some
changes in the flow, frequency,
or length of my period
3. I stopped having my menstrual
periods
4. I stopped having menstrual
periods because of surgery

How long has it been since your last
menstrual period?

Two response options:
1. Less than a year
2. More than a year

Please indicate the severity of your hot
flashes.

Four response options:
1. None
2. Mild
3. Moderate
4. Severe

Next, please indicate the frequency of
your hot flashes over the course of one
day.

Four response options:
1. None
2. 1 to 2
3. 3 to 4
4. 5 or more

Are hot flashes affecting your life?
(Please check all appropriate
responses)

Seven response options:
1. Hot flashes are not affecting my
life at all
2. I am constantly embarrassed
3. I feel anxious all the time
4. I am constantly sweating
5. Sometimes I feel a little
uncomfortable
6. It’s disruptive when I’m working
7. Hot flashes affect my personal
life
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Please indicate the severity of your
night sweats.

Four response options:
1. None
2. Mild
3. Moderate
4. Severe

I experience night sweats over the
course of one night:

Four response options:
1. Not at all
2. Once
3. Twice
4. Three times or more

Indicate all that describe how night
sweats affect your life.
(Check all that apply)

Six response options:
1. No effect
2. Lack of energy
3. Constantly tired
4. Have trouble sleeping through
the night
5. Sleep is frequently interrupted
6. Irritable

Describe any vaginal symptoms you
might be experiencing:
• Dryness
• Itching
• Irritation
• Pain with sexual activity

Four response options:
1. None
2. Mild
3. Moderate
4. Severe

Check all that accurately describe how
vaginal symptoms affect your life.
(Check all that apply)

Four response options:
1. No effect
2. The symptoms make me
uncomfortable sometimes
3. Sexual activity often leads to
bleeding
4. Sexual activity is limited due to
frequent discomfort

From the eleven total questions that comprised the PREMARIN and
PREMPRO “Menopausal Symptoms Assessor” tools, one question asked about
the consumer’s age, two questions were related to menstrual status, three
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questions inquired about hot flashes, three more questions asked about night
sweats, and two final questions asked about vaginal symptoms. As witnessed
with the other symptom tools, the web site user was asked to indicate the
severity of symptoms and how hot flashes, night sweats, and vaginal symptoms
were “affecting” their life (PREMARIN web site: http://www.premarin.com.
Retrieved: January 18, 2010). Once again, the prevalence of negative language,
such as being asked to indicate the “severity of symptoms,” served to
characterize symptoms as problematic.
As seen in Table 25, the consumer was presented with seven response
options to indicate how hot flashes were “affecting” their life. The consumer was
also instructed to “check all appropriate responses” to the question, meaning that
they could select several response categories. In fact, the use of the words
“anxious,” “embarrassed,” “disruptive,” and “uncomfortable” in the majority of the
response options helped to provide a context in which symptoms were portrayed
in a negative light.

In other words, the presentation of the choices was not

balanced. As such, the pharmaceutical companies effectively portrayed the
symptoms as “problematic” and “bothersome” on these online symptom tools
through the use of negative language thereby setting the stage for use of their
HT products.
In particular, the construction of response categories was interesting because
they were not mutually exclusive categories. The response options that a
consumer could select included: “hot flashes are not affecting my life at all,” “I am
constantly embarrassed,” “I feel anxious all the time,” “sometimes I feel a little
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uncomfortable,” “it’s disruptive when I’m working,” and “hot flashes affect my
personal life” (PREMARIN web site: http://www.premarin.com. Retrieved:
January 29, 2010). Specifically, these categories were not mutually exclusive
because overlap in the response options was present. For example, a web site
visitor could indicate both that “hot flashes are not affecting my life at all” and “I
feel anxious all the time.” Hence, whenever response options are not mutually
exclusive, respondents have more than one legitimate way to answer the
question. Furthermore, the response options helped make a connection between
hot flashes and their ability to “disrupt” work and “affect” one’s personal life. As a
result, the eleven questions that overall constitute the PREMARIN and
PREMPRO symptom tools helped to illustrate how language could be
instrumental in creating a context for the web site user to assess their
menopausal symptoms and the degree of severity.
One unique difference of the PREMARIN and PREMPRO symptom tools was
an online glossary feature built into the symptom tools. For example, web site
users could “roll over” words with their computer mouse to learn definitions of
certain words. For instance, definitions for hot flashes and night sweats could be
obtained. After completing the questions, consumers were once again presented
with a report and were encouraged to “print it out and take it with you to your next
doctor’s

appointment”

(PREMARIN

web

site:

http://www.premarin.com.

Retrieved: January 27, 2010). In fact, the PREMARIN and PREMPRO symptom
tools tell consumers to share “the results with your health care professional to
help

have

an

effective

discussion”

(PREMARIN

web

site:
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http://www.premarin.com. Retrieved: January 27, 2010). By suggesting that
sharing the results of the online symptom tool could help achieve an “effective
discussion” with a health care professional, the implication of this statement was
that the self-diagnosing tool could lead to enhanced or improved communication
among consumers and health care providers.
At this point, I will review the ways in which my analysis suggests the selfdiagnosing symptom tools functioned as another type of presentation form to
convey messages about menopause in the online advertisements for HT. Their
use of language was amplified on the web sites for HT where consumers were
asked to indicate the severity and frequency of their symptoms. First, the use of
language in the online self-diagnosing symptom tools provided a particular
context for web site users as they interacted with the tools to assess their
symptoms and the degree of severity of these symptoms. Specifically,
symptoms, such as sweats and vaginal dryness, were presented to consumers in
terms of physical symptoms and then these symptoms were linked negatively to
having an impact on personal and social relations. The language observed in the
question wording about menopausal symptoms, as well as certain words used in
the response categories, conveyed the message that symptoms were unnatural,
bothersome, and problematic. After all, we were reminded, menopause is a
“natural part of life, but these symptoms don’t have to be” (ANGELIQ web site:
http://www.angeliq-us.com. Retrieved: January 18, 2010). The use of such words
as “anxious,” “embarrassed,” “disruptive,” and “uncomfortable” further helped to
illustrate this point (PREMARIN web site: http://www.premarin.com. Retrieved:
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January 29, 2010). Certainly, the portrayal of menopausal symptoms as
“impacting” and “affecting” daily activities, work, and relationships as stated
across the four symptoms tools may also give impetus for seeking medical
attention and set the stage for hormone use.
Second, the categories of questions found on the self-diagnosing symptom
tools ranged from vasomotor symptoms (commonly known as hot flashes and
night sweats), vaginal symptoms, sexual health, and psychological symptoms. As
I have highlighted, the inclusion of psychological “symptoms,” such as anxiety,
irritability, sadness, and difficulty concentrating, was one technique that I
observed on the HT web sites. While the online symptom tools capitalized on
lists of menopausal symptoms generated in the biomedical literature, this
technique functioned to further expand the list of possible “menopausal
symptoms” that could be treated with HT. Indeed, the very fact that the list of
symptoms incorporated into the online symptom tools were gleaned from
biomedical research further demonstrated how the pharmaceutical companies
drew upon the dominant medical discourse (Mansfield and Voda, 1997; Rostosky
and Travis, 1996). Such negative descriptions of symptoms characterized any
changes as “problematic” and helped to set the stage for the use of their HT
products.
Upon closer examination, I also found a significant dimension of the online
self-diagnostic symptom tools was their attempt to encourage contact with a
health care provider. All four of the online self-diagnosing symptom tools
encouraged consumers to share the “results” of the symptom tools with a health
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care professional. Therefore, following-up with a health care provider to inquire
about which HT treatment might be appropriate was consistently emphasized to
consumers. Moreover, printer-friendly versions of the “symptom reports” were
also provided as an option for consumers at the completion of the four online
self-diagnostic symptom tools. Since the symptom “reports” could be printed out
and shared with a health care provider, the HT web sites further helped to draw
the connection that communicating with a health care provider was a logical next
step. Ultimately, these instances where contact with a health care provider was
encouraged further deferred to medical authority which, in turn, helps the
pharmaceutical companies in their efforts to promote the use of their HT products
which are only available by prescription.
While examining the online symptom tools, concerns about the reliability and
validity of the symptoms tools also emerged.

According to Creswell (2003),

reliability is concerned with the accuracy of the actual survey instrument and
validity is concerned with the instrument’s success at measuring what the
researcher originally set out to measure (i.e. menopause symptoms).
Nevertheless, the four HT web sites did not state if the online symptom tools
were tested for reliability and validity.
I also assessed the reading level of the four online symptom tools. To
accomplish this, I utilized an online tool called “TxReadability,” a free application
developed by the Accessibility Institute at the University of Texas at Austin. Using
the Flesch-Kincaid Grade level, this tool indicates the grade a person will have to
reach to be able to understand the text (Accessibility Institute at the University of
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Texas web site: http://webapps.lib.utexas.edu/TxReadability/app. Retrieved:
March 9, 2010). The Flesch-Kincaid Grade level is one of the common formulas
used to assess reading levels (Kars, Baker, and Wilson, 2008). For example, a
score indicating the grade level of seven means that a seventh grader should be
able to understand the text. An analysis of the text of the four online selfdiagnosing symptom tools in this study sample (found on the ANGELIQ,
ENJUVIA, PREMARIN, and PREMPRO web sites) yielded a combined score of
7.74. This score falls between a 7–8th grade reading level in the United States.
Considering it is estimated that one in four adults in the United States read at or
below the 3rd grade reading level, this grade level far surpasses the estimated
reading level of the average adult in the U.S. (National Adult Literacy Survey,
1992).
Individually, the online symptom tools also exceeded the estimated national
reading level. The readability score of ANGELIQ symptom tool was 7.9 which is
close to a 8th grade reading level. Next, the ENJUVIA symptom tool received a
score of 9.78 which is equivalent to a 9-10th grade reading level. Finally, the
PREMARIN and PREMPRO online symptom tools yielded a score of 6.95
requiring a 6-7th grade reading level to understand the information. Both
PREMARIN and PREMPRO online symptom tools received the same score
because they were the same tool produced by the same pharmaceutical
manufacturer (Wyeth Pharmaceuticals). Notwithstanding, the reading levels were
too high on all four of the online symptom tools in the study sample. This analysis
was fruitful because I identified another technique that may encourage
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consumers to follow-up with health care providers. In this case, consumers may
seek assistance in “making sense” of the information which I have shown was
written at a high reading level on the web sites. In sum, the online self-diagnosing
symptom tools were presented as a way for consumers to learn “what their
bodies are telling them,” functioned to expand the range of menopausal
symptoms to include psychological symptoms, and encouraged contact with a
health care provider.

Tests for Medicalization

Kaufert and Gilbert (1986) describe several “tests for medicalization” that
can be applied to the pharmaceutical web sites to help determine if the process
of medicalization was occurring. One sign is when the decline of estrogen
production has become a central theme (Kaufert and Gilbert, 1986). As noted
above, the loss of hormones was used across all of the pharmaceutical web sites
in the sample to explain a “reason” for menopause. Thus, menopause was
defined exclusively as a biological event on the pharmaceutical web sites for HT.
Another sign of medicalization is if proposed treatment options for
menopause involve the use of hormone therapies to supplement or balance this
loss of hormones (Kaufert and Gilbert, 1986). Since menopause was presented
as disease-like requiring medical management, the online advertisements helped
to introduce the idea of using HT to restore or balance hormone levels.
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Moreover, symptoms were portrayed as unnatural, problematic, and bothersome
further setting the stage for use of HT.
One more indication that medicalization is occurring is when women are
told that they should depend on a physician to have their menopausal status
recognized and defined, rather than relying on their own judgment (Kaufert and
Gilbert, 1986). This sentiment was also articulated on the pharmaceutical web
sites. For example, consumers were informed on the ENJUVIA web site that
health care professionals “can determine which treatment is right.” Further, the
ANGELIQ web site told women it was “important for you to pay attention to how
you are feeling and talk to your healthcare professional about it” (ANGELIQ web
site: http://www.angeliq-us.com. Retrieved: July 13, 2009). Once again, a health
care provider’s knowledge was privileged. As the above quotes demonstrated,
the “expert” role of physicians in their ability to define and categorize women’s
experiences was reinforced.
In general, the web sites in the study sample conformed to these “tests for
medicalization.” The web sites explained menopause in biomedical terms
implying it was a medical event to be medically managed, focused on the loss of
hormones, introduced HT to restore or balance hormone levels, and reinforced
medical authority in providing a medical diagnosis. My analysis also revealed
another medicalizing technique. Since the reading level of the four online
symptom tools far surpassed the estimated reading level of the average adult in
the United States, this created a context for which medicalization can occur.
Since the reading level of information found on the pharmaceutical web sites in
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the sample was too high, it suggested consumers may need to consult with a
health care to make sense of the information. In this way, it also reinforced the
role of physician as an “expert.” As a result of this finding, I propose this is one
more sign of medicalization and can be used to further demonstrate how the
process of medicalization was operating on the pharmaceutical web sites for HT.
When we take these “signs” together as a whole, we gain a sense of how the
process of medicalization was occurring on the pharmaceutical web sites for HT.
However, there were some marked differences across the HT web sites.
As stated, all of the web sites in the sample drew heavily on the “menopause as
disease” discourse and emphasized the loss of hormones as a “reason” or
explanation for menopause. While an emphasis on change was clear on the web
sites, only one web site (PREMARIN) actually used the word “decline.” Other
web sites, such as ANGELIQ, CombiPatch, and femhrt, employed the terms
“adjustment” and “balance.” However, together the language used on the web
sites helped to set the stage for using the HT products in order to restore
hormone levels.
The ENJUVIA web site was unique among the study sample for its use of
biomedical rhetoric for describing symptoms. I noted that the terms “vasomotor
symptoms” and “vaginal atrophy” were used on the ENJUVIA web site. This
biomedical nomenclature suggested a disease-like nature of menopause and
placed these “symptoms” within a medical context.
I also noted how symptoms were presented in terms of physical
symptoms, such as night sweats and vaginal dryness. The physical symptoms
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were then associated with having a negative impact on social and personal
relations. This technique was particularly evident on the ENJUVIA web site which
proclaimed that poor sleep quality resulting from night sweats could lead to a
“reduced sense of self.”

By characterizing symptoms as “disruptive,” the

negative language further set the stage for using the HT products.
In comparison to the other online symptom tools, the ENJUVIA symptom
tool was the only one to include psychological symptoms among the list of
possible menopausal symptoms. Specifically, the ENJUVIA “Menopause Impact
Tool” included psychological symptoms such as anxiety, irritability, sadness, and
difficulty concentrating. The inclusion of such psychological symptoms in the
ENJUVIA online tool implied to consumers that they were both important and
also linked to menopause.
Moreover, the ENJUVIA web site further listed irregular periods, weight
gain, and dry skin as “other” symptoms of menopause (ENJUVIA web site:
http://www.enjuvia.com. Retrieved: July 14, 2009). Additional menopausal
“symptoms” were listed on the CombiPatch web site, including mood changes,
mood swings, and irritability. These changes are not necessarily related to
menopause and by having these listed as so-called symptoms of menopause on
the CombiPatch and ENJUVIA web sites suggested a possible link or association
with menopause.
Moreover, the CombiPatch web site described menopause as when a
woman’s “reproductive system slowly shuts down” (CombiPatch web site:
http://www.combipatch.com. Retrieved: July 13, 2009).

The mechanical
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language in this example was reminiscent of the biomedical model in which the
body is viewed as a machine breaking down. On the CombiPatch web site, the
aging female body was compared to a machine “breaking down,” which in turn,
illustrated how menopause was being articulated as a declining biological
function.
The above examples illustrate the differences among the HT web sites. In
comparison to other web sites the sample, CombiPatch and ENJUVIA
represented menopause as a highly medicalized process with their use of
biomedical rhetoric (i.e. “atrophy” and “ovaries shutting down”). Furthermore, the
CombiPatch and ENJUVIA web sites included psychological symptoms and
linked them with menopause. For these reasons, I concluded that the degree of
medicalization across the web sites varied with the CombiPatch and ENJUVIA
web sites being more explicit in their adoption of a biomedical perspective.

Summary

From my analysis, several things became clear. First, descriptions of
menopause found on the pharmaceutical web sites for HT articulated and
advanced a biomedical perspective of menopause. In adopting a medical
perspective, menopause was described as a “change of life” or a “stage”
requiring medical management. Second, the biomedical rhetoric used to explain
the “reasons” for menopause emphasized the loss of hormones and end of
regular menstruation thereby setting the stage for using HT products to adjust or
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restore this balance. Third, the web sites employed the terminology of illness,
including the term “symptoms” which is a medically symbolic term. In the online
advertisements for HT, women were told that their symptoms were to be
assessed, tracked, and managed which clearly relates to a disease-like model of
menopause. Likewise, symptoms were presented to consumers as problematic
and bothersome. If left untreated, the web sites implied that symptoms could lead
to hampered sex lives and a reduced sense of self. Fourth, the web sites were
prescriptive and advocated certain consumer behaviors or actions. Specifically,
women were told to “discuss” or “ask” their health care provider about HT. By
following-up with a physician to inquire about HT, consumers would learn more
about the “relief” they could expect from using HT. Hence, the biomedical
definitions and explanations of menopause, list of symptoms needing to be
medically managed, and the consumer actions being advocated on the web sites
worked together in unison to set the stage for using HT to balance hormone
levels and alleviate symptoms.
Throughout my analysis, attention to language and word choice was vital
for gaining an understanding of how the pharmaceutical companies portrayed
menopause in the online advertisements. During my analysis, I found that the
online advertisements for HT continued to reflect a biomedical understanding of
menopause by presenting menopause as a loss of hormones accompanied by
problematic and bothersome symptoms for which HT may help to balance
hormone levels. Thus, my analysis adds to our understanding of how menopause
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was being portrayed on web sites for HT and elucidated several mechanisms
through which the process of medicalization can occur.
Having

considered

the

representation

of

menopause

in

online

advertisements for HT, I would now like to expand my analysis in two ways. First,
I examined the presentation of benefits of HT to consumers on the web sites.
Second, I explored how the possible side effects of HT were portrayed in the
online advertisements for HT. Therefore, at center stage of my analysis in the
next chapter was how the benefits, side effects, and risks of HT were portrayed
by drug manufacturers in online advertisements for HT.
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CHAPTER 8
PRESENTATION OF BENEFITS AND SIDE EFFECTS
OF HORMONE THERAPIES

In this chapter, my analysis of the presentation of benefits and side effects
of hormone therapies (HT) in the online advertisements is offered. To help
contextualize the discussion, it is important to briefly review direct-to-consumer
(DTC) advertising and its regulation. In 1999, the U.S. Food and Drug
Administration (FDA) provided recommendations for the mass media promotion
of direct-to-consumer promotion of prescription drugs (FDA Web site:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation
/Guidances/ucm070065.pdf. Retrieved: May 23, 2010). The FDA further issued
an update for print advertisements in 2004 which focused on conveying risk
information

for

consumers

(FDA

Web

site:

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation
/Guidances/ucm069984.pdf. Retrieved: May 23, 2010). As such, existing FDA
rules require all DTC prescription drug advertisements that mention the brand
name and treated disease to present a “fair balance of the benefits and risks
associated with the drug” (Huh and Cude, 2004, p. 530). Unfortunately, the FDA
itself has not provided an explicit definition for their “fair balance” disclosure
(Holtz, 1998).
To complicate matters, the FDA “has not written any regulations specific to
DTC prescription drug websites” (Huh and Cude, 2004, p. 530). Thus,
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pharmaceutical web sites are viewed largely as an “extension of traditional print
advertising” (Davis, Cross, and Crowley, 2007, p. 35). Therefore, if a web site
mentions a drug by name, it must meet the standard applied to print advertising
(Moore and Newton, 1998).
Despite the “growing importance of prescription drug websites,” few
empirical

studies

have

examined

consumer-targeted

prescription

drug

advertising in the online environment (Huh and Cude, 2004, p. 529).
In light of this situation, I first examined the portrayal of benefits of HT to
consumers on the web sites. In addition, I also explored how benefits of HT were
presented to health care professionals. Next, I investigated how side effects were
presented in the online advertisements for HT. As researchers have noted, risk
information, such as side effects and contraindications, may be critical
information that consumers seek from a web site (Holtz, 1998; Huh and Cude,
2004). As such, also of particular interest to my analysis was how the Women’s
Health Initiative (WHI) was framed in discussions for consumers and health care
providers. Finally, the chapter concludes with a discussion of issues that
emerged from my analysis pertaining to how benefits, side effects, and the WHI
were portrayed by drug manufacturers in online advertisements for HT.

Location of Benefits

To examine the portrayal of benefits of HT on the web sites, I started by
assessing the location of benefits information on the HT web sites. According to
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the FDA, a benefit is “help provided by a drug for the person who is taking it”
(FDA

Web

site:

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdverti
sing/ucm072025.htm. Retrieved: February 13, 2010). In this study, I employed
this definition provided by the FDA in order to identify where the web sites
discussed the positive outcomes that could be expected as a result of using the
various HT products.
All of the HT web sites (N=8) discussed the benefits of HT on a specific web
page devoted to benefits information. In every instance, benefits information for
consumers was located on a web page titled “About” followed by name of the
particular HT product (N=8). For example, the proclaimed benefits of using
ANGELIQ were observed on a web page entitled “About ANGELIQ” on the HT
web site. Likewise, the advertised benefits of using PREMARIN were presented
on a web page labeled “About PREMARIN.” As such, this was a recurring pattern
across all of the HT web sites.
Furthermore, two HT web sites highlighted benefits information in two
separate places. The PREMARIN and PREMPRO web sites, both products from
Wyeth Pharmaceuticals, provided two web pages for consumers to learn about
the benefits of the HT products. In these cases, the benefits of PREMARIN and
PREMRO were found on a web page titled “About PREMARIN/PREMPRO” as
well as another web page with identical information labeled “Benefits of
PREMARIN/PREMPRO.” By having the benefits information listed on the
pharmaceutical web sites in multiple places, web site users would be more likely
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to find this information in case they did not know to look for this information under
the “About” menu option. The significance of the placement of benefits
information of HT on specific web pages illustrated that the proclaimed benefits
of each HT product were prominently featured on each of the web sites.
Moreover, two HT web sites in particular (PREMARIN and PREMPRO) used the
repetition of this information in two distinct places to announce beneficial aspects
of their HT products to web site users. Next, I take a closer look at the description
of the “benefits” of HT in the online advertisements.

Presentation of Benefits to Consumers

Table 26 shows the advertised benefits of HT to consumers were
represented by a number of key phrases or words. In the online advertisements,
key phrases used to describe the benefits of HT included “effectively control,”
“significantly reduce,” and “rapid relief” from menopausal symptoms. According to
the ENJUVIA web site, ENJUVIA was “demonstrated to effectively control hot
flashes, night sweats, vaginal dryness, and pain with sex” (ENJUVIA web site:
http://www.enjuvia.com. Retrieved: July 14, 2009).
“significantly

reduces

daily

hot

flashes”

Furthermore, Estrasorb
(Estrasorb

http://www.estrasorb.com. Retrieved: July 15, 2009).

web

site:

Another example was

found on the ANGELIQ web site which stated the ANGELIQ pill provided “rapid
relief of hot flashes, night sweats, and vaginal dryness” (ANGELIQ web site:
http://www.angeliq-us.com. Retrieved: July 13, 2009).
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Other descriptions of benefits observed included that CombiPatch was
“easy

to

apply,

discreet,

and

small”

(CombiPatch

web

site:

http://www.combipatch.com. Retrieved: July 13, 2009). CombiPatch was also
“designed to stay on during various activities including swimming, showering and
bathing. So you can enjoy an active lifestyle while wearing the patch”
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009). In
addition, using Estrasorb “fits easily into your beauty routine… [and] leaves your
legs

soft,

smooth,

and

moisturized”

(Estrasorb

web

site:

http://www.estrasorb.com. Retrieved: July 15, 2009).
As seen in Table 26, six of the HT web sites stated benefits for hot
flashes, night sweats, and vaginal symptoms (ANGELIQ, CombiPatch, ENJUVIA,
Femring, PREMARIN, and PREMPRO). The femhrt web site highlighted benefits
for hot flashes and night sweats. Finally, the Estrasorb web site mentioned
benefits for night sweats. None of the pharmaceutical web sites in the study
sample (N=8) linked back the U.S. Food and Drug Administration (FDA) web site.

181
Table 26: Description of Benefits of HT for Consumers
Name of HT
Product

Description of Benefits for Consumers

ANGELIQ

•
•

CombiPatch

•
•
•
•

ENJUVIA

•
•
•

Estrasorb

•
•
•
•
•
•

femhrt

•
•

Femring

•
•
•

Rapid relief of hot flashes, night sweats, and vaginal
dryness
Reduction of hot flashes and night sweats
Reduce hot flashes
Treat hot flashes, and vaginal dryness, itching and
burning
Easy to apply, discreet and small
Ultra Convenience: The patch is designed to stay
on during various activities including swimming,
showering and bathing. So you can enjoy an active
lifestyle while wearing the patch.
Demonstrated to effectively control hot flashes,
night sweats, vaginal dryness, and pain with sex
Shown to lower the number and severity of hot
flashes and night sweats
Significantly reduced the severity of vaginal dryness
and pain with sex
Significantly reduces daily hot flashes:
Easy to use
Fits easily into your beauty routine. Just apply
Estrasorb lotion once a day to each leg.
Leaves your legs soft, smooth, and moisturized
Effective: in a clinical study, hot flashes were
reduced by 85%
Well-tolerated: very few skin reactions have been
reported
Treatment of menopause symptoms such as hot
flashes/night sweats
Help reduce your chances of developing
osteoporosis

Effective way to treat menopause symptoms
Convenient and discreet delivery option
Aids in the relief of hot flashes, night sweats, and
vaginal dryness
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PREMARIN

•

Help reduce menopausal symptoms

•

You can expect relief from your menopausal
symptoms to begin quickly with PREMARIN. (You
may begin to feel relief from hot flashes in 1 to 3
weeks.)
Hot flashes and night sweats are likely to become
less frequent and intense.
Relief from vaginal symptoms
Help reduce your chances of developing
osteoporosis
Proven to increase bone mineral density at the hip
and the spine and help prevent postmenopausal
osteoporosis

•
•
•
•

PREMPRO

•
•
•
•

Proven to effectively relieve hot flashes, night
sweats, and vaginal symptoms
Hot flashes and night sweats are likely to become
less frequent and less intense
Help reduce your chances of developing
osteoporosis
proven to increase bone mineral density at the hip
and spine and help prevent postmenopausal
osteoporosis

Further analysis revealed that the “benefits” of HT advertised to
consumers could be grouped into two main themes. One of the primary benefits
of HT presented on the HT web sites was symptom reduction. Specifically,
mention of this benefit was observed on all of the HT web sites (N=8). According
to one web site, ANGELIQ provided a “reduction of hot flashes and night sweats”
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).
ENJUVIA was also “shown to lower the number and severity of hot flashes and
night sweats” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14,
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2009).

Furthermore, ENJUVIA “significantly reduced the severity of vaginal

dryness and pain with sex” (ENJUVIA web site: http://www.enjuvia.com.
Retrieved: July 14, 2009). Similarly, “hot flashes and night sweats are likely to
become less frequent and intense” with PREMARIN (PREMARIN web site:
http://www.premarin.com. Retrieved: July 17, 2009). Thus, the reduction in the
number and severity of menopausal symptoms, such as hot flashes, night
sweats, and vaginal dryness, was highlighted as a benefit on all of the HT web
sites. As Table 26 illustrates, the terms “reduce” or “reduction” were observed
across all of the HT web sites in the study sample.
It is worth noting that the Estrasorb web site asserted “the number of hot
flashes per day were reduced by 85%” in a clinical study (Estrasorb web site:
http://www.estrasorb.com. Retrieved: July 15, 2009). Interestingly, a citation to
the actual research study was not provided for consumers on the Estrasorb web
site to support this claim. With regards to this omission, perhaps there was an
assumption that women did not want to know this scientific information, or maybe
they did not need to know, or possibly women would not be able to track down
the medical study. Nevertheless, claims of a scientific basis raise important
questions around the use of such declarations whenever there is insufficient
evidence provided to consumers. In fact, this claim may also be seen as an
attempt to differentiate this particular HT product from other hormone products
that do not make such claims.
The prevention of osteoporosis was another principal “benefit” of HT
presented to consumers in the online advertisements. This preventative benefit
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was observed on three HT web sites (femhrt, PREMARIN, and PREMPRO).
According to one web site, femhrt could “help reduce your chances of developing
osteoporosis

by

increasing

bone

mass”

(femhrt

web

site:

http://www.wcrx.com/products/femhrt. Retrieved: July 25, 2009). Likewise,
PREMARIN informed consumers the HT product reduced “your chances of
developing osteoporosis” (PREMARIN web site: http://www.premarin.com.
Retrieved: July 17, 2009). In addition, PREMPRO could also “help prevent
postmenopausal osteoporosis” (PREMPRO web site: http://www.prempro.com.
Retrieved: July 17, 2009). While the FDA acknowledges that hormones “may
reduce your chances of getting thin, weak bones,” the FDA informs consumers
there are “other medicines and things you can do to help your bones” (FDA web
site: http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118624.htm.
Retrieved: February 14, 2010). Unfortunately, the FDA does not provide further
details about these other medicines or “things” that one can do to slow bone loss.
Nonetheless, this particular comment about bone health from the FDA
was also echoed in another statement for health care providers which
recommended “when these drugs are being prescribed only to prevent
osteoporosis, health care providers are encouraged to consider other treatments
before prescribing estrogen or estrogen with progestin” (FDA web site:
http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135339.htm.
Retrieved: February 22, 2010). As mentioned in an earlier chapter, previous
research found that drug advertisements in women’s magazines encouraged all
women over thirty-five years to consider taking hormones for osteoporosis as a
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“preventive measure” (Worcester and Whatley, 1992, p. 9). The technique of
casting menopause as a “risk” for osteoporosis and therefore promoting HT for
the prevention of bone loss and fractures has also been reported in the literature
as a way of expanding the list of possible symptoms treatable with HT (Dukes,
1997; Palmlund, 1997; Worcester, 2004; Worcester and Whatley, 1992). Here,
my analysis suggests there was also a trend in the online drug advertisements of
promoting HT for osteoporosis as a preventive measure.
To summarize, symptom reduction and the prevention of osteoporosis
were two main benefits of HT promoted to consumers in the online drug
advertisements. Another feature that I observed on the HT web sites was the use
of “patient stories” or testimonials to support claims of a product’s benefits. To
illustrate the “benefits” of HT, three of the web sites (Estrasorb, PREMARIN, and
PREMPRO) turned to “real life” stories. In these three online HT advertisements,
women’s stories were portrayed as first-person accounts of using HT. In all three
instances, the women depicted in these stories made reference to seeking
further medical advice as a means of alleviating menopausal symptoms. Under
the “Personal Experiences” menu option found on the Estrasorb web site,
consumers were introduced to a Caucasian woman named “Alice.” Consumers
were told that Alice was a 58 year old executive suffering from severe hot flashes
and night sweats which were “disrupting sleep patterns and getting in the way of
daily activities and relationships” (Estrasorb web site: http://www.estrasorb.com.
Retrieved: July 15, 2009). Alice was quoted as saying that her situation was
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“intolerable… [and] I’m going to talk with my doctor about Estrasorb” (Estrasorb
web site: http://www.estrasorb.com. Retrieved: July 15, 2009).
The “Women’s Stories” found on PREMARIN and PREMPRO web sites
provided further examples of personal stories attesting to the benefits of HT and
encouraging medical intervention for menopausal symptoms. On the PREMARIN
web site, consumers were introduced to a Caucasian woman named “Maureen.”
Unlike what was witnessed with the Estrasorb character “Alice,” Maureen’s age
and occupation were not provided on the PREMARIN web site. Nevertheless,
Maureen informed web site users that she went to see her doctor to inquire about
PREMARIN. Maureen recounted that “one of the best things she said to me was
that she uses it and she thinks it’s great. And that really helped me feel
comfortable

about

utilizing

PREMARIN”

(PREMARIN

web

site:

http://www.premarin.com. Retrieved: July 17, 2009). By suggesting that a health
care provider also used PREMARIN, this story further reassured consumers
about the appropriateness of HT for menopausal symptoms while also adding
legitimacy to the claim. One more example was found on the PREMPRO web
site in which a different Caucasian woman named “Debbie” stated “when I first
started experiencing symptoms, I didn’t know what was happening, so I asked
my doctor about it” (PREMPRO web site: http://www.prempro.com. Retrieved:
July 17, 2009). After taking PREMPRO, Debbie further noted that her hot flashes
“got significantly better” after about two weeks (PREMPRO web site:
http://www.prempro.com. Retrieved: July 17, 2009).
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In fact, I realized that these women’s stories adhered to a biomedical model
of illness by discussing topics such as signs of symptoms of menopause,
diagnosis, and treatment. Even more troubling was a disclaimer found on the
Estrasorb web site that stated that the “patient profiles are hypothetical [and]
models are used for illustrative

purposes

only” (Estrasorb

web

site:

http://www.estrasorb.com. Retrieved: July 15, 2009). I should also note that it
was not known if the “Women’s Stories” found on the PREMARIN and
PREMPRO web sites were actual patients or hypothetical scenarios.
Nonetheless, the women’s stories attested to the proclaimed benefits of HT
thereby encouraging consumers to seek medical treatment. Consequently, the
use of “women’s stories” were constructed as first-person testimonials about
experiences with HT and functioned to support a product’s claims about benefits.

Presentation of Benefits to Health Care Professionals

My analysis also revealed that benefits of HT were presented differently to
health care providers than consumers in the online advertisements. In this
section of the chapter, I further inspect how the benefits of HT were portrayed on
portions of the HT web sites designated specifically for health care professionals.
Table 27 illustrates the various “selling points” of HT presented to health care
professionals on the HT web sites.
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Table 27: Selling Points of HT Emphasized to Health Care Professionals
Name of HT
Product

Description of Selling Points for Health Care
Professionals

ANGELIQ

None

CombiPatch

•
•
•
•

ENJUVIA

•
•

•
•

It’s a convenient alternative for patients seeking
relief for menopausal symptoms
Two strengths of CombiPatch are available
It’s comfortable: has a low incidence of skin
irritation and side effects
It’s discreet: CombiPatch is small and transparent
Delivers effective relief of vasomotor symptoms,
and vaginal dryness and pain with sex to your
symptomatic menopausal patients
Significantly reduces the frequency and severity of
vasomotor symptoms and vaginal dryness and
pain with sex, symptoms of vulvar and vaginal
atrophy, associated with menopause
ENJUVIA is something you—and your patients—
will be glad to discover
ENJUVIA dosing is flexible, too.

Estrasorb

•
•
•
•
•

femhrt

None

Femring

None

PREMARIN

•
•
•
•

Fast, effective symptom relief
Proven in a well-controlled clinical trial
85% reduction in daily hot flashes
Demonstrated safety and tolerability
Demonstrated patient satisfaction: 91% of patients
liked the way their skin felt after applying
Estrasorb

A blend of estrogens with extensive evidence to
support your recommendation
Significant relief of vasomotor symptoms as early
as 3 weeks
Significant increase in spine and hip bone mineral
density
Range of dosing options
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PREMPRO

•
•
•
•

More dosing options than any other single-tablet
combination hormone therapy
Individualize her therapy with a range of dosing
options
Significant reduction in moderate to severe hot
flashes, even at low dose
Significant increase in spine and hip bone mineral
density, even at low dose

As Table 27 demonstrates, six of the HT web sites (n=6) presented selling
points of HT to health care professionals. Notably, four HT web sites (n=4)
highlighted a range of dosage options. The CombiPatch web site informed health
care professionals that two strengths of CombiPatch were available (CombiPatch
web site: http://www.combipatch.com. Retrieved: July 13, 2009).

Another

example was found on the PREMARIN web site which highlighted a “range of
dosing options” on the section of the web site aimed to health care professionals
(PREMARIN web site: http://www.premarin.com. Retrieved: July 17, 2009).
Furthermore, PREMPRO claimed to offer “more dosing options than any other
single-tablet

combination

hormone

therapy”

(PREMPRO

web

site:

http://www.prempro.com. Retrieved: July 17, 2009). Finally, health care
professionals were reminded that “ENJUVIA dosing is flexible, too” (ENJUVIA
web site: http://www.enjuvia.com. Retrieved: July 14, 2009). Clearly, a range of
dosage options was viewed as an attractive feature that would appeal to health
care professionals.
Also visible on sections of the HT web sites for health care providers were
references to “evidence” to support claims about the products’ benefits.
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Specifically, two of the HT web sites (n=2) referenced “evidence” for health care
providers. According to the Estrasorb web site, the HT product had been “proven
in a well-controlled clinical trial” (Estrasorb web site: http://www.estrasorb.com.
Retrieved: July 15, 2009).

PREMARIN was also described to health care

professionals as a “blend of estrogens with extensive evidence to support your
recommendation” (PREMARIN web site: http://www.premarin.com. Retrieved:
July 17, 2009). On the Estrasorb and PREMARIN web sites, citations to studies
supporting these beneficial claims were provided for health care professionals.
Therefore, my analysis revealed that references to actual studies were provided
only on portions of the HT web sites aimed at health care providers. In fact, five
of the HT web sites (CombiPatch, ENJUVIA, Estrasorb, PREMARIN, and
PREMPRO) provided references to actual studies for health care professionals.
In contrast, consumers were not provided with clinical evidence to support
pharmaceutical companies’ claims about the benefits of HT.
Other selling points emphasized to health care providers that were
observed included the mention of “convenience” and “patient satisfaction.”
CombiPatch was described as a “convenient alternative for patients seeking
relief

for

menopausal

symptoms”

(CombiPatch

web

site:

http://www.combipatch.com. Retrieved: July 13, 2009). In addition, the Estrasorb
web site referred to “demonstrated patient satisfaction” which is further explained
by the statement “91% of patients liked the way their skin felt after applying
Estrasorb” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15,
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2009). Thus, “convenience” and “patient satisfaction” were additional selling
points promoted to health care professionals in the online advertisements for HT.
To summarize, the presentation of benefits of HT in the online drug
advertisements varied depending on the intended audience. Consumers were
informed about the possibility of symptom reduction and the prevention of
osteoporosis. On the other hand, health care professionals were told about the
range of dosage options, evidence to support claims of efficacy, and patient
satisfaction with HT products. Similar to my earlier findings in which I found that
the pharmaceutical companies employed different product slogans for different
web site audiences, here I also observed variations in the types of “benefits” or
“selling points” emphasized for consumers and health care professionals.
Another distinguishing characteristic was the lack of scientific evidence provided
for consumers. Moreover, patient testimonials, such as the hypothetical stories
presented on the Estrasorb web site, were used to support product claims on
several of the HT web sites. Next, I examined how the side effects of HT were
presented across the HT web sites.

Location of Side Effects

This section of the chapter analyzes the location of information about the
possible side effects of HT on the web sites. Table 28 shows where the side
effects of HT were discussed in the online advertisements. Specifically, I was
interested in the location in which these side effects were disclosed.
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Table 28: Location of Side Effects Information on the HT Web Sites
Name of HT
Product

Separate Web
Page for Side
Effects

Name of Web Page with
Side Effects Information

ANGELIQ

Yes

“Safety Information”

CombiPatch

Yes

“Risks and Benefits of
Hormone Therapy”

ENJUVIA

Yes

“Safety and Tolerability”

Estrasorb

No

N/A

femhrt

Yes

“Important Safety Information”

Femring

Yes

“Important Safety Information”

PREMARIN

Yes

“Side Effects and Safety”

PREMPRO

Yes

“Side Effects and Safety”

As Table 28 indicates, seven of the HT web sites (n=7) had specific web
pages discussing possible side effects. Six of the HT web sites (n=6) used the
word “safety” in the title of the web page where the side effects of HT were
discussed. For example, the names of the web pages on the PREMARIN and
PREMPRO sites where side effects were mentioned were called “Side Effects
and Safety.” The Femring and femhrt web sites had a page called “Important
Safety Information” which outlined the possible side effects associated with HT.
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Additionally, the ANGELIQ web site had a page entitled “Safety Information” and
ENJUVIA highlighted side effects on a page called “Safety and Tolerability.”
In particular, one HT web site did not have a specific web page where side
effects were discussed. On the Estrasorb web site, possible side effects were
found in a footer at the bottom of the web site. Although this footer appeared
throughout the web site, the text in this footer was notably a smaller font size
compared to the main content found on the Estrasorb web site. Therefore, this
online advertisement did not present a balance of information about the drug's
possible side effects compared to the advertised benefits because the location
and smaller font size minimized the importance of side effects. As a result, the
side effects could potentially be overlooked by web site users due to the fact that
this information appeared in a smaller font size than the benefits information and
was placed at the bottom of the advertisement far from the benefits. Thus, both
the location and font size of the possible side effects on the Estrasorb web site
was a cause for concern. This example illustrated the need for better and
consistent risk communication in online drug advertisements. Next, I examined
how the side effects of HT were portrayed in the online drug advertisements.

Presentation of Side Effects

According to the FDA, a side effect of a drug refers to “what can go wrong
when

the

drug

is

used”

(FDA

Web

site:

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdverti
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sing/ucm072025.htm. Retrieved: February 20, 2010). Table 29 illustrates the
language used to describe possible side effects of HT on the web sites. Here, I
was most interested in the way language was used by the pharmaceutical
companies to describe these side effects. My analysis shows that the side effects
were presented as either “common” side effects or “less common but serious”
side effects.
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Table 29: Description of “Common” Side Effects and
“Less Common but Serious” Side Effects
Name of HT Product

“Common” Side Effects

“Less Common but
Serious” Side Effects

ANGELIQ

•
•
•

•
•

•
•

Headache
Breast pain
Irregular vaginal
bleeding or spotting
Stomach/abdominal
cramps, bloating
Nausea and vomiting
Hair loss

CombiPatch

•
•
•

Breast pain
Vaginal bleeding
Headache

N/A

ENJUVIA

•
•
•

Headache
Breast pain
Irregular vaginal
bleeding or spotting
Stomach/abdominal
cramps, bloating
Nausea and vomiting
Hair loss

N/A

•

•
•
•

Estrasorb

•
•
•
•
•
•
•

•
•
•
•
•
•
•
•

Breast lumps
Unusual vaginal
bleeding
Dizziness and
faintness
Changes in speech
Severe headaches
Chest pain
Shortness of breath
Pains in your legs
Changes in vision
Vomiting

N/A
Headache
Breast pain
Irregular vaginal
bleeding or spotting
Stomach/abdominal
cramps, bloating
Nausea and vomiting
Skin irritation, redness or
rash at application site
Hair loss
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femhrt

•
•
•
•
•
•

Femring

•
•
•
•
•
•

PREMARIN

•
•
•
•

PREMPRO

•
•
•
•
•

Headache
Breast pain
Irregular vaginal
bleeding or spotting
Stomach/abdominal
cramps, bloating
Nausea and vomiting
Hair loss

•
•

•
•
•
•
•
•
•

Breast lumps
Unusual vaginal
bleeding
Dizziness and
faintness
Changes in speech
Severe headaches
Chest pain
Shortness of breath
Pains in your legs
Changes in vision
Vomiting

Headache
Vaginal infection
Breast tenderness
Vaginal bleeding or
spotting
Back ache
Abdominal bloating

•
•
•
•
•
•
•
•

Breast cancer
Cancer of the uterus
Stroke
Heart attack
Blood clots
Dementia
Gallbladder disease
Ovarian cancer

Vaginitis due to yeast or
other causes
Vaginal bleeding
Painful menstruation
Leg cramps

N/A

Breast pain/enlargement
Vaginitis due to yeast or
other causes
Leg cramps
Vaginal
spotting/bleeding
Painful menstruation

N/A

•
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As demonstrated in Table 29, breast pain and vaginal bleeding were two
common side effects observed across all of the HT web sites (N=8). In fact, six of
the HT web sites (n=6) listed the same “common” side effects of HT. These six
possible side effects were headaches, breast pain, irregular vaginal bleeding or
spotting, stomach/abdominal cramps or bloating, nausea and vomiting, and hair
loss. Such statements of possible side effects coincided with the FDA which has
also noted these six side effects as common with estrogen and estrogen with
progestin

drug

products

(FDA

Web

site:

http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135339.htm.
Retrieved: February 22, 2010).
In the previous chapter, I discussed my findings from analyzing the reading
levels of the information presented on the four online symptom tools in the study
sample. My analysis revealed the information was written at grade levels that
exceeded the estimated reading level of the average adult in the U.S. (National
Adult Literacy Survey, 1992). I further assessed the reading level of these six
common side effects of HT. To accomplish this, I again utilized an online tool
called “TxReadability,” a free application developed by the Accessibility Institute
at the University of Texas at Austin. To summarize briefly, the Flesch-Kincaid
Grade level indicates the grade a person will have to reach to be able to
understand the text (Accessibility Institute at the University of Texas web site:
http://webapps.lib.utexas.edu/TxReadability/app. Retrieved: March 9, 2010). For
instance, a score indicating the grade level of seven means that a seventh grader
should be able to understand the text. An analysis of the text describing the six
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common side effects of HT across the eight web sites in this study sample
yielded a score of 12.94. This score is equivalent to a 12th grade reading level in
the United States or some college education. As I previously noted, considering it
is estimated that one in four adults in the United States read at or below the 3rd
grade reading level, this grade level far surpasses the estimated reading level of
the average adult in the U.S. (National Adult Literacy Survey, 1992). Moreover,
the Wayne State University Institutional Review Boards (IRB) also provides
guidelines for documents used in the informed consent process in participant
research studies. Generally, the IRB requires consent forms to be written at 6th8th grade reading level (Wayne State University Human Investigation Committee
web site: http://www.hic.wayne.edu/policies/9-1_informed_consent_options.pdf.
Retrieved: May 14, 2010). In this context, it is plausible to conclude that the
information presented across all of the HT web sites about “common” side effects
was too difficult for many of the intended web sites users, thus it should be
rewritten to take into consideration lower literacy levels.
Further, when compared to the reading level of the online symptoms tools,
which was a combined score of 7.74 falling between a 7–8th grade reading level,
the information about common side effects was even higher. This finding
demonstrated a range in reading levels and accessibility of information on the
pharmaceutical web sites. Interestingly, I found that information on the
pharmaceutical web sites was not consistently written at the same reading level.
Rather, the reading level varied making some information less accessible, such
as the side effects information which I reported was written at an even higher
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reading level than information from the online symptom tools. Once again, since
important information about possible side effects was not as readily accessible
for consumers, I speculate that consumers may need to consult with health care
professionals in order to make sense of the information about side effects
provided on the pharmaceutical web sites. In light of this, consumers would have
to rely on the “expertise” and medical knowledge of a health care professional to
acquire relevant information about possible side effects.
Other side effects associated with HT were also mentioned in the online drug
advertisements. Three of the HT web sites (Femring, PREMARIN, and
PREMPRO) listed “vaginal infection” or “vaginitis” as a common side effect. In
addition, two of the HT web sites (PREMARIN and PREMPRO) listed “leg
cramps” as a common side effect. As Table 29 shows, two of the HT web sites
(PREMARIN and PREMPRO) also listed “painful menstruation” as a common
side effect. Another example of a “common” side effect observed was skin
irritation (Estrasorb cream).
In addition to “common” side effects, three web sites (ANGELIQ, femhrt,
and Femring) listed “less common but serious” side effects. As Table 29
illustrates, ANGELIQ listed “unusual vaginal bleeding” as a “less common but
serious” side effect (ANGELIQ web site: http://www.angeliq-us.com. Retrieved:
July 13, 2009). However, ANGELIQ also stated “irregular vaginal bleeding or
spotting” was a common side effect (ANGELIQ web site: http://www.angeliqus.com. Retrieved: July 13, 2009).

Consequently, I noticed some overlap

between the “common” and “less common but serious” side effects presented on
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the HT web sites. This trend continued on the femhrt web site which listed
“vaginal bleeding” and “vomiting” as both common and “less common but
serious” side effects (femhrt web site: http://www.wcrx.com/products/femhrt.
Retrieved: July 25, 2009). As witnessed on the ANGELIQ and femhrt web sites,
the pattern of presenting side effects to consumers as both “common” and “less
common but serious” could be a potential source of confusion for consumers.
In summary, both the location of the side effects information and the language
used to describe possible side effects of HT illuminated several issues. First,
seven of the HT web sites (n=7) had specific web pages discussing the possible
side effects. However, possible side effects were found only in a footer at the
bottom of the Estrasorb web site thereby underscoring the need for better risk
communication. Regarding the description of side effects, possible side effects of
HT were presented as either “common” and “less common but serious” in the
online drug advertisements. Indeed, breast pain and vaginal bleeding were two
common side effects observed across all of the HT web sites. However, one
noticeable trend was the presentation of the same side effects to consumers as
both “common” and “less common but serious” which could lead to confusion
amongst consumers and warrants further clarification.
In light of the Women’s Health Initiative (WHI), concerns about hormones
being linked to an increased risk for cancer, heart attacks, and dementia were
also addressed on the web sites. In the online drug advertisements, information
about risks associated with HT were observed in the footer across all of the HT
web sites in the study sample (N=8). Specifically, three main statements about
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risks of HT were repeated consistently across all of the HT web sites. First, it was
noted that estrogens increase the chance of getting cancer of the uterus.
Second, it was mentioned that using estrogens (with or without progestins) may
increase the chance of getting heart attacks, strokes, breast cancer, and blood
clots. Finally, all of the HT web sites (N=8) stated that using estrogens (with or
without progestins) may increase the chance of getting dementia. These three
statements found across all of the HT web sites were consistent with FDA
statements that also noted these as possible risks associated with HT (FDA Web
site:
http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135339.htm.
Retrieved: February 24, 2010). Given the ongoing concerns about risks
associated with using HT, which were raised by the WHI clinical trial, next I
examined how and where the WHI was mentioned on the HT web sites.

References to Women’s Health Initiative (WHI)

In examining the portrayal of the WHI on the web sites, the location of where
WHI was discussed was an important consideration. Table 30 indicates where
information about the WHI was found across the eight HT web sites. As Table 30
indicates, all of the HT web sites (N=8) directly referred to the WHI. However, the
location of the information about the WHI is deserving of attention.
Five of the HT web sites (n=5) referred to the WHI in sections of the web
site aimed at health care providers. Out of these five HT web sites, four of them
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(ENJUVIA, Estrasorb, PREMARIN, and PREMPRO) mentioned the WHI in the
footer of web pages intended for health care providers. Unique among the study
sample, CombiPatch was the only HT web site that discussed the WHI for health
care providers on a specific web page appropriately entitled the “Women’s Health
Initiative” (CombiPatch web site: http://www.combipatch.com. Retrieved: July 13,
2009). In addition, the CombiPatch web site also provided health care
professionals with a link to the official WHI web site (http://www.whi.org/findings)
for more information about the WHI study’s findings.
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Table 30: Web Sites that Mention WHI and Location of WHI Information
Name of HT
Product

Mention of WHI Location of Where WHI
is Mentioned

Intended for
Consumer or
Health Care
Provider

ANGELIQ

Yes

“Recent News about
Hormone Therapy”

Consumer

CombiPatch

Yes

“Women’s Health
Initiative”

Health Care
Provider

ENJUVIA

Yes

Mentioned in footer on
Health Care
web page for health care Provider
providers

Estrasorb

Yes

Mentioned in footer on
Health Care
web page for health care Provider
providers

femhrt

Yes

“Recent Concerns
Regarding HT”

Consumer

Femring

Yes

“Hormone Therapy
News”

Consumer

PREMARIN

Yes

Mentioned in footer on
web page “Health Care
Professionals’ Info”

Health Care
Provider

PREMPRO

Yes

Mentioned in footer on
web page “Health Care
Professionals’ Info”

Health Care
Provider

The pharmaceutical web sites differed in how they presented and framed
the WHI. By way of contrast, only three web sites in the sample discussed the
WHI on specific sections of the web site intended for consumers (ANGELIQ,
femhrt, and Femring). On these three HT web sites, the titles of the web page
where the WHI was referenced placed an emphasis on “recent concerns” or
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“news” about HT. For instance, the ANGELIQ web page discussing the WHI was
entitled “Recent News about Hormone Therapy” (ANGELIQ web site:
http://www.angeliq-us.com. Retrieved: July 13, 2009). On the femhrt web site,
the WHI was mentioned on the web page “Recent Concerns Regarding HT”
(femhrt web site: http://www.wcrx.com/products/femhrt. Retrieved: July 25,
2009). In addition, the “Hormone Therapy News” web page on the Femring site
provided consumers with information about the WHI (Femring web site:
http://www.wcrx.com/products/femring. Retrieved: July 17, 2009). Since only
three of the HT web sites offered discussions about the WHI for consumers, the
lack of proper attention to the WHI and any discussion regarding the implications
for consumers was noticeably deficient on the HT web sites.
I also noted other distinguishable differences across the pharmaceutical
web sites. The Femring and femhrt web sites, both products from Warner
Chilcott, highlighted benefits reported from the WHI. These two web sites cited
fewer hip fractures and fewer cases of colorectal cancer among users of HT in
the WHI clinical trial. Indeed, putting a positive “spin” on the WHI was an
interesting way to frame the WHI results that effectively minimized commonly
held concerns about hormone use. Further, the ANGELIQ web site stated that
HT “still may be appropriate for many” and encouraged consumers to ask their
health care providers if the “possible benefits of HT outweigh the risks”
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).
Clearly, these three web sites painted a positive picture of the WHI study results
by emphasizing potential benefits of HT. Again, these three web sites were the
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only pharmaceutical web sites for HT in the study sample that specifically
discussed the WHI with consumers. As evident, the framing of the WHI on these
three web sites minimized the risks and concerns associated with the WHI for
consumers by highlighting positive findings of the WHI. It was further suggested
that possible benefits may outweigh potential risks.
On the three consumer-oriented portions of the HT web sites where the
WHI was referenced (ANGELIQ, femhrt, and Femring), consumers were further
encouraged to ask a health care provider for more information about the WHI
findings. According to ANGELIQ web site “many aspects of the findings were not
clear. However, hormone therapy still may be appropriate for many. This is
something each individual woman should discuss with her healthcare provider”
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). In
another example, consumers were informed their “health care provider can
discuss

what

[the

WHI]

results

mean

to

you”

(femhrt

web

site:

http://www.wcrx.com/products/femhrt. Retrieved: July 25, 2009). The Femring
web site also encouraged consumers to also discuss the WHI results with their
health care provider and to “review your hormone therapy options with your
health care provider” (Femring web site: http://www.wcrx.com/products/femring.
Retrieved: July 17, 2009). As a consequence, the WHI was referenced in a
limited manner on consumer-oriented sections of the HT web sites. Given the
limited information about the WHI study provided to consumers, scant discussion
about any implications, and inadequate educational information, consumers were
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encouraged to follow-up with their health care providers for further explanations
about the WHI findings and to discuss HT options.
My analysis revealed that the manner in which the WHI was framed
depended on the intended audience. In contrast, the WHI was referenced in a
different manner to health care providers. In the online drug advertisements for
HT, discussions of the WHI for health care providers centered on warnings about
cardiovascular and other risks brought to light by the WHI study. Mention of
these cardiovascular and other risks were observed on the five HT web sites
which referenced the WHI for health care providers. For example, the ENJUVIA
web site stated “the estrogen alone substudy of the Women's Health Initiative
(WHI) reported increased risks of stroke and deep vein thrombosis (DVT) in
postmenopausal women (50 to 79 years of age)” (ENJUVIA web site:
http://www.enjuvia.com. Retrieved: July 14, 2009). Furthermore, the ENJUVIA
web site went on to state “the estrogen-plus-progestin substudy of the WHI
reported increased risks of myocardial infarction, stroke, invasive breast cancer,
pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to
79 years of age)” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14,
2009).
Thus, how the WHI was discussed on the HT web sites depended on the
intended audience. Interestingly, the CombiPatch also stated the FDA “now
recommends smaller doses over a shorter time for temporary symptom relief”
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009). A
final point to note in this discussion was that all of the HT web sites mentioned
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smaller doses of HT or “low-dose” HT options. Table 31 shows that “low-dose”
HT options were emphasized to both consumers and health care providers on
the HT web sites. As Table 31 indicates, four the HT web sites (CombiPatch,
ENJUVIA, PREMARIN, and PREMPRO) repeated the availability of “low-dose”
HT options in several places. I argue that this was an important reflection of postWHI concerns being acknowledged by the pharmaceutical companies. Indeed,
mention of “low-dose” HT options was in alignment with the current FDA
recommendation regarding HT which states “hormones should be used at the
lowest dose that helps and for the shortest time” (FDA Web site:
http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118624.htm.
Retrieved: February 22, 2010).
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Table 31: Web Sites that Mention “Low-Dose” HT
Name of HT Product

Mention “Low-Dose” HT

Wording/Phrase Used

ANGELIQ

Yes

ANGELIQ should be taken
for the shortest duration of
time at the lowest dose.

CombiPatch

Yes

Two places:
1. For Consumers: You
and your health care
professional should talk
regularly about whether
you are taking the
lowest dose that works
for you. (in footer)
2. For Health Care
Professionals: The FDA
and the North American
Menopause Society
(NAMS) now
recommend smaller
doses over a shorter
time for temporary
symptom relief.

ENJUVIA

Yes

Two places:
1. For Consumers:
estrogens should be
used at the lowest dose
for the shortest period
of time. (in footer)
2. For Health Care
Professionals: LowDose Efficacy With the
ENJUVIA

Estrasorb

Yes

Estrogens with or without
progestins should be
prescribed at the lowest
effective doses and for the
shortest duration consistent
with treatment goals and
risks for the individual
woman.
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(in footer for health care
professionals)
femhrt

Yes

Low-Dose femhrt 0.5/2.5 is
the lowest effective dose
approved by the FDA to
treat menopausal
symptoms with this
combination of hormones.

Femring

Yes

For treatment of
menopausal symptoms,
recent guidelines
recommend the lowest
effective dose for
menopause for the shortest
time.

PREMARIN

Yes

Four places:
1. For Consumers: flexible
low-dose options
2. For consumers:
PREMARIN has been
proven to relieve
menopausal symptoms
even at the lowest dose
3. For Consumers: The
lowest effective dose of
PREMARIN should be
used.
4. For Health Care
Professionals:
estrogens with or
without progestins
should be prescribed at
the lowest effective
doses and for the
shortest duration
consistent with
treatment goals and
risks for the individual
woman. (in footer)

PREMPRO

Yes

Four places:
1. For Consumers:
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PREMPRO offers
effective hormone
therapy with low-dose
options to treat your
menopausal symptoms
2. For consumers:
PREMPRO should be
used at the lowest
effective dose and for
the shortest duration
consistent with your
treatment goals and
risks.
3. For Consumers:
PREMPRO comes in
several dosage
strengths—including
two low-dose
formulations. These
options allow your
health care professional
to choose the one that
is right for you.
4. For Health Care
Professionals:
estrogens with or
without progestins
should be prescribed at
the lowest effective
doses and for the
shortest duration
consistent with
treatment goals and
risks for the individual
woman. (in footer)

Summary

In summary, this chapter expanded my analysis in two ways. First, I
examined the presentation of benefits of HT to consumers and health care
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professionals on the web sites. My analysis indicated different benefits were
emphasized for these two potential markets. Benefits promoted to consumers
included symptom reduction and the prevention of osteoporosis. I also observed
an expanded list of “benefits” were being promoted to consumers beyond what
the HT products were originally FDA-approved for, such as smooth skin and the
convenience of HT fitting “easily into a daily beauty routine.” Interestingly, claims
of benefits for consumers were not supported by actual scientific sources and the
use of hypothetical stories on several of the HT web sites to support product
claims of benefits were perplexing patterns that I witnessed. On the other hand,
health care professionals were presented with several “selling points,” were
informed about the range of available dosing options, provided with evidence to
support claims of efficacy, and told about patient satisfaction with HT products.
Second, I explored how the side effects of HT were portrayed in the online
advertisements for HT. Notably, the side effects were presented as either
“common” or “less common but serious” side effects across the HT web sites.
Indeed, I found some overlap between these two categories of side effects. Thus,
the pattern of presenting side effects to consumers as both “common” as well as
“less common but serious” may be a source of potential confusion for
consumers. Equally noticeable was the location of the side effects information. In
particular, the Estrasorb web site only discussed possible side effects in the
footer of the web site and in a smaller font size which could easily be overlooked.
Therefore, the location and font size of the possible side effects on the Estrasorb
web site, as well as the high reading level across all of the HT web sites, were

212
causes for concern and highlighted the need for better risk communication in
online drug advertisements.
Finally, I found that the discussion of the WHI was presented in a positive
light to consumers and repetition of the availability of “low-dose” HT options
reflected post-WHI concerns. Up to this point, I have examined how the location
of information and actual descriptions were contributing factors to how the
proclaimed benefits, possible side effects, and potential risks of HT were
portrayed by drug manufacturers in online advertisements for HT. In the next
chapter, I move on to summarize and discuss my key findings.

213
CHAPTER 9
DISCUSSION

Direct-to-consumer advertising (DTCA) appears to be flourishing (Conrad and
Leiter, 2008). Since the Internet has become another direct avenue for
pharmaceutical companies to reach consumers, it is important to determine how
online advertisements are portraying menopause. This portrayal is relevant for
understanding society’s views of menopause and it also “sheds light on how
women are informed about this life-changing experience” (Hust and Andsager,
2003, p. 114). My study of pharmaceutical web sites for hormone therapies (HT)
indicated that a medicalized view of menopause remained consistent in the
online advertisements. In particular, a number of conclusions can be drawn from
my findings.

Biomedical Perspective of Menopause

First, the pharmaceutical web sites for HT consistently articulated a
biomedical perspective of menopause. An underlying assumption of the
biomedical model is that menopause is “best understood in terms of the biology
of disease mechanisms” (Derry, 2002, p. 20). In adopting a medical perspective,
descriptions on the pharmaceutical web sites for HT described menopause as a
“change of life” or a “stage” requiring medical management.

The web sites

consistently advocated that this “change” was best managed by a medical
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professional. Thus, the physician’s role and expertise in offering a diagnosis was
reinforced. This finding is consistent with previous research that has also noted
women are often told they should depend on a physician’s medical expertise
rather than on their own judgment (Kaufert and Gilbert, 1986).
Previous studies have also shown that menopause has been framed in
popular magazines as a “deficiency disease” easily fixed with drugs (Cimons,
2008; Lupton, 1996; Meyer, 2001; Shoebridge and Steed, 1999). In this study, I
found that explanations for menopause on the web sites focused exclusively on
the loss of hormones and the end of regular menstruation. By emphasizing
menstrual cycle changes and declining estrogen production, the HT web sites
drew on biomedical definitions of menopause. With such words as adjusting,
balance, and decline found on the HT web sites, the implication was that women
need to “balance” or “make up” for the loss of estrogen production. Therefore,
“deficiency” and “loss” were common themes on the pharmaceutical web sites.
This finding is similar to other researchers that found the terms “deficiency” and
“atrophy” were used in self-help texts about menopause (Lyons and Griffin,
2003). Clearly, this language reflected a biomedical model that views menopause
as an “estrogen deficiency disease for which estrogen replacement is the therapy
of choice” (Kaufert and Gilbert, 1986, p. 8). Importantly, these words on the web
sites also set the stage for the idea of using prescription HT products to restore
this balance. As Derry (2008) notes, postmenopausal women “do produce
estrogen in their bodies [but] these lower levels of hormones were assumed to be
negligible” (p. 722).
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To further illustrate this point, menopause was described on the
CombiPatch web site as when a woman’s “reproductive system slowly shuts
down.” By describing a woman’s reproductive system as “slowly shutting down,”
the mechanical language was reminiscent of the biomedical model in which the
body is viewed as a machine breaking down. Here, this particular online
advertisement likened the aging female body to a machine “breaking down.”
Again, this comparison contributed to the portrayal of menopause as a declining
biological process or function. My finding reinforces previous research also
showing menopause has been socially constructed by clinical communities and
pharmaceutical companies as a pathological and an abnormal condition in need
of medical intervention (Dillaway, 2005; McCrea, 1983; Posner, 1979; Riessman
1983; Whittaker, 1998).
Further analysis revealed that the pharmaceutical web sites were
prescriptive and advocated certain consumer behaviors or actions. Specifically,
women were told to “discuss” or “ask” their health care provider about HT. The
web sites implied by following-up with a physician to inquire about HT, women
would learn more about the “relief” they could expect from using HT. Hence, the
biomedical definitions of menopause, explanations of menopause focusing on
estrogen loss, and the consumer actions being advocated on the pharmaceutical
web sites worked together to portray menopause as a medical event to be
medically managed.

Presentation of “Problematic” Symptoms
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As Rostosky and Travis (1996) noted, menopause continues to be defined
by a long list of symptoms derived from the biomedical research. This pattern
persisted on the pharmaceutical web sites for HT in which a range of
menopausal “symptoms” were listed. One of the most sweeping aspects of the
HT web sites was the overall portrayal of symptoms in a negative light. This was
accomplished by presenting symptoms in terms of physical symptoms, such as
hot flashes, night sweats, and vaginal dryness. The physical symptoms were
then associated with having a negative impact on social and personal relations.
Symptoms such as hot flashes and vaginal changes were presented to
consumers as “problematic” using such language as debilitating, reduced sense
of self, and hampered sex lives.
The term “symptom” itself is commonly associated with problems and
illness (Rostosky and Travis, 1996). By portraying symptoms as “disruptive,”
such symptoms were presented as problematic to consumers thereby further
positioning them within a disease-like model requiring medical treatment. Women
were also told on the web sites that their symptoms were to be tracked and
managed which related to a disease-like model of menopause. The terms
“tracking,” “assessing,” and “managing” are also symbolic medical terms that
stem from a dominant biomedical view of menopause.

Certainly, the use of

negative language in the portrayal of symptoms helped to set the stage for using
the HT products. Such negative language consistently conveyed the message
that symptoms were bothersome and problematic for which HT was a viable
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treatment. As noted, extremes were presented to consumers, namely that
symptoms could become debilitating, lead to a reduced sense of self, and result
in hampered sex lives if left untreated. It is also noteworthy that the use of
positive language was not observed on any of the web sites in the sample, such
as describing menopause as a “beginning” or “freedom.”
Further, consumers visiting the ANGELIQ web site were greeted by the
message: “Menopause. It’s a natural part of life, but these symptoms don’t have
to be” (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).
From this statement, consumers were told that menopause was natural.
However, the statement further implied that symptoms were “unnatural.” Here,
the tension between “natural” (in this case, menopause) and “unnatural”
(menopausal symptoms) was conveyed and created a context for consumers to
learn how to “treat” such undesirable symptoms with HT products. In this sense,
it encouraged women to regard any changes as unacceptable symptoms.
One of the most discernable differences across the various the HT web
sites were the additional symptoms listed on the CombiPatch and ENJUVIA web
sites. In particular, mood changes, mood swings, and irritability were also
observed on the CombiPatch and ENJUVIA web sites. Moreover, the ENJUVIA
web site further listed irregular periods, weight gain, and dry skin as “other”
symptoms of menopause. These changes are not necessarily related to
menopause and just because a woman may experience mood changes or
irritability during the menopausal transition “does not mean that menopause
caused the condition” (Mansfield and Voda, 1997, p. 60, italics in the original).
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The web sites incorporated lists of menopausal symptoms from the existing
biomedical literature and were able to imply a connection by listing these as
possible

symptoms

and

linking

them

with

menopause

in

the

online

advertisements for HT.
Additionally, three web sites in the sample (CombiPatch, femhrt, and
PREMARIN) linked osteoporosis with menopause in such a way that
“osteoporosis practically becomes identified as a symptom of menopause”
implying HT could be taken to stop this process (Worcester and Whatley, 1992).
The technique of promoting HT for the prevention of osteoporosis has been
reported in the literature as a way to expand the list of symptoms to include
conditions that have not been traditionally associated with menopause (Dukes,
1997; Palmlund, 1997; Worcester, 2004; Worcester and Whatley, 1992).

By

suggesting to potential consumers that their physical and emotional issues might
fit medical models of menopause, the online advertisements capitalized on
already existing lists of symptoms found in the biomedical literature and linked
these symptoms with menopause to include emotional changes and the
prevention of osteoporosis. While this finding is consistent with previous
research, my analysis contributes to the existing body of literature to include
analyses of pharmaceutical advertisements in an online environment. Here
again, the dominant biomedical discourse of menopause was prominent on the
pharmaceutical web sites for HT.

Online Self-Diagnosing Symptom Tools

219

Likewise, the negative portrayal of menopause persisted in the online
symptom tools found on four of the HT web sites in the study sample. In these
instances, information was provided to consumers by means of a set of
diagnostic questions, such as an online symptom tool that women could use to
assess their menopausal symptoms. The use of language in the online selfdiagnosing symptom tools provided a particular context for web site users as
they interacted with the tools to assess their symptoms and the degree of
severity of these symptoms. The prevalence of negative language observed in
the question wording about menopausal symptoms and the response categories
contributed to the negative portrayal of menopause. Words such as “anxious,”
“embarrassed,” “disruptive,” and “uncomfortable” characterized symptoms as
problematic. Certainly, presenting symptoms as “impacting” and “affecting” daily
activities, work, and relationships may also give motivation for seeking medical
advice. As such, symptoms were portrayed as “problematic.” Through the use of
such negative language observed across the online symptom tools, this also
helped to set the stage for use of prescription HT products.
Moreover, the categories of questions found on the self-diagnosing symptom
tools ranged from vasomotor symptoms (commonly known as hot flashes and
night sweats), vaginal symptoms, sexual health, and psychological symptoms.
Once again, the inclusion of psychological “symptoms,” such as anxiety,
irritability, sadness, and difficulty concentrating, was a technique that I have
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noted on the HT web sites. Here again, this technique further expand the list of
possible “menopausal symptoms” that could be treated with HT.
Upon closer examination, I also found a significant dimension of the online
self-diagnostic symptom tools was their attempt to encourage contact with a
health care provider. All four of the online self-diagnosing symptom tools
encouraged consumers to share the “results” of the symptom tools with a health
care professional. By encouraging women to regard any “discomforts as
unacceptable symptoms” that should be reported to a health care provider, this
further provided evidence of the adoption of the biomedical model of menopause
on the web sites (Derry, 2002, p. 22). A similar finding was found by Lyons and
Griffin (2003) in which menopause was discussed in self-help books as requiring
ongoing management by a medical professional. While previous research has
reported that traditional print advertisements found in magazines and self-help
books have framed menopause as necessitating medical supervision, my
research extends the existing literature by adding an analysis of online selfdiagnosing symptoms tools that is absent from current discussions on the
portrayal of menopause and menopausal symptoms. Thus, we saw how the
online symptom tools provided female consumers with a context for interacting
with the tools to assess the “impact” and severity of their symptoms.
In addition, I also assessed the reading level of the four online symptom tools
and found that the information presented to consumers far surpassed the
estimated reading level of the average adult in the U.S. (National Adult Literacy
Survey, 1992). Indeed, since the reading level of pharmaceutical advertisements
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for hormone therapies has not been addressed in previous studies, this is
another dimension of my research that extends the existing body of literature. In
sum, the online self-diagnosing symptom tools functioned to expand the range of
menopausal symptoms to include psychological symptoms, encouraged
consumers to report their symptoms to a health care provider, and presented
information written at a reading level that was too high for many of the intended
web site users.

Portrayal of Characters

In addition, I analyzed the images of characters in the online
advertisements. My findings indicated that female characters were mostly
middle-aged Caucasian women depicted as passive and shown in domestic
settings. As Coney (1994) states, hormone therapy has been “predominantly
used by white, middle-class women” (p. 224). Thus, the majority of the female
characters in the online advertisements were Caucasian women which closely
mirrored the demographic characteristics of the typical users of hormone
therapies.
Only one image of a health care provider was presented. In this case, the
image portrayed the Caucasian female health care provider talking with a female
patient in what was presumably an exam room. Not surprisingly, I found that the
use of such iconic imagery, such as the white coat and stethoscope, reflected
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symbols commonly associated with the health care environment making the
health care provider easy to identify in the image.
All of the images on the pharmaceutical web sites in the sample depicted
people smiling. Some images showed women participating in recreational
activities, further depicting “healthy” appearing people. While such lifestyle
factors, such as exercising were depicted, the web sites did not state that these
non-medical options and activities could help to reduce symptoms as previous
research has shown (Mansfield and Voda, 1997). Rather, a woman was shown
jogging and yet this web site stated HT was one of the most effective options to
help manage menopausal symptoms such as hot flashes, night sweats, vaginal
dryness, and potential bone loss. Another web site showed a woman walking in
hiking boots and consumers were told that the HT product (a patch) would allow
women to “get back” to an active lifestyle. Therefore, the underlying premise was
that hormones could help to achieve the activity that was being presented. To
this end, the visual images helped to convey health, activity, and vitality that
could be achieved through the use of HT. According to the online
advertisements, the “treated” woman was healthy, active, and happy. Similarly,
Kaufert and Lock (1997) found pictures of bright, healthy, and beautiful women
appearing in pharmaceutical brochures. Thus once again, according to the online
advertisements for HT, the “treated” woman was portrayed as healthy, active,
and happy.
As noted in an earlier chapter, I also found that menopause was described
as “natural” on one of the web sites, but consumers were then told that their
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symptoms were unnatural. The ANGELIQ web site stated “Menopause. It’s a
natural part of life, but these symptoms don’t have to be” (ANGELIQ web site:
http://www.angeliq-us.com. Retrieved: July 13, 2009). From this statement,
consumers were told that menopause was natural. However, the statement
further implied that symptoms were “unnatural.” Here, the tension between
“natural” (in this case, menopause) and “unnatural” (menopausal symptoms) was
conveyed and created a context for consumers to learn how to “treat” such
undesirable symptoms with HT products. Another example was evident in the
statement “while there’s no way to avoid menopause” HT can reduce the impact
of symptoms (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13,
2009). On the surface these statements might appear to be the “menopause as
natural” discourse as described by Lyons and Griffin (2003) found in self-help
books; however, a closer examination showed these statements were not
resisting the biomedical discourse of “menopause as a disease” as one would
expect to see if a feminist or socio-cultural perspective of menopause was being
articulated. In these cases, menopausal symptoms were still being portrayed as
problematic thereby warranting treatment with HT.
Thus, symptoms and proposed medical treatments were presented within
a biomedical realm which reflected the traditional medical paradigm. For these
reasons, I concluded that the web sites were not offering an alternative to the
biomedical discourse. Rather, the images and portrayal of problematic symptoms
requiring medical treatment helped to further articulate a biomedical model of
menopause on the pharmaceutical web sites.
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Information Content

My analysis showed how the online information content was presented
differently for two potential markets, female consumers and health care providers
because specific sections of the web sites were clearly labeled for each intended
audience. Additionally, the use of feminine imagery on the HT web sites, such as
curves and ribbons, and the use of the colors white and purple were strategically
used as a way to make connections with femininity in order to appeal to potential
female consumers.
With regards to the pharmaceutical web sites, I was concerned with what
information was given to women and health care providers about menopause
and HT, how information was presented to these two audiences, and what
information was suspiciously lacking or absent. My analysis demonstrated that
the menu options presented to consumers differed from the content for health
care providers. First and foremost, consumers were introduced to the HT
products and HT treatment options.
The advertising slogans further illustrated an important distinction between
the content being presented to consumers and health care providers. Consumers
were informed about what can be expected from using the HT products from the
repeated use of the words “relief,” “discover,” and “treat” observed in the
advertising slogans. Notably, pictures of HT products and their packaging were
included on the web sites for consumers to aid in easier consumer identification
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of the product. In comparison, health care providers were informed about the
range of available “treatment options” and dosage strengths. In other words, the
information content on the pharmaceutical web sites differed depending on the
potential market. Indeed, consumers were presented with different menu
choices, different advertising slogans, and pictures of the actual HT products
compared to health providers.
The proclaimed benefits of HT were also strikingly different in their
presentation to consumers in comparison to the content provided to health care
professionals. As Conrad (2007) pointed out, early medical articles reported that
estrogen could “reduce menopausal symptoms” (p. 121). Primary benefits
promoted to consumers on the pharmaceutical web sites for HT could be
grouped into two themes: symptom reduction and the prevention of osteoporosis.
Clearly, this reflected a current trend of focusing on symptom management in the
promotion of hormone therapies (Voda and Ashton, 2006). Interestingly, claims
of benefits for consumers were not supported by actual scientific sources and the
use of hypothetical stories on several of the HT web sites to support claims of
benefits were patterns that I also witnessed. Similarly, Carlson, Li, and Holm
(1997) found that authors of articles in popular magazines did not provide
references for claims of efficacy about HT. This is troubling given that women
have cited the popular media as a main source of information on menopause
(Clinkingbeard et al., 1999).
In comparison, health care professionals were presented with several
“selling points” and were informed about the range of available dosing options,
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provided with evidence to support claims of efficacy, and told about patient
satisfaction with HT products. The major finding here was that the creation of
distinct web portals for consumers and health care professionals enabled the
drug manufacturers to organize and present information to potential markets for
their products. As such, this analysis contributes to our understanding of how the
web site content differed in its presentation depending on the target audience.
The presentation of the side effects of HT underscored the need for better
risk communication to patients in the online drug advertisements. Notably, the
side effects were presented as either “common” or “less common but serious”
side effects across the HT web sites. Under further scrutiny, I found some
overlap between these two categories of side effects. Thus, the pattern of
presenting side effects to consumers as both “common” as well as “less common
but serious” may be a source of potential confusion. Equally noticeable was the
location of the side effects information. In particular, one web site only discussed
possible side effects in the footer of the web site and in a smaller font size which
could easily be overlooked. Therefore, both the location and font size of the
possible side effects on the web site in the study sample was a cause for
concern.
Furthermore, an analysis of the reading level of the text describing the six
common side effects of HT across the web sites in this study exceeded the
estimated reading level of the average adult in the U.S. (National Adult Literacy
Survey, 1992). In light of this, I concluded that the information presented across
all of the HT web sites about “common” side effects was too difficult for many of
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the intended web sites users. As a result, this important drug information should
be rewritten for consumers to make informed drug-related decisions.

Framing of the Women’s Health Initiative

Further, I found that the discussion of the Women’s Health Initiative (WHI) for
consumers minimized potential risks and framed the WHI in a positive light.
Among the study sample, there were only three pharmaceutical web sites that
provided discussions about the WHI to consumers (ANGELIQ, Femring, and
femhrt). In particular, the Femring and femhrt web sites highlighted benefits
reported from the WHI. These two web sites cited fewer hip fractures and fewer
cases of colorectal cancer among users of HT in the WHI clinical trial. Clearly,
putting a positive “spin” on the WHI results minimized concerns expressed by
women about possible side effects associated with hormone use as reported in
the literature (Mansfield and Voda, 1994). Further, the ANGELIQ web site stated
that possible benefits of HT may outweigh the risks. Indeed, these three web
sites painted a positive picture of the WHI study results by emphasizing potential
benefits of using HT. Unfortunately, these three web sites were the only
pharmaceutical web sites for HT in the study sample that furnished information
about the WHI to consumers. As evident on these three web sites, concerns
about the WHI findings were minimized by highlighting positive findings of the
WHI and the web sites suggested that possible benefits may outweigh the
potential risks of using HT.
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As a consequence, the WHI was discussed in a limited manner on
consumer-oriented sections of the HT web sites. Given the limited information
about the WHI study provided to consumers, scant discussion about any
implications,

and

inadequate

educational

information,

consumers

were

encouraged to follow-up with their health care providers for explanations about
the WHI findings and to discuss HT treatment options. Further analysis also
revealed an emphasis on the availability of “low-dose” HT options repeated
across the HT web sites. Thus, I posit that the pharmaceutical manufacturers
were attempting to re-position HT as a viable treatment by highlighting positive
results from the WHI study and emphasizing the availability of “low-dose options”
while effectively minimizing any WHI-related concerns. As stated by Voda and
Ashton (2006), “post-WHI risks to women’s health persist” (p. 410).

Medicalization of Menopause

One of the stronger points of this study was its ability to demonstrate how
the pharmaceutical web sites adopted a biomedical model of menopause, which
in turn, helped to create a context for the process of medicalization to occur.
Conrad (2007) explained the process of medicalization as defining a problem in
medical terms, adopting a medical framework, and proposing to treat a problem
with medical interventions. In fact, Conrad (2007) identified the pharmaceutical
industry as one of the emerging forces providing momentum for further
medicalization.
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Kaufert

and

Gilbert

(1986)

further

outlined

several

“tests

for

medicalization” that I applied to the pharmaceutical web sites to help determine if
the process of medicalization could be occurring. One important sign is when the
decline of estrogen production has become a central theme (Kaufert and Gilbert,
1986). As evident in my findings, the loss of hormones was used across all of
the web sites in the sample to explain a “reason” for menopause. As a result,
menopause was defined exclusively as a biological event.
Another sign of medicalization is when proposed treatment options for
menopause involve the use of hormone therapies to supplement or balance the
loss of hormones (Kaufert and Gilbert, 1986). Here again, since menopause was
presented

as

disease-like

requiring

medical

management,

the

online

advertisements helped to introduce the idea of using HT to restore or balance
hormone

levels.

Furthermore,

symptoms were

portrayed

as

unnatural,

problematic, and bothersome further setting the stage for use of HT.
Another indication that medicalization can be occurring is when women
are told that they should depend on a physician to have their menopausal status
recognized and defined, rather than relying on their own judgment (Kaufert and
Gilbert, 1986). On the ENJUVIA web site, consumers were informed that health
care professionals “can determine which treatment is right.” As the above quote
demonstrated, the “expert” role of physicians was reinforced as well as their
authority to define and categorize women’s experiences.
In this context, the web sites in the study sample exhibited the “signs”
that medicalization could be occurring. Primarily, the web sites explained
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menopause in biomedical terms implying it was a medical event to be medical
managed. Further, the loss of hormones was a common theme on the web sites
which introduced HT as a way to restore or balance hormone levels. The web
sites also reinforced medical authority in providing a medical diagnosis over
women’s experiences.
My analysis also revealed another important technique missing from
previous discussions about medicalization in the literature. The reading level of
the online symptom tools and side effects information far surpassed the
estimated reading level of the average adult in the United States, thus creating a
context for which medicalization could also occur. Since the reading level of
information found on the pharmaceutical web sites in the sample was too high, it
suggested consumers may need to consult with a health care to make sense of
the information. In this way, it also reinforced the role of physician as an “expert.”
This finding pushes and extends the existing literature to include a new
“test” for medicalization. As a result of this finding, I propose the reading level of
information is one more sign further demonstrating how the process of
medicalization was operating on the pharmaceutical web sites for HT. Hence,
this finding adds and contributes new dimensions to the analyses of the
medicalization of menopause in direct-to-consumer advertisements. When taken
together as a whole, we gain a sense of how the web sites provided a context for
the process of medicalization to occur on the pharmaceutical web sites for HT.

Comparison of Pharmaceutical Web Sites
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Although my findings revealed some unifying themes across the HT web
sites, there were some marked differences across the pharmaceutical web sites.
All of the web sites in the sample drew heavily on the “menopause as disease”
discourse and emphasized the loss of hormones as a “reason” or explanation for
menopause. While an emphasis on change was clear on the web sites, only one
web site (PREMARIN) actually used the word “decline.” Other web sites, such as
ANGELIQ, CombiPatch, and femhrt, employed the terms “adjustment” and
“balance.” Yet, when taken together the language on the web sites helped to set
the stage for using the HT products in order to balance or restore hormone
levels.
Unique among the study sample was the ENJUVIA web site for its use of
biomedical rhetoric for describing symptoms. Specifically, the terms “vasomotor
symptoms” and “vaginal atrophy” were used on the ENJUVIA web site. This
biomedical nomenclature suggested a disease-like nature of menopause and
placed these “symptoms” within a medical context.
In comparison to the other online symptom tools, the ENJUVIA symptom
tool was the only one to include psychological symptoms among the list of
possible menopausal symptoms. Specifically, the ENJUVIA “Menopause Impact
Tool” included psychological symptoms such as anxiety, irritability, sadness, and
difficulty concentrating. The inclusion of such psychological symptoms in the
ENJUVIA online tool implied to consumers that they were both important and
also linked to menopause.
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Additional menopausal “symptoms” were listed on the CombiPatch and
ENJUVIA web sites, including mood changes, mood swings, and irritability.
Moreover, the ENJUVIA web site further listed irregular periods, weight gain, and
dry skin as “other” symptoms of menopause. These changes are not necessarily
related to menopause and by having these listed as so-called symptoms of
menopause on the CombiPatch and ENJUVIA web sites suggested a possible
link or association.
Moreover, the CombiPatch web site described menopause as when a
woman’s “reproductive system slowly shuts down.” The mechanical language
was reminiscent of the biomedical model in which the body is viewed as a
machine breaking down.

Here, the aging female body was compared to a

machine “breaking down” illustrating how menopause was being articulated as a
declining biological function.
The above examples help to illustrate the differences among the HT web
sites. In comparison to other web sites the sample, CombiPatch and ENJUVIA
presented menopause as a highly medicalized process with their use of
biomedical rhetoric (i.e. “atrophy” and “ovaries shutting down”). Furthermore, the
CombiPatch and ENJUVIA web sites included psychological symptoms and
linked them with menopause. For these reasons, I concluded that the degree of
medicalization across the web sites varied with the CombiPatch and ENJUVIA
web sites being more explicit in their adoption of a biomedical perspective and
perpetuating that menopause

was

a medical event

requiring medical
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management. In the final chapter, I discuss several policy implications of my
findings and ideas for future research.
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CHAPTER 10
CONCLUSIONS

Advertisements are one of the most important cultural factors molding and
reflecting our lives (Williamson, 2002). In fact, 30% of adults surveyed in the
United States claim that they have talked with a physician about a specific
medication as a result of some form of direct-to-consumer advertising (Kaiser
Family Foundation, 2001). Meanwhile, Conrad and Leiter (2008) note how the
Internet has become “another direct avenue from pharmaceutical companies to
consumers” (p. 834). Hence, the proliferation of online health information
provided to consumers on pharmaceutical web sites provides momentum for
investigations of media representations of health, disease, and illness. In
particular, consumer-targeted prescription drug advertising serves as an
interesting lens through which we can begin to examine the portrayal of
menopause in online drug advertisements. Therefore, the aim of this study was
to explore the portrayal of menopause on web sites sponsored by
pharmaceutical companies for hormone therapies (HT).
In this study, menopause was defined as a natural part of the aging process,
rather than an event that limits women’s psychological or physical capacities
(McCrea,

1983).

Previous

research

has

illuminated

aspects

of

the

pharmaceutical industry’s involvement in the promotion of hormone therapies
(HT) for the treatment of menopausal symptoms, such as hot flashes, night
sweats

and

vaginal

changes,

to

physicians

and

consumers

through
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advertisements in medical journals, newspapers, and popular magazines. Yet,
little is known about the convergence of women and menopause in
advertisements for HT in the online environment.
In this study, I was particularly concerned with the representation of
menopause in online advertisements for HT. Therefore, the main purpose of this
study was to explore the portrayal of menopause on web sites sponsored by
pharmaceutical companies for FDA-approved HT. To address this issue more
fully, I investigated the descriptions of menopause, portrayal of menopausal
“symptoms,” and the use of online self-diagnosing symptom tools. Additionally, I
analyzed the presentation of proclaimed benefits and possible side effects as
well as the portrayal of various characters depicted in the online drug
advertisements. I also sought to examine if the online information was presented
differently for various web site audiences, such as consumers and health care
professionals.
To unravel these questions, a qualitative content analysis of web sites for
FDA-approved

hormone

therapies

(HT)

was

undertaken

to

gain

an

understanding of how menopause was being portrayed in online drug
advertisements. Using this qualitative method allowed the researcher to perform
some exploratory research that suggests additional qualitative research in this
area would be productive. A total number of 608 printed pages of web site
content from eight web sites (N=8) for HT were analyzed in this study. The fulltext of the web pages was analyzed with a focus on the content and contextual
meaning of the text and visual elements. In order to make the study as
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reproducible and systematic as possible, I developed a coding instrument to help
characterize the online drug advertisements.
Four research questions guided data collection and analysis. The four
research questions again were:

1. What was the prominent discourse about menopause on the
pharmaceutical web sites? Did it vary across the web sites? If
the biomedical perspective was used in the portrayal of
menopause, then menopause would be presented as a medical
event to be medically managed. Furthermore, “deficiency” would
be a common theme if the biomedical perspective was
accepted. If a feminist perspective was used in the portrayal of
menopause, I would expect to see an alternative discourse that
rejected the medical construction of menopause as requiring
medical

treatment

professional.

and

supervision

by

a

health

care

In addition, I explored how symptoms were

presented and if the symptoms were the same across the web
sites.
2. How was the Women’s Health Initiative (WHI) framed on the
pharmaceutical web sites? Likewise, I also examined if
evidence of actual clinical studies, such as the WHI or others,
were referenced on the pharmaceutical web sites.
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3. Who were the intended target audience or audiences of the web
sites? To help determine if the web sites were geared towards a
specific audience, I examined the language and/or visual cues
employed on the pharmaceutical web sites.
4. Was the information presented differently for various audiences,
and if so, how? (i.e. health professionals, consumers, etc.). For
example, I investigated if the advertising slogans differed
depending on the target audience. In addition, I examined what
(if anything) was absent or lacking on the web sites.

These questions also set the stage for my analysis which was divided into
five chapters spanning an overview of the web site characteristics, textual and
visual elements of the web sites, the portrayal of menopause, and the
presentation of benefits and side effects of HT. In particular, Chapters 5 and 6
focused on the characteristics of the direct-to-consumer web sites for HT. In
these chapters, I examined the menu options, slogans, color schemes, and
imagery employed on the web sites for both consumers and health care
professionals. Two questions were explored in these chapters. In particular, I
identified two main audiences for the HT web sites, consumers and health care
providers, and I also investigated how the online information was presented
differently for these two potential markets.
Chapter 7 explored the portrayal of menopause on the web sites for HT.
One key question was examined in this chapter. Specifically, this chapter
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revealed how menopause was being portrayed in the online advertisements by
analyzing the definitions of menopause, descriptions of menopausal “symptoms,”
and self-diagnosing symptom tools found across the HT web sites in the study
sample. Chapter 8 analyzed the presentation of benefits and side effects of HT.
This chapter helped to illuminate what was deficient or missing in the online drug
advertisements for HT, such as references to actual clinical studies to support
proclaimed benefits and scant discussion of the Women’s Health Initiative for
consumers. Chapter 9 offered a discussion of my key findings and drew on
similar studies from the literature.

Key Findings

My study of pharmaceutical web sites for hormone therapies (HT) indicated
that a medicalized view of menopause was consistent in the online
advertisements. In general, menopause was portrayed on the pharmaceutical
web sites as a medical event caused by a loss of hormones often accompanied
by “problematic” symptoms that could be alleviated by hormone therapies. Other
authors have reached similar conclusions about the biomedical framing of
menopause in traditional print magazine advertisements (Gannon and Stevens,
1998; Hust and Andsager, 2003; Lyons and Griffin, 2003; Shoebridge and Steed,
1999). My analysis contributed to the existing literature by adding an analysis of
pharmaceutical advertisements in the online environment. Hence, my findings
reinforced the overall dominance of the biomedical perspective of menopause in
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advertisements. One of the stronger points of this study was its ability to
demonstrate how a biomedical model of menopause was adopted and advanced
on the pharmaceutical web sites which, in turn, created a context for which the
process of medicalization could occur. To this end, several important findings
emerged from my analyses.
First and foremost, the web sites drew heavily on terms that were negative
and focused overwhelmingly on hormone loss thereby contributing to the
disease-like conceptualization of menopause. In particular, “deficiency” and
“loss” were common themes. In doing so, the pharmaceutical companies were
able to effectively set the stage for using their HT products to adjust or balance
hormone levels. My findings also showed that potential female consumers were
exposed to an array of models and visual cues associated with positive
characteristics (i.e. healthy, active, and smiling) that consumers might identify
with. Moreover, the images of women found on the pharmaceutical web sites
frequently depicted women within the domestic realm. Given that the majority of
the female characters in the online advertisements were Caucasian women this
also mirrored the demographic characteristics of both the common users of
hormone therapies and typical users of the Internet. To be sure, this is important
because if consumers identify with the models in the online advertisements for
HT, then they “may also be more likely to engage in health care behaviors
needed to gain access to the advertised products” (Cline and Young, 2004, p.
151).
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Further analysis revealed that drug manufacturers promoted the
widespread use of HT for an extended range of menopausal “symptoms”
treatable with HT, such as weight gain and dry skin. To this end, I also found that
claims of benefits for consumers were not supported by actual scientific sources
on the web sites and the use of hypothetical “women’s stories” to support product
claims was also observed. One web site discussed possible side effects in the
footer of the web site and in a smaller font size which could easily be overlooked.
The finding that a biomedical perspective was prominent on the
pharmaceutical web sites was, in general, consistent with previous research on
the framing of menopause in print magazine advertisements. However, my
analysis of the reading level of information and the online self-diagnosing
symptom tools offered new dimensions to research on the framing of menopause
in advertisements. As a result of my findings, I propose that the high reading
level of information contained in the advertisements is one more “test” signifying
that medicalization was operating on the pharmaceutical web sites for HT. This
finding pushes and extends the existing body of literature to include a new “test”
for medicalization.
Moreover, limited information was provided to consumers about the
Women’s Health Initiative (WHI) study while pharmaceutical companies
appeared to be re-positioning HT as a viable treatment by emphasizing “lowdose options.” As noted, three pharmaceutical web sites highlighted positive
benefits from the WHI study and consumers were encouraged to ask their health
care providers if potential benefits of using HT may outweigh the risks. Given
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these findings, my analysis suggests there is a need for better risk
communication in online drug advertisements for HT.

Limitations of the Study

This study had some limitations. First, the dataset was only comprised of
FDA-approved Estrogen and Estrogen-Progestin products for the treatment of
postmenopausal women. While the degree of medicalization within the dataset
was observed and analyzed, it was not clear how this compared with other online
DTC advertisements for menopause such as herbs, supplements, and alternative
therapies. Second, due to the subjective and interpretive nature of this qualitative
research, two researchers might have arrived at different conclusions of the
online advertisements for hormone therapies. Furthermore, the study sample
was small and consisted of eight web sites for FDA-approved hormone therapies.
At the time of the study, only eight pharmaceutical companies for FDA-approved
hormone therapies had active web sites available for analysis. Further, this study
was a cross-sectional observation and the dataset was collected at one point in
time. Therefore, this study by design did not set out to investigate if online drug
advertisements for HT have changed over time. Finally, this analysis was based
on a particular perspective grounded in the sociology of health and illness and
medicalization frameworks. Although the pharmaceutical web sites were
analyzed from this perspective, my findings indicate that future research can help
to examine the marketing decisions behind the development of such web sites
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and how women have responded to the online drug advertisements for hormone
therapies.

Directions for Future Research

This study demonstrates the need for further examination of gender and
aging in online drug advertisements. This study focused on FDA-approved HT
products for the treatment of postmenopausal women. Therefore, another
productive area of future research might be analyzing online advertisements for
other menopausal remedies, such as natural and herbal supplements. In
addition, in-depth interviews with women users of the web sites could help
illuminate how consumers search for and evaluate the credibility of information
on the World Wide Web about menopause. A better understanding of the users
of the web sites, such as their age, race, education level, and their use of the
online symptom tools (i.e. do women print off the symptom assessment tools and
share them with a health care provider?), would also be useful.
Another possible study could investigate if the portrayal of menopause has
changed over time in direct-to-consumer advertisements. Such an analysis would
add an extra layer of complexity missing from past discussions of the
representation of menopause in advertising. It might also be interesting to
compare the portrayal of menopause across various types of media, including
print, television, and online media.
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Further research is also needed to examine online drug advertisements
for “male” menopause and “female” menopause. With the advent of Viagra and
other treatments aimed at male consumers, it would be interesting to explore
how this portrayal is framed for different audiences. Hence, such a study could
help elucidate the messages about gender and aging manifested in online drug
advertisements.

Policy Implications

Three major implications arise from this study. First, there is a need for
better risk communication in online drug advertisements for HT. In particular, the
location of side effects information was observed only in the footer on one web
site and in a smaller font size. Therefore, this important information is likely to be
overlooked. Furthermore, an overlap between the “common” side effects and
“serious but less common” side effects was noted across the web sites in the
study sample which could be a source of potential confusion for patients. This
study has also shown that there was little discussion of the concerns brought to
light by Women’s Health Initiative (WHI) study for consumers on the web sites. In
fact, three pharmaceutical web sites highlighted positive benefits from the WHI
study and suggested to consumers that potential benefits of using HT may
outweigh the risks. As noted, another distinguishing characteristic was the lack of
scientific evidence provided for consumers to support various advertised benefits
of HT. Given the vagueness of the statements about benefits and limited

244
discussion about risks, more information is needed for women to be able to
weigh the benefits and risks of HT. Hence, the need for better communication
and educational information for consumers in online advertisements for HT was
evident.
Second, this study revealed the promotion of an expanded list of “benefits”
to consumers beyond what the HT products were originally FDA-approved for. By
proposing such an expansive range of symptoms could be “fixed” with HT
products, such as dry skin and irritability, the online advertisements proposed HT
as a viable option for a range of so-called symptoms. Furthermore, the use of
“hypothetical” women’s stories to support product claims of benefits and efficacy
was another pattern observed on several of the web sites. Taken together, these
patterns illustrated a process by which non-medical problems were being defined
as medical problems along with proposed medical interventions (Conrad, 2007).
Therefore, a closer examination of how online drug advertisements are making
claims about their products is warranted.
Third, data from this analysis also demonstrated that the reading level of
the online symptoms tools and side effects information found on the
pharmaceutical web sites far surpassed the reading level of the average adult in
the United States (National Adult Literacy Survey, 1992). As such, this finding
served as an important reminder. Clearly, safety and risk information in online
drug advertisements must be written at an appropriate reading level and
considerations for those with limited literacy skills should also be taken into
account.
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This research contributed to the critical reflection of direct-to-consumer
advertising with implications for information literacy in the digital age. Women
seeking health-related information about prescription drug products can use the
following questions as a set of guidelines whenever evaluating pharmaceutical
web sites. Moreover, this education can be further facilitated by nurses,
physicians, health educators, and librarians when working with consumers
seeking online health-related information:

•

Who is the intended audience (or audiences) of the pharmaceutical
web site?

•

When was the web site last updated?

•

Who provided the information on the web site and what are their
credentials?

•

Is contact information provided in case you have questions or need
further information?

•

Does the web site provide a link to U.S. Food and Drug
Administration (FDA) web site?

•

Were you able to locate both the benefits and side effects
information about the pharmaceutical product being advertised?

•

Is a “fair balance” of the proposed benefits and potential risks
provided on the web site?

•

Is any information on the web site provided in a smaller font size? If
so, is this information difficult to read?
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•

Does the web site encourage you to ask a health care provider
about a specific prescription drug product?

•

Does the web site provide an online self-diagnosing symptom tool
to assess the frequency and severity of your symptoms?

•

If so, does the web site encourage you to print off and share your
“symptom report” with a health care provider?

•

Does the pharmaceutical web site provide information about nonmedical options, such as exercise and diet modifications, that might
help to reduce symptoms?

•

If claims about a prescription drug product are being made, are
citations to scientific sources provided to support these claims?

Summary

Advertising deconstruction “is not trivial” (Cortese, 2008, p. 4).
Pharmaceutical companies spend a substantial amount of money on direct-toconsumer advertising. Since the FDA’s relaxation of its regulation in 1997,
pharmaceutical industry spending on direct-to-consumer advertising (DTCA) has
more than tripled reaching $4.2 billion in 2005 for American broadcast DTCA
efforts (Conrad and Leiter, 2008). Additionally, advertisements are visually
appealing, symbolic, and persuasive. To better understand the construction of
menopause in online drug advertisements, the specific aim of this study was to
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explore how menopause was being portrayed on direct-to-consumer web sites
for HT sponsored by pharmaceutical companies.
To accomplish this, I employed a qualitative content analysis approach to
data collection and analysis in order to develop a fuller understanding of the
phenomenon under investigation. By analyzing the information content and how
menopause was portrayed on web sites for HT, my analysis offered insight into
how menopause was constructed in online direct-to-consumer advertisements
and addressed a knowledge gap in relation to representations of menopause on
pharmaceutical web sites. This qualitative investigation provided evidence
demonstrating how menopause was portrayed as a medical event necessitating
medical treatment in the online advertisements for HT.

Overall, the online

advertisements articulated a biomedical perspective of menopause.
In conclusion, the findings of this study illuminated how menopause was
being portrayed in online advertisements for HT and the means that were used to
construct this portrayal. Findings from this research are useful for understanding
how menopause was portrayed in drug advertisements for hormone therapies in
the online environment. The bottom line is that negative language and visual
images portrayed symptoms of menopause as “problematic” thereby effectively
placing menopause under the rubric of medical supervision. In this way, the
portrayal of menopause as “disease-like” set the stage for use of the HT products
advertised on the pharmaceutical web sites to alleviate “problematic” and
bothersome symptoms. Further, by suggesting to potential female consumers
that their physical and emotional issues might fit medical models of menopause,
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the online advertisements expanded the list of possible menopausal symptoms.
Conrad (2007) identified “diagnostic expansion” as one way in which
medicalization can occur (p. 47). As a result, my analysis of the pharmaceutical
web sites revealed an expansion of definitional boundaries to include new
problems and potentially new markets beyond what HT was originally designated
for.
Several of my findings reinforced the acceptance and dominance of the
biomedical model of menopause in advertising. Additionally, one of the strengths
of this study was my analysis of the reading level, online symptom tools, and the
framing of the WHI in online pharmaceutical advertisements for HT. To this end,
this research contributes to the existing body of literature to include analyses of
representations of menopause on pharmaceutical web sites for HT. Indeed, while
physicians are “still the gatekeepers for many drugs, the pharmaceutical
companies have become a major player in medicalization” (Conrad, 2007, p.
134). As online direct-to-consumer advertising becomes increasing prevalent,
research that delves into the intersection of gender, aging, and consumertargeted prescription drug advertising on the World Wide Web is further
warranted.
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APPENDIX A
CODE SHEET
FOR DTC WEB SITE ADVERTISEMENTS

Categories Examined:

1. Type of product (tablet, lotion, ring, or patch)
2. Name of product
3. How menopause is defined
4. “Causes” of menopause
5. How symptoms are portrayed
6. Presentation of benefit
7. Presentation of side effects
8. Prescription for action (action/behavior being advocated)
9. Nature of portrayal of patients (characteristics)
10. Nature of portrayal of health care providers (characteristics)
11. Mention of WHI (yes or no? location?)
12. Web site characteristics:
•

Number of web sites with lay person and health provider portals

•

How are the portals labeled? (i.e. how many web sites portals use
the term “health care providers”?)

•

Number of menu items on the site for consumers

•

Menu options for consumers (list by web site)

•

Number of menu items on the site for health care providers

•

Menu options for health providers (list by web site)

•

Slogans for consumers
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•

Slogans for health care providers

•

Information provided to health professionals to distribute to
patients? (On every web site? in PDF? need to order?)

•

How many web sites include references or citations? (If so, where
are they located? Consumer pages or health provider pages?)

•

How many web sites show pictures of HT products? Packaging?

•

How many web sites have self-diagnosis tools? (symptom tools)

•

How many web sites have guide or list of questions to ask your
health provider?

•

How many web sites have coupons or free samples?

•

Colors used on web site

•

Imagery: How many use flowers, nature, ribbons, etc.
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CODE SHEET

1. Type of product

(tablet, lotion, ring, or patch)

2. Name of product
3. How menopause is defined

Description: (describe how menopause
is defined)

4. “Causes” of menopause

Description (check all that apply):

5. Portrayal of symptoms

6. Presentation of benefit

•

Aging

•

End of reproductive capacity

•

Other:
________________________

Description (check all that apply):
•

“Deficiency”

•

“Burden”

•

“End”

•

“Beginning”

•

“Transition”

•

“Natural”

•

“Inevitable”

•

Other: ___________________

Description (check all that apply):
•

“effective”

•

“proven”

•

“works”
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7. Presentation of side effects

•

“reliable”

•

“cure”

•

“prevents”

•

“prolongs”

•

“controls”

•

“manages”

•

Other: _____________________

•

Are testimonials / personal
stories used to support benefit?
(Yes/No)

•

Are studies cited to support
benefit? (Yes/No)

Description (language used)
•

Are potential side effects
mentioned? (Yes/No)

•

How are potential side effects
presented?
o Font consistent with other
sections of the Web site
o Smaller font
o Side effects are not
mentioned

8. Prescription for action

(action or behavior being advocated /
encouraged)
•

See your doctor

•

Feel healthy again

•

Other:
_______________________
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9. Nature of portrayal of
patients/characters

10. Nature of portrayal of health
providers

11. WHI (mentioned /
referenced?)
12. Web site characteristics
•

Number of web sites
with lay person and
health provider portals

•

How are the portals
labeled? (i.e. how many
web site portals use the
term “health care
providers”?)

(characteristics)
•

Gender

•

Estimated age

•

Estimated race

•

Dress (business suit, jogging suit,
etc.)

•

Primary setting

•

Primary behavior/activity

(characteristics)
•

Gender

•

Estimated age

•

Estimated race

•

Dress

•

Primary setting

•

Primary behavior/activity

•

Are any credentials listed?

•

WHI mentioned? Yes/No

•

Location/where on web site?
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•

Number of menu items
on the site for
consumers

•

Menu options for
consumers (list by web
site)

•

Number of menu items
on the site for health
care providers

•

Menu options for health
providers (list by web
site)

•

Slogans for consumers

(Advertising message that appears in
the largest font)

•

Slogans for health care
providers

(Advertising message that appears in
the largest font)

•

Information provided to
health professionals to
distribute to patients?
(On every web site? in
PDF? need to order?)

•

How many web sites
include references or
citations? (If so, where
are they located?
Consumer pages or
health provider pages?)

•

How many web sites
show pictures of HT
products? Packaging?

•

How many web sites
have self-diagnosis
tools? (symptom tools)

•

Symptom Tool: Yes/No

•

How many web sites
have guide or list of

•

Guide to Talking with Health

255
questions to ask your
health provider?
•

How many web sites
have coupons or free
samples?

•

Colors used on web site

•

Imagery: How many use
flowers, nature, ribbons,
etc.

Provider: Yes/No
•

Coupons: Yes/No

•

Free samples: Yes/No
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Consumer-targeted prescription drug advertising serves as an interesting
lens through which we can examine the portrayal of menopause in online drug
advertisements. The aim of this study was to explore the portrayal of menopause
on web sites sponsored by pharmaceutical companies for hormone therapies
(HT). To unravel this question, a qualitative content analysis of web sites for
FDA-approved hormone therapies was employed. A total number of 608 printed
pages of web site content from eight web sites (N=8) were analyzed. Key
findings elucidated how menopause was portrayed on the pharmaceutical web
sites. First, descriptions of menopause articulated a biomedical perspective of
menopause. In adopting a biomedical perspective, menopause was described as
a medical event requiring medical treatment. Second, the web sites employed
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the terminology of illness, including the term “symptoms” which is a medically
symbolic term. Women were told that their symptoms were to be assessed,
tracked, and managed which related to a disease-like model of menopause. If left
untreated, the web sites implied that symptoms could lead to hampered sex lives
and a reduced sense of self. Third, the web sites were prescriptive and
advocated consumer behaviors. Specifically, women were told to “ask” their
health care provider about HT. Likewise, the “expert” role of the physician in
providing a diagnosis was also reinforced. Fourth, another distinguishing
characteristic was the lack of scientific evidence provided for consumers to
support proclaimed benefits. The Women’s Health Initiative (WHI) was framed in
a positive light and consumers were told that potential benefits of HT may
outweigh the risks. Finally, the reading level of the pharmaceutical web sites far
surpassed the reading level of the average adult in the United States. Overall, my
findings reinforced the acceptance and dominance of the biomedical model of
menopause in advertising. Additionally, one of the strengths of this study was the
analysis of the reading level, online self-diagnosing symptom tools, and the
framing of the WHI in online pharmaceutical advertisements. To this end, this
research contributes to the existing body of literature to include analyses of
representations of menopause on pharmaceutical web sites.
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